Hepatocellular Carcinoma

MONDO:0007256 Pathograph 16 Show in embeddings browser liver carcinoma

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, typically arising in the setting of chronic liver disease and cirrhosis. Major risk factors include chronic hepatitis B or C infection, alcohol-related liver disease, and metabolic dysfunction-associated steatotic liver disease (MASLD/NAFLD). HCC pathogenesis involves multiple molecular pathways including WNT/beta-catenin, TP53, telomere maintenance, and chromatin remodeling. The combination of atezolizumab (anti-PD-L1) plus bevacizumab (anti-VEGF) has established immunotherapy as first-line treatment for advanced HCC, based on the IMbrave150 trial.

Ask OpenScientist

Ask a research question about Hepatocellular Carcinoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🏷

Classifications

ICD-O Morphology

Harrison's Part

🔗

Mappings

MONDO

MONDO:0007256 hepatocellular carcinoma

MONDO provides an exact disease term for hepatocellular carcinoma.

NCIT

NCIT:C3099 Hepatocellular Carcinoma

NCIT provides an exact neoplasm term for hepatocellular carcinoma.

ICD-10-CM

ICD10CM:C22.0 Liver cell carcinoma

ICD-10-CM provides an exact code for liver cell carcinoma / hepatocellular carcinoma.

NCIT

NCIT:C3099 Hepatocellular Carcinoma

NCIT provides an exact neoplasm term for hepatocellular carcinoma.

◆

Subtypes

Viral Hepatitis-Associated HCC

HCC arising in the context of chronic hepatitis B or C infection. HBV can be directly oncogenic through viral integration, while HCV promotes HCC primarily through cirrhosis and chronic inflammation.

MASLD-Associated HCC

HCC arising in metabolic dysfunction-associated steatotic liver disease (formerly NAFLD/NASH). Increasingly common subtype that can occur even without cirrhosis. May have distinct immune microenvironment features affecting immunotherapy response.

Fibrolamellar HCC NCIT:C4131

NCIT NCIT:C4131

Rare variant occurring in younger patients without cirrhosis. Characterized by DNAJB1-PRKACA fusion. Distinct clinical behavior and treatment considerations.

NCIT: Fibrolamellar Carcinoma (skos:closeMatch) NCIT:C4131

Comorbidities

Liver Cirrhosis <-> Hepatocellular Carcinoma

◈

Mechanistic Hypotheses

RNase P Pre-tRNA Processing as the RPP40-mTOR/MYC Bridge

rpp40_rnase_p_pretrna_mtor_myc_bridge EMERGING

Evidence balance 4 support

Elevated RPP40 may sustain mTOR/MYC output in established hepatocellular carcinoma specifically because its contribution to RNase P preserves 5-prime pre-tRNA maturation and translational capacity. This narrow model predicts that an RNase P/pre-tRNA defect after acute RPP40 loss precedes signaling decline and is phenocopied by an RNase-P-specific perturbation. RPP40 is also shared with RNase MRP, however, and independent HCC evidence linking RPP40 to ribosomal-RNA and ribosomal-gene expression makes an RNase MRP/pre-rRNA or broader ribosome-biogenesis route a direct competitor. Neither published HCC study establishes the proposed RNase P ordering.

This hypothesis is intentionally not wired as a causal pathograph edge. Evidence supports the flanking RPP40 and mTOR/MYC observations, not the proposed RNase-P/pre-tRNA bridge.

Deep research

OpenScientist citations 27 citations 2026-07-26T04:50:40.525995

Show evidence (4 references)

PMID:42424930 SUPPORT Human Clinical

"Analysis showed that RPP40 expression was markedly upregulated in HCC tissues compared to adjacent normal tissues. High RPP40 expression correlated with poorer clinical outcomes, even among patients with matched histological grade or pathological stage."

Multi-dataset human-tumor associations support expression and prognostic correlation, but they do not establish whether RPP40 is a driver, dependency, or consequence of proliferative state.

PMID:42424930 SUPPORT In Vitro

"RPP40 suppression attenuated cellular migration and proliferation, whereas its overexpression enhanced these malignant phenotypes both in vitro and in vivo."

This item classifies the cell-culture component of the mixed result. The Huh-7 and HepG2 perturbations support an RPP40-dependent malignant phenotype in vitro, but did not test pre-tRNA maturation or RNase-P specificity.

PMID:42424930 SUPPORT Model Organism

"RPP40 suppression attenuated cellular migration and proliferation, whereas its overexpression enhanced these malignant phenotypes both in vitro and in vivo."

This separately classifies the subcutaneous mouse-xenograft component of the mixed result. It supports an in-vivo model phenotype but neither human-tumor causality nor an RNase-P/pre-tRNA mechanism.

+ 1 more reference

Discussions and Knowledge Gaps

Does RPP40 sustain mTOR/MYC signaling in hepatocellular carcinoma specifically through RNase P-mediated 5-prime pre-tRNA maturation, or are the reported effects better explained by RNase MRP/pre-rRNA and ribosome biogenesis, an RPP40-specific noncanonical activity, or expression downstream of proliferative state?

KNOWLEDGE GAP OPEN gap_rpp40_trna_processing_mtor_myc_causality

Attached to

mechanistic_hypotheses#rpp40_rnase_p_pretrna_mtor_myc_bridge pathophysiology#PI3K/AKT/mTOR Pathway Activation pathophysiology#Enhanced Hepatocyte Proliferation

RNase P and RNase MRP are distinct ribonucleoprotein complexes that share RPP40: RNase P removes 5-prime leaders from pre-tRNAs, whereas RNase MRP processes pre-rRNA in ribosome biogenesis. PMID:42424930 reports RPP40 perturbation phenotypes and nominates mTOR/MYC, but it does not measure either RNA-processing branch or establish temporal ordering. PMID:40517827 independently links RPP40 to ribosomal-RNA and ribosomal-gene transcription in HCC cells, making an rRNA/ribosome-biogenesis route a concrete competing explanation without proving RNase MRP catalytic mediation. Pan-cancer profiling further classifies RPP40 as a broadly essential, cell-cycle-coupled dependency, raising a generic biosynthetic-demand alternative without proving that RPP40 elevation is merely downstream in HCC. Independent HCC evidence also places mTORC1 upstream of a ribosome-biogenesis effector, so reverse directionality remains plausible. The current evidence therefore does not justify a causal RPP40-to-mTOR/MYC graph edge.

Proposed experiments

Acute complex-specific RPP40-RNase P/RNase MRP branch test

time-resolved complex-specific perturbation study

exp_rpp40_processing_dependence_and_epistasis

First compare acute depletion of shared-subunit RPP40 with an RNase-P-specific perturbation and an RNase-MRP-specific perturbation in two authenticated HCC-derived lines. Collect targeted RNA-processing, signaling, and proliferation measurements before loss of viability. Only after this primary branch-selection stage should branch-specific rescue, mTOR/MYC epistasis, global omics, or organoid validation be added.

Model systems

Authenticated HCC-derived cell-line pair

Use Huh-7 plus an independently authenticated HCC-derived line such as Hep3B, with short time courses and matched perturbation efficiency.

HepG2 seed-study replication model

Retain HepG2 only as a secondary replication context because it was used in the cited study; label it correctly as hepatoblastoma-derived rather than as an HCC-derived line.

Perturbations

Acute RPP40 depletion

gene#RPP40

Use inducible degradation or CRISPR interference with multiple reagents and sample before secondary cell-cycle arrest or loss of viability.

RPP40 hgnc:20992

RNase-P-specific perturbation

gene#RPP21

Acutely deplete RPP21, an RNase-P-specific protein subunit, with an orthogonal RPPH1 perturbation reserved for confirmation.

RPP21 hgnc:21300

RNase-MRP-specific perturbation

gene#C18orf21

Acutely deplete the RNase-MRP-specific subunit C18orf21 (RMP24), with an orthogonal RMRP perturbation reserved for confirmation.

C18orf21 hgnc:28802

Combined RNase-P-specific and RNase-MRP-specific perturbation

gene#RPP21

Acutely co-deplete RPP21 and C18orf21, with simultaneous RPPH1 and RMRP perturbation as an orthogonal confirmation, to reproduce the dual RNase-P and RNase-MRP loss caused by shared-subunit RPP40 depletion. This arm is required before an RPP40-only phenotype is interpreted as noncanonical rather than as synergy between the two processing defects.

RPP21 hgnc:21300 C18orf21 hgnc:28802

Conditional downstream mTOR/MYC epistasis

pathophysiology#PI3K/AKT/mTOR Pathway Activation

After a processing branch is selected, test whether independent mTORC1 or MYC activation rescues the branch-specific signaling and proliferation phenotype. This orders downstream signaling but cannot by itself identify the upstream RNA-processing branch.

MTOR hgnc:3942 MYC hgnc:7553

Reciprocal mTOR/MYC and proliferation-state perturbation

pathophysiology#PI3K/AKT/mTOR Pathway Activation

After the branch-selection stage, acutely inhibit mTORC1 or MYC and independently impose a matched proliferation arrest without depleting RPP40. Measure early RPP40 transcript and protein abundance and both RNA-processing outputs to test the competing possibility that RPP40 elevation is downstream of oncogenic signaling or proliferative state.

MTOR hgnc:3942 MYC hgnc:7553

Readouts

RNase P pre-tRNA maturation

biological_process#tRNA processing

Quantify 5-prime-leader-containing pre-tRNAs and precursor-to-mature-tRNA ratios at early time points.

tRNA processing GO:0008033

precursor-specific RT-qPCR northern blot

RNase MRP pre-rRNA and 40S maturation

biological_process#rRNA processing

Quantify uncleaved ITS1-containing pre-rRNA, mature 18S-rRNA production, and the 40S-to-60S ribosomal-subunit ratio at matched early time points.

rRNA processing GO:0006364

ITS1-specific RT-qPCR and northern blot sucrose-gradient polysome profiling

mTOR/MYC temporal response

pathophysiology#PI3K/AKT/mTOR Pathway Activation

Measure phospho-S6K, phospho-4E-BP1, and MYC protein alongside nascent translation before proliferation or viability diverges.

immunoblot time course nascent-protein-synthesis assay

Proliferation and viability

pathophysiology#Enhanced Hepatocyte Proliferation

Measure EdU incorporation, cell-cycle state, and viability so early pathway effects can be separated from later generic ribosome-loss toxicity.

EdU incorporation assay live-cell viability assay

Controls

Perturbation controls

Use non-targeting and multiple independent guides, mock-degron controls, matched perturbation efficiencies, and prespecified early sampling windows.

Complex-specific activity controls

Require RPP21 loss to produce its expected pre-tRNA defect and C18orf21 loss to produce its expected pre-rRNA defect before interpreting a negative signaling result.

Matched dual-complex activity control

Require the combined RPP21-plus-C18orf21 or RPPH1-plus-RMRP arm to match the early pre-tRNA and pre-rRNA defects produced by RPP40 loss before using a discordant signaling phenotype to infer an RPP40-specific noncanonical activity.

Decision criterion

The RNase-P/pre-tRNA bridge is supported only if RPP40 loss and RNase-P-specific loss share an early pre-tRNA defect followed by the same mTOR/MYC decline, while a validated RNase-MRP-specific perturbation causes its expected pre-rRNA defect without that early signaling signature. An RNase MRP alternative is favored, and the narrow RNase P hypothesis is refuted in that model, if RPP40 and C18orf21/RMRP perturbations instead share an ordered pre-rRNA/40S defect and mTOR/MYC decline while RPP21/RPPH1 loss impairs pre-tRNA maturation without the signaling effect. A signaling change unique to RPP40 favors a noncanonical role only if a combined RNase-P-specific plus RNase-MRP-specific perturbation matches both early processing defects without reproducing that signaling change; discordance from either single perturbation alone may instead reflect dual-loss synergy. Signaling changes that appear only after generalized translation failure, cell-cycle arrest, or loss of viability do not establish either branch. Reciprocal mTOR/MYC inhibition and matched proliferation arrest support the downstream-state alternative if they reduce RPP40 before either processing output changes. Branch-specific rescue and bidirectional mTOR/MYC epistasis should be attempted only after this primary discriminator is met.

Would support

mechanistic_hypotheses#rpp40_rnase_p_pretrna_mtor_myc_bridge

Would refute

mechanistic_hypotheses#rpp40_rnase_p_pretrna_mtor_myc_bridge

Show evidence (2 references)

PMID:41136609 SUPPORT In Vitro

"Notably, RNase P includes a unique subunit, RPP21, whereas no RNase MRP-specific proteins have been found in humans, limiting molecular analyses of RNase MRP function. Here, we identify the RNase MRP-specific proteins, C18orf21 (RMP24) and NEPRO (RMP64)."

This human-cell study supplies experimentally defined complex-specific perturbation handles for the primary RNase P-versus-RNase MRP discriminator; it does not establish an HCC mechanism.

PMID:40533478 SUPPORT In Vitro

"Here we report that rapid depletion of RNase MRP, a deeply conserved RNA-based enzyme required for rRNA biosynthesis, induces a long-term yet reversible proliferative arrest in human cells. Severely compromised biogenesis of rRNAs along with acute transcriptional reprogramming precede a gradual..."

The temporal sequence after rapid RNase MRP depletion supports early RNA-processing measurements and cautions against interpreting later proliferative arrest as an HCC-specific mTOR/MYC mechanism.

Show evidence (6 references)

PMID:42424930 SUPPORT Other

"While the ribonucleoprotein complex subunit RPP40 plays a critical role in precursor tRNA processing and has demonstrated prognostic value in several cancer types, its specific function and underlying mechanisms in HCC pathogenesis remain poorly understood."

The seed paper explicitly identifies the unresolved HCC mechanism while separating RPP40's known canonical role from the HCC-specific question.

PMID:40517827 SUPPORT In Vitro

"Our findings reveal that RPP40 can coordinate the transcription of ribosomal RNA and the expression of ribosomal genes, thereby promoting the malignancy of HCC."

A separate HCC-cell study provides a concrete rRNA/ribosomal-gene alternative to the proposed pre-tRNA bridge, but does not establish RNase MRP-mediated pre-rRNA processing or temporal ordering upstream of mTOR/MYC.

PMID:41933259 SUPPORT Human Clinical

"RPP40 expression was significantly upregulated in most cancers and their subtypes"

Pan-cancer patient-tumor expression supports a broadly shared association and motivates testing HCC selectivity. It does not establish dependency, directionality, or an HCC-specific processing mechanism.

+ 3 more references

Does ACAA2-dependent mitochondrial acetyl-CoA homeostasis regulate metabolic switching from oxidative phosphorylation to aerobic glycolysis in HCC specifically through MPC1 protein acetylation and proteasomal stability, or do alternative mechanisms of acetyl-CoA-dependent regulation (histone acetylation, other protein targets, non-acetylation sensing) dominate?

KNOWLEDGE GAP OPEN gap_acaa2_mpc1_acetylation_pyruvate_transport

Attached to

pathophysiology#Aerobic Glycolysis and Metabolic Reprogramming

PMID:42520527 demonstrates that ACAA2 downregulation reduces mitochondrial acetyl-CoA, leading to MPC1 acetylation loss, MPC1 proteasomal degradation, and impaired pyruvate transport with consequent glycolytic shift. However, the paper does not directly measure acetyl-CoA-dependent protein acetylation stoichiometry, does not use acetylation-site-specific MPC1 mutations to establish acetylation as mechanistically sufficient, and does not test proteasomal inhibitors or direct acetyl-CoA supplementation. Alternative explanations remain open: direct allosteric effects of acetyl-CoA on MPC1, ACAA2-FAO support for histone acetylation and epigenetic reprogramming upstream of MPC1, acetylation of autophagy or mitochondrial chaperone machinery affecting MPC1 indirectly, and competing acetyl-CoA sources (glutaminolysis, pyruvate carboxylase) that may bypass this pathway.

Proposed experiments

Acetyl-CoA and MPC1 acetylation-site mechanism

protein acetylation and metabolic switching mechanism study

exp_acaa2_acetyl_coa_mpc1_acetylation_causality

Test acetylation-site sufficiency by combining acute ACAA2 depletion, direct acetyl-CoA pathway manipulation (ACS2 inhibition, pyruvate carboxylase inhibition), and MPC1 acetylation-site mutation (K99R or identified sites) in HCC-derived lines (Huh-7, Hep3B). Measure MPC1 acetylation stoichiometry via mass-spec or acetyl-lysine blots, MPC1 protein stability (pulse-chase or proteasomal inhibition), pyruvate oxidation (13C-pyruvate tracing), and glycolytic flux (ATP, ECAR, lactate) to validate the proposed chain. Use catalytically defective ACAA2 variants to distinguish FAO-dependent acetyl-CoA from other ACAA2 functions.

Model systems

HCC-derived cell lines with metabolic tracing

Huh-7 and Hep3B lines with 13C-pyruvate tracing to distinguish pyruvate oxidation, glycolytic lactate, alanine synthesis, and anaplerosis under perturbation.

Show evidence (2 references)

PMID:42520527 SUPPORT Other

"While acetyl-CoA acts as a pivotal metabolic molecule involved in protein acetylation, whether ACAA2 regulates metabolic reprogramming through acetyl-CoA-mediated mitochondrial protein acetylation remains unclear."

Authors explicitly identify the unresolved role of acetyl-CoA-mediated protein acetylation in ACAA2-dependent metabolic switching, the core of this gap.

PMID:42520527 SUPPORT Other

"Mounting evidence indicates that metabolic reprogramming contributes substantially to tumor development by promoting cancer cell proliferation and metastasis. However, the underlying mechanisms remain incompletely understood."

Establishes the broader mechanistic gap in HCC metabolic reprogramming that this ACAA2-acetyl-CoA-MPC1-pyruvate axis helps address.

⚙

Pathophysiology

Chronic Liver Injury and Cirrhosis

Most HCC arises in the context of chronic liver disease and cirrhosis. Persistent hepatocyte death and regeneration in an inflammatory environment promotes accumulation of genetic alterations. Cirrhosis itself is a premalignant condition with ongoing oxidative stress and genomic instability.

hepatocyte CL:0000182

liver UBERON:0002107

Downstream

Telomere Dysfunction and Genomic Instability Repeated hepatocyte division leads to telomere shortening

Accumulation of Driver Mutations Chronic regeneration promotes mutation accumulation

Show evidence (1 reference)

PMID:41567639 SUPPORT

"HCC typically arises in patients with chronic liver disease, including hepatitis, cirrhosis, and non-alcoholic fatty liver diseases."

This abstract states that HCC commonly arises in chronic liver disease and cirrhosis, supporting the mechanism described.

Telomere Dysfunction and Genomic Instability

Chronic hepatocyte proliferation leads to telomere shortening, causing genomic instability. TERT promoter mutations, which are the most common HCC mutations, reactivate telomerase to enable unlimited replication. This creates a checkpoint bypass allowing survival of genetically unstable cells.

telomere maintenance GO:0000723 ⚠ ABNORMAL

Downstream

WNT/Beta-Catenin Pathway Activation Genomic instability promotes acquisition of pathway-activating mutations

Accumulation of Driver Mutations

Multiple driver genes are recurrently mutated in HCC, including TERT promoter (60%), TP53 (30%), CTNNB1 (30%), AXIN1 (10%), and ARID1A (10%). These mutations affect telomere maintenance, cell cycle control, WNT signaling, and chromatin remodeling.

DNA repair GO:0006281 ↓ DECREASED

Downstream

PI3K/AKT/mTOR Pathway Activation Somatic and expression-level pathway changes select for oncogenic growth signaling.

WNT/Beta-Catenin Pathway Activation

Activating mutations in CTNNB1 (beta-catenin) or inactivating mutations in AXIN1 lead to constitutive WNT pathway activation. This drives cell proliferation and is associated with a distinct molecular subclass of HCC with specific clinical features including cholestasis and immune exclusion.

Wnt signaling pathway GO:0016055 ↑ INCREASED

Downstream

Enhanced Hepatocyte Proliferation WNT signaling drives cell proliferation and stemness

Portal Vein Invasion and Tumor Thrombus Wnt/beta-catenin activation promotes hepatocyte migration and survival and can contribute to vascular invasion and metastatic progression in a subset of HCCs.

PI3K/AKT/mTOR Pathway Activation

PI3K/AKT/mTOR signaling is a recurrent oncogenic axis in HCC. PI3K/Akt activation is reported in 40-60% of HCC tissue, and dysregulated pathway-associated genes and upstream receptor inputs increase AKT/TOR signaling, supporting hepatocyte survival, anabolic growth, proliferation, and immune infiltration patterns relevant to targeted therapy and immunotherapy response.

TOR signaling GO:0031929 ↑ INCREASED phosphatidylinositol-mediated signaling GO:0048015 ↑ INCREASED

Downstream

Enhanced Hepatocyte Proliferation PI3K/AKT/mTOR activation promotes tumor-cell growth and survival signaling.

Immune Evasion and Immunosuppressive Microenvironment Pathway-associated signatures correlate with immune infiltration and checkpoint expression.

Aerobic Glycolysis and Metabolic Reprogramming Oncogenic PI3K/AKT/mTOR signaling drives the anabolic, glycolytic reprogramming modeled by the deregulated-cellular-energetics module.

Show evidence (2 references)

PMID:29984212 SUPPORT Human Clinical

"The signaling pathways known to be activated in HCC tissue include the Wnt/β-catenin pathway (up to 50% of HCC), the phosphatidylinositol-3-kinase and protein kinase B (PI3K/Akt) pathway (40–60% of HCC), the Myc pathway (30–60%), the Hedgehog pathway (50–60%), and the MET pathway (30–40%)."

This review summarizes human HCC tissue data and supports recurrent PI3K/Akt activation in a large fraction of HCC.

PMID:35592706 SUPPORT Computational

"The dysregulated PI3K/AKT/mTOR pathway acts as the main regulator of tumorigenesis in hepatocellular carcinoma (HCC)."

This bioinformatic HCC cohort analysis directly supports PI3K/AKT/mTOR dysregulation as an oncogenic signaling axis and links pathway-associated gene signatures to immune infiltration.

TP53 Pathway Inactivation

TP53 mutations are common in HCC, particularly in HBV-associated and aflatoxin-associated tumors. Loss of p53 function removes a critical checkpoint, allowing survival of cells with DNA damage and promoting genomic instability.

apoptotic process GO:0006915 ↓ DECREASED

Enhanced Hepatocyte Proliferation

Combined effects of telomerase reactivation, cell cycle checkpoint loss, and mitogenic signaling drive uncontrolled hepatocyte proliferation and tumor growth.

cell population proliferation GO:0008283 ↑ INCREASED

Angiogenesis and VEGF Signaling

HCC is a highly vascular tumor dependent on angiogenesis. VEGF signaling promotes new blood vessel formation supplying the tumor. VEGF also has immunosuppressive effects, contributing to the immune-excluded microenvironment. This provides the rationale for anti-VEGF therapy in combination with immunotherapy.

angiogenesis GO:0001525 ↑ INCREASED

Downstream

Immune Evasion and Immunosuppressive Microenvironment VEGF-mediated immunosuppression contributes to T cell exclusion and checkpoint upregulation

Show evidence (1 reference)

PMID:19637355 SUPPORT

"Hepatocellular carcinoma (HCC) is a highly vascular tumor, and angiogenesis is believed to play a considerable role in its development and progression."

Abstract notes HCC is highly vascular and angiogenesis plays a major role, supporting this mechanism.

Immune Evasion and Immunosuppressive Microenvironment

HCC develops in a chronically inflamed liver with an inherently immunosuppressive microenvironment. Tumor cells upregulate PD-L1, VEGF-mediated immunosuppression excludes effector T cells, and recruitment of regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages creates an immune-tolerant niche. The combination of anti-PD-L1 with anti-VEGF addresses both the checkpoint-mediated and VEGF-mediated immunosuppression.

CD8-positive, alpha-beta T cell CL:0000625

Negative Regulation of T Cell Mediated Immunity GO:0002710 ↑ INCREASED

Show evidence (2 references)

PMID:32158599 SUPPORT Other

"The HCC tumor microenvironment is characterized by a dysfunction of the immune system through multiple mechanisms, including accumulation of various immunosuppressive factors, recruitment of regulatory T cells and myeloid-derived suppressor cells, and induction of T cell exhaustion accompanied..."

Review specifically describes HCC's immunosuppressive microenvironment including Treg and MDSC recruitment, T cell exhaustion, and checkpoint ligand-receptor interactions — directly supporting all claims in this node about HCC immune evasion mechanisms.

PMID:41794264 SUPPORT Other

"The liver tumor microenvironment plays a pivotal role in hepatocellular carcinoma (HCC) progression by fostering immune suppression, which impairs anti-tumor responses and enables tumor growth, invasion, and metastasis."

Supports the immunosuppressive microenvironment enabling invasion and metastasis; folded in from the former Metastatic_HCC entry.

Aerobic Glycolysis and Metabolic Reprogramming

HCC cells reprogram metabolism from oxidative phosphorylation to aerobic glycolysis (Warburg effect), enabling rapid ATP regeneration and providing carbon intermediates for biosynthesis. This metabolic shift is driven by oncogenic signaling (PI3K/AKT, MYC) and supports the high proliferative rate of hepatocellular carcinomas. The mechanism linking mitochondrial acetyl-CoA homeostasis to pyruvate transport and glycolytic switching remains incompletely characterized.

Glycolytic Process GO:0006096 ↑ INCREASED

Downstream

Enhanced Hepatocyte Proliferation The glycolytic shift supplies the ATP and biosynthetic carbon that sustain the high proliferative rate; PMID:42520527 reports impaired mitochondrial pyruvate transport promoting glycolysis and cell proliferation together.

Show evidence (2 references)

PMID:19460998 SUPPORT Other

"most cancer cells produce large amounts of lactate regardless of the availability of oxygen"

Directly states the Warburg phenotype this node models — lactate production despite adequate oxygen. This is the same on-claim evidence the module's central-effector node carries. Evidence source is OTHER because this is a review article.

PMID:42520527 SUPPORT In Vitro

"Mechanistically, ACAA2 downregulation reduces mitochondrial acetyl-CoA levels, thereby decreasing mitochondrial pyruvate carrier 1 (MPC1) acetylation and accelerating its proteasomal degradation, which ultimately impairs mitochondrial pyruvate transport to promote glycolysis and cell proliferation."

HCC-specific specialization of the generic module claim: work in HCC-derived lines shows loss of mitochondrial pyruvate transport driving the glycolytic shift, and links that shift directly to proliferation.

Portal Vein Invasion and Tumor Thrombus

Vascular invasion is a defining step in metastatic HCC. Tumor cells leave the cancer nest, traverse extracellular matrix and vascular barriers, and colonize the portal vein, creating portal vein tumor thrombus and enabling dissemination.

cell migration GO:0016477 ↑ INCREASED positive regulation of cell migration GO:0030335 ↑ INCREASED

Show evidence (1 reference)

PMID:36318440 SUPPORT Human Clinical

"Liver cancer cells potentially experienced multi-steps during PVTT process, including cancer cells leave from cancer nest, migrate in extracellular matrix, invade the vascular barrier, and colonize in the portal vein."

This directly supports the sequential invasion biology underlying portal vein tumor thrombus.

✶

Histopathology

Hepatocellular Carcinoma VERY_FREQUENT

Hepatocellular carcinoma is the most common primary liver malignancy.

Show evidence (1 reference)

PMID:27785449 SUPPORT

"Hepatocellular carcinoma (HCC) is the most common primary liver malignancy"

Abstract states that HCC is the most common primary liver malignancy.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Digestive 4

Hepatomegaly FREQUENT HP:0002240

Ascites FREQUENT HP:0001541

Show evidence (1 reference)

PMID:36396345 SUPPORT Human Clinical

"Patients with advanced hepatocellular carcinoma (HCC) have specific palliative care needs owing to the influence of the disease on abdominal pain, jaundice, bleeding, appetite, ascites, liver function and hepatic encephalopathy."

This supports ascites as a key clinical feature of advanced HCC.

Jaundice OCCASIONAL HP:0000952

Show evidence (1 reference)

PMID:36396345 SUPPORT Human Clinical

This supports jaundice as a key clinical feature of advanced HCC.

Nausea FREQUENT HP:0002018

Constitutional 2

Abdominal Pain FREQUENT HP:0002027

Show evidence (1 reference)

PMID:36396345 SUPPORT Human Clinical

This supports abdominal pain as a key clinical feature of advanced HCC.

Fatigue VERY_FREQUENT HP:0012378

Growth 1

Weight Loss VERY_FREQUENT HP:0001824

🧬

Genetic Associations

TERT Promoter (Somatic Activating Mutation)

Show evidence (1 reference)

PMID:40243493 SUPPORT Human Clinical

"Our analysis, encompassing over 4000 HCC cases, revealed that TERTp mutations were present in 49.2% of tumors, with C228T being the predominant variant (93.3% among mutated cases)."

Supports TERT promoter mutation as the most frequent somatic alteration in HCC.

TP53 (Somatic Loss of Function)

Gene: TP53 hgnc:11998

Show evidence (1 reference)

PMID:29391887 SUPPORT Human Clinical

"The most common somatic mutations identified were tumor protein 53 (TP53; 35.6%) and β-catenin 1 (CTNNB1; 30.5%), and the most frequent variants of those genes were missense variants."

Supports TP53 as a recurrent somatic alteration in HCC.

CTNNB1 (Somatic Activating Mutation)

Gene: CTNNB1 hgnc:2514

Show evidence (1 reference)

PMID:40243493 SUPPORT Human Clinical

"CTNNB1 exon 3 mutations were identified in 23.1% of HCCs, showing a similar association with viral etiology, being more common in HCV-related cases (30.7%) than in HBV-related tumors (12.8%)."

Supports CTNNB1 as a frequent driver mutation in HCC with etiology-specific patterns.

AXIN1 (Somatic Loss of Function)

Gene: AXIN1 hgnc:903

ARID1A (Somatic Loss of Function)

Gene: ARID1A hgnc:11110

💊

Medical Actions

Atezolizumab plus Bevacizumab

Action: immunotherapy Ontology label: Immunotherapy NCIT:C15262

Agent: atezolizumab NCIT:C106250 bevacizumab NCIT:C2039

First-line standard of care for unresectable HCC based on IMbrave150 trial. Anti-PD-L1 (atezolizumab) combined with anti-VEGF (bevacizumab) demonstrated superior overall survival compared to sorafenib. Requires adequate liver function (Child-Pugh A) and no high-risk varices. Immunotherapy trials in HCC require careful interpretation due to delayed treatment effects and potential violations of proportional hazard assumptions, which may affect the apparent magnitude of benefit from surrogate endpoints like PFS.

Mechanism Target:

INHIBITS Immune Evasion and Immunosuppressive Microenvironment — Atezolizumab (anti-PD-L1) blocks PD-L1-mediated T cell suppression while bevacizumab (anti-VEGF) reverses VEGF-mediated immunosuppression, together restoring anti-tumor immunity in HCC.

Show evidence (1 reference)

PMID:39687036 SUPPORT Human Clinical

"Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib"

Superior outcomes with combined anti-PD-L1/anti-VEGF demonstrate that targeting both checkpoint-mediated and VEGF-mediated immunosuppression is effective in HCC.

INHIBITS Angiogenesis and VEGF Signaling — Bevacizumab directly inhibits VEGF-driven angiogenesis that sustains HCC tumor growth.

Show evidence (1 reference)

PMID:32402160 SUPPORT Human Clinical

"atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib."

The IMbrave150 trial established the anti-VEGF antibody bevacizumab (combined with atezolizumab) as effective first-line therapy, supporting its action on the angiogenesis/VEGF-signaling node in HCC.

Show evidence (4 references)

PMID:39687036 SUPPORT Human Clinical

"Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib"

IMbrave150 abstract reports improved overall and progression-free survival with atezolizumab plus bevacizumab versus sorafenib.

PMID:42184925 SUPPORT Other

"immunotherapy has introduced challenges to traditional statistical models through delayed treatment effects and violations of the proportional hazard assumption"

This methodology review highlights critical interpretation issues for immunotherapy trials in HCC, including delayed treatment effects and proportional hazards violations that affect OS and PFS endpoint validity in IMbrave150 and similar trials.

PMID:38502889 SUPPORT Other

"Atezolizumab + bevacizumab (atezo + bev) or durvalumab + tremelimumab (durva + treme) may be offered first-line for patients with advanced HCC, Child-Pugh class A liver disease, and Eastern Cooperative Oncology Group performance status 0-1."

The 2024 ASCO guideline recommends atezolizumab plus bevacizumab as a first-line option for advanced HCC with Child-Pugh A liver function.

+ 1 more reference

Durvalumab plus Tremelimumab

Action: immunotherapy Ontology label: Immunotherapy NCIT:C15262

Agent: durvalumab NCIT:C103194 tremelimumab NCIT:C49085

Alternative first-line immunotherapy option. HIMALAYA trial demonstrated durvalumab (anti-PD-L1) with single priming dose of tremelimumab (anti-CTLA-4) improves survival compared to sorafenib. Option for patients who cannot receive bevacizumab. Like other HCC immunotherapy trials, trial interpretation requires careful consideration of delayed treatment effects and proportional hazards violations when assessing surrogate endpoints.

Mechanism Target:

INHIBITS Immune Evasion and Immunosuppressive Microenvironment — Durvalumab (anti-PD-L1) blocks adaptive immune resistance while tremelimumab (anti-CTLA-4) priming dose expands the T cell repertoire, together overcoming the immunosuppressive HCC microenvironment.

Show evidence (1 reference)

PMID:38382875 SUPPORT Human Clinical

"STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly improved overall survival (OS) versus sorafenib; durvalumab monotherapy was noninferior to sorafenib for OS."

The phase III HIMALAYA study shows dual anti-CTLA-4/anti-PD-L1 blockade (STRIDE) improves survival, supporting its action on the immune-evasion and immunosuppressive-microenvironment node in HCC.

Show evidence (2 references)

PMID:38382875 SUPPORT Human Clinical

"STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly improved overall survival (OS) versus sorafenib; durvalumab monotherapy was noninferior to sorafenib for OS."

The phase III HIMALAYA trial provides primary efficacy evidence that the STRIDE regimen (durvalumab plus a single priming dose of tremelimumab) significantly improved overall survival versus sorafenib, directly anchoring the efficacy claim in the treatment description.

PMID:42184925 SUPPORT Other

"The validity of surrogate endpoints in hepatocellular carcinoma remains debated due to tumor heterogeneity, competing risks related to liver disease, and the influence of post‑progression therapies"

This methodology review clarifies critical context for HIMALAYA trial interpretation: surrogate endpoints (PFS, TTP, ORR) in HCC are complicated by tumor heterogeneity, competing risks from underlying cirrhosis, and post-progression therapy confounding, highlighting why OS improvement is particularly meaningful for durvalumab + tremelimumab.

Sorafenib

Action: targeted therapy Ontology label: Targeted Therapy NCIT:C93352

Agent: sorafenib CHEBI:50924

Multi-kinase inhibitor targeting RAF, VEGFR, and PDGFR. Was first systemic therapy to improve survival in HCC. Now used in second line or when immunotherapy is contraindicated.

Mechanism Target:

INHIBITS Angiogenesis and VEGF Signaling — Sorafenib is a multikinase inhibitor with anti-angiogenic activity (VEGFR/PDGFR/RAF), suppressing the VEGF-driven neovascularization that sustains HCC growth.

Show evidence (1 reference)

PMID:38502889 SUPPORT Other

"Where there are contraindications to these therapies, sorafenib, lenvatinib, or durvalumab may be offered first-line."

The 2024 ASCO guideline offers sorafenib (or lenvatinib/durvalumab) first-line when atezolizumab-bevacizumab or durvalumab-tremelimumab are contraindicated.

Lenvatinib

Action: targeted therapy Ontology label: Targeted Therapy NCIT:C93352

Agent: lenvatinib CHEBI:85994

Multi-kinase inhibitor with activity against VEGFR, FGFR, PDGFR, RET, and KIT. Non-inferior to sorafenib in first line. Alternative when immunotherapy not appropriate.

Mechanism Target:

INHIBITS Angiogenesis and VEGF Signaling — Lenvatinib is a multikinase inhibitor targeting VEGFR1-3 and FGFR1-4, inhibiting tumor angiogenesis in HCC.

Surgical Resection

Action: hepatic resection Ontology label: Hepatectomy NCIT:C15249

Potentially curative for early-stage HCC in patients with preserved liver function (Child-Pugh A). Limited by underlying cirrhosis in many patients. Requires adequate future liver remnant.

Liver Transplantation

Action: organ transplantation Ontology label: Organ Transplantation NCIT:C15289

Potentially curative treatment that addresses both tumor and underlying cirrhosis. Milan criteria (single tumor 5 cm or less or up to 3 tumors each 3 cm or less, no vascular invasion, no metastases) guide patient selection. Limited by organ availability.

Transarterial Chemoembolization (TACE)

Action: chemotherapy Ontology label: Chemotherapy NCIT:C15632

Locoregional therapy delivering chemotherapy directly to tumor via hepatic artery followed by embolization. Standard for intermediate-stage HCC (BCLC-B). Can be used as bridge to transplant or with systemic therapy.

Radiofrequency/Microwave Ablation

Action: ablation therapy Ontology label: Ablation Therapy NCIT:C20985

Thermal ablation for small tumors (typically less than 3 cm). Effective alternative to resection for early-stage HCC, particularly in patients with limited liver function.

🌍

Environmental Factors

Chronic hepatitis B or C infection

Viral hepatitis is a major substrate for hepatocarcinogenesis and later metastasis.

Show evidence (1 reference)

PMID:41567639 SUPPORT Human Clinical

"HCC typically arises in patients with chronic liver disease, including hepatitis, cirrhosis, and non-alcoholic fatty liver diseases."

This supports chronic hepatitis as a foundational risk factor for HCC.

Mechanism Target:

TRIGGERS Chronic Liver Injury and Cirrhosis — Persistent viral hepatitis is one of the chronic liver injury states this node is made of, supplying the regenerative pressure and inflammation on which the tumour arises. The exposure constitutes the node rather than acting on it from outside.

Show evidence (1 reference)

PMID:41567639 SUPPORT Human Clinical

"HCC typically arises in patients with chronic liver disease, including hepatitis, cirrhosis, and non-alcoholic fatty liver diseases."

States that hepatocellular carcinoma typically arises in patients with chronic liver disease including hepatitis, naming both the exposure and this node's substrate.

Alcohol and aflatoxin exposure

Alcohol and aflatoxin can cooperate with viral and cirrhotic injury to drive aggressive HCC.

Show evidence (1 reference)

PMID:29984212 SUPPORT Human Clinical

"The interaction of aflatoxin B1 (a contaminant found in food) with HBV infection is believed to increase the prevalence of HCC."

This supports aflatoxin exposure as a contributor to HCC risk, particularly in the context of HBV co-infection.

Mechanism Target:

PREDISPOSES Chronic Liver Injury and Cirrhosis — Graded below the hepatitis and cirrhosis links into this same node for two reasons that are worth stating rather than leaving to inference: the cited sentence covers only the aflatoxin half of this bundled exposure and says nothing about alcohol, and it is hedged as a belief about prevalence rather than a measured interaction.

Show evidence (1 reference)

PMID:29984212 SUPPORT Human Clinical

"The interaction of aflatoxin B1 (a contaminant found in food) with HBV infection is believed to increase the prevalence of HCC."

Reports that aflatoxin B1 interacting with hepatitis B infection is believed to raise hepatocellular carcinoma prevalence. It supports the aflatoxin component only, and at the level of population prevalence rather than liver substrate.

🔬

Biochemical Markers

Alpha-Fetoprotein (AFP)

Liver Function Tests

PIVKA-II (DCP)

🔬

Diagnosis

Ultrasound and AFP Surveillance

High-risk patients, especially those with cirrhosis or chronic HBV, are surveilled with repeated liver ultrasonography plus serum alpha-fetoprotein to detect HCC at an earlier, potentially curable stage.

ultrasonography procedure NCIT:C19337

Markers: Alpha-fetoprotein (AFP)

Results: Detection of a suspicious liver lesion or rising AFP prompts diagnostic cross-sectional imaging.

Show evidence (1 reference)

DOI:10.3350/cmh.2024.0824 SUPPORT Human Clinical

"Biannual liver ultrasonography and serum α-fetoprotein are the primary surveillance tools for early HCC detection among high-risk patients (e.g., cirrhosis, chronic HBV)."

This review summarizes current surveillance practice using liver ultrasound plus AFP in high-risk patients.

Multiphasic CT/MRI or Contrast-Enhanced Ultrasound Imaging Diagnosis

In high-risk patients, HCC can be diagnosed noninvasively using guideline imaging algorithms such as LI-RADS/EASL that combine arterial phase hyperenhancement, washout, capsule, size, and growth features on contrast-enhanced CT, MRI, or ultrasound.

clinical assessment NCIT:C124351

Results: LI-RADS or comparable guideline category consistent with definitive HCC.

Show evidence (2 references)

DOI:10.1007/s00330-024-10606-w SUPPORT Human Clinical

"These allow the diagnosis of HCC in high-risk patients in the presence of typical imaging features on contrast-enhanced CT, MRI, or contrast-enhanced ultrasound."

ESR/ESGAR practice recommendations summarize the noninvasive imaging context for HCC diagnosis.

DOI:10.1007/s00330-024-10606-w SUPPORT Human Clinical

"Size, non-rim arterial phase hyperenhancement, non-peripheral washout, enhancing capsule, and growth are major imaging features and they should be combined for the diagnosis of HCC."

This supports the specific imaging features used in LI-RADS/EASL-style diagnostic algorithms.

BCLC Staging Assessment

Barcelona Clinic Liver Cancer staging integrates tumor burden, liver function, and performance status to classify HCC stage and guide treatment selection.

clinical assessment NCIT:C124351

Results: BCLC stage assignment used for prognosis and treatment planning.

Show evidence (1 reference)

DOI:10.1007/s12029-023-00961-0 SUPPORT Human Clinical

"Fourteen guidelines (67%) endorsed using the BCLC staging system."

This systematic review of guidelines supports BCLC staging as a commonly endorsed HCC staging framework.

🪜

Stages

Localized

Disease confined to the liver without vascular invasion or extrahepatic spread, where resection, transplantation, ablation, or transarterial therapy with curative or disease-controlling intent is possible.

Advanced/Metastatic

Advanced HCC with vascular invasion, portal vein tumor thrombus, or extrahepatic spread most often to lung, bone, adrenal gland, or lymph node. The metastatic phenotype develops on a background of chronic liver disease, viral hepatitis, cirrhosis, and frequent activation of Wnt/beta-catenin and angiogenic signaling pathways.

Folded in from the former Metastatic_HCC entry (cancer granularity ladder, design decisions §3a). Portal vein invasion and extrahepatic spread define the transition from locally advanced to metastatic biology; alpha-fetoprotein (AFP) is an important biomarker in advanced HCC when interpreted alongside imaging and underlying liver function. Clinically detected extrahepatic metastasis develops in roughly 13% of treated HCC patients by 5 years (PMID:18710423).

Show evidence (1 reference)

PMID:18710423 SUPPORT Other

"The incidence rate of extrahepatic metastasis, as detected during the lifetime after medical treatment of HCC, was approximately 13% at 5 years."

Quantifies progression to the extrahepatic metastatic stage after HCC treatment.

📊

Related Datasets

Exome-sequencing identifies new oncogenes and tumor suppressor genes recurrently altered in hepatocellular carcinoma ega:EGAS00001000217

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. High-resolution copy number analysis of 125 tumors of which 24 were subjected to whole-exome sequencing identified 135 homozygous deletions and 994 somatic gene mutations with predicted functional consequences. We identified new recurrent alterations in 4 genes (ARID1A, RPS6KA3, NFE2L2 and IRF2) not previously described in HCC. Functional analyses demonstrated tumor suppressor properties for IRF2 whose inactivation, exclusively found in hepatitis B virus related tumors, leads to impaired TP53 function.

human WES

PMID:22561517

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Hepatocellular Carcinoma"); description-level mentions were not accepted. EGA study_type: Exome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

Whole genome sequencing of hepatocellular carcinoma tumors and their matched noncancerous liver tissues and the background germline ega:EGAS00001000325

We performed whole-genome sequencing on multifocal hepatocellular carcinoma tumors and their matched noncancerous liver tissues and the background germline. We found that the noncancerous liver tissues presented varying degrees of genomic alterations that were associated with the background liver diseases. Most of the genomic alterations in the metastatic tumors were inherited from the primary tumor and a small number developed de novo. Few genomic alterations were shared between the multicentric tumors with the exception of the alterations that also existed in the noncancerous liver tissue.

human WGS

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Hepatocellular Carcinoma"); description-level mentions were not accepted. EGA study_type: Whole Genome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

Poly(A) RNA sequencing of hepatocellular carcinoma tumors and their matched noncancerous liver tissues ega:EGAS00001000372

We performed poly(A) RNA sequencing on multiple hepatocellular carcinoma tumors and their matched noncancerous liver tissues.

human BULK RNA SEQ

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Hepatocellular Carcinoma"); description-level mentions were not accepted. EGA study_type: Transcriptome Analysis. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma metabolomics_workbench:ST000230

Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Hepatocellular Carcinoma"). Retrieved 2026-08-02.

Identification of Race-Associated Metabolite Biomarkers for Hepatocellular Carcinoma metabolomics_workbench:ST000865

Metabolomic Analysis of Liver Tissues for Characterization of Hepatocellular Carcinoma metabolomics_workbench:ST001152

A Single-Cell Atlas of the Multicellular Ecosystem of Primary and Metastatic Hepatocellular Carcinoma ega:EGAS00001004468

Hepatocellular carcinoma (HCC) represents a paradigm of the relation between tumor microenvironment (TME) and tumor development. Here, we generated a single-cell atlas of the multicellular ecosystem of HCCs from four relevant sites. Antitumor central memory T (TCM) cells were found in tertiary lymphoid structures (TLSs). Chronic HBV/HCV infection increases infiltration of CD8+ T cells in tumors but aggravates T cell exhaustion. We identified CD11b+ macrophages to be terminally differentiated tumor-associated macrophages (TAMs) and two distinct differentiation trajectories contribute to their accumulation.

human

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Metastatic Hepatocellular Carcinoma"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

{ }

Source YAML

click to show

name: Hepatocellular Carcinoma
creation_date: '2026-01-26T02:55:13Z'
description: >-
  Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, typically
  arising
  in the setting of chronic liver disease and cirrhosis. Major risk factors include
  chronic
  hepatitis B or C infection, alcohol-related liver disease, and metabolic dysfunction-associated
  steatotic liver disease (MASLD/NAFLD). HCC pathogenesis involves multiple molecular
  pathways
  including WNT/beta-catenin, TP53, telomere maintenance, and chromatin remodeling.
  The
  combination of atezolizumab (anti-PD-L1) plus bevacizumab (anti-VEGF) has established
  immunotherapy as first-line treatment for advanced HCC, based on the IMbrave150
  trial.
categories:
- Gastrointestinal Cancer
- Hepatobiliary Cancer
- Liver Cancer
parents:
- liver carcinoma
has_subtypes:
- name: Viral Hepatitis-Associated HCC
  description: >-
    HCC arising in the context of chronic hepatitis B or C infection. HBV can be directly
    oncogenic through viral integration, while HCV promotes HCC primarily through
    cirrhosis
    and chronic inflammation.
- name: Alcohol-Related HCC
  description: >-
    HCC arising in alcohol-related liver disease and cirrhosis. Associated with specific
    molecular features and generally presents at more advanced stage.
- name: MASLD-Associated HCC
  description: >-
    HCC arising in metabolic dysfunction-associated steatotic liver disease (formerly
    NAFLD/NASH).
    Increasingly common subtype that can occur even without cirrhosis. May have distinct
    immune microenvironment features affecting immunotherapy response.
- name: Fibrolamellar HCC
  description: >-
    Rare variant occurring in younger patients without cirrhosis. Characterized by
    DNAJB1-PRKACA
    fusion. Distinct clinical behavior and treatment considerations.
  mappings:
    ncit_mappings:
    - term:
        id: NCIT:C4131
        label: Fibrolamellar Carcinoma
      mapping_predicate: skos:closeMatch
      mapping_source: NCIT
      mapping_justification: NCIT provides a closely aligned fibrolamellar carcinoma term for this HCC subtype.
mechanistic_hypotheses:
- hypothesis_group_id: rpp40_rnase_p_pretrna_mtor_myc_bridge
  hypothesis_label: RNase P Pre-tRNA Processing as the RPP40-mTOR/MYC Bridge
  status: EMERGING
  description: >-
    Elevated RPP40 may sustain mTOR/MYC output in established hepatocellular
    carcinoma specifically because its contribution to RNase P preserves
    5-prime pre-tRNA maturation and translational capacity. This narrow model
    predicts that an RNase P/pre-tRNA defect after acute RPP40 loss precedes
    signaling decline and is phenocopied by an RNase-P-specific perturbation.
    RPP40 is also shared with RNase MRP, however, and independent HCC evidence
    linking RPP40 to ribosomal-RNA and ribosomal-gene expression makes an
    RNase MRP/pre-rRNA or broader ribosome-biogenesis route a direct competitor.
    Neither published HCC study establishes the proposed RNase P ordering.
  evidence:
  - reference: PMID:42424930
    reference_title: RPP40, a subunit of Ribonuclease P, facilitates hepatocellular carcinoma proliferation by activating the mTOR/MYC signaling.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Analysis showed that RPP40 expression was markedly upregulated in HCC
      tissues compared to adjacent normal tissues. High RPP40 expression
      correlated with poorer clinical outcomes, even among patients with
      matched histological grade or pathological stage.
    explanation: >-
      Multi-dataset human-tumor associations support expression and prognostic
      correlation, but they do not establish whether RPP40 is a driver,
      dependency, or consequence of proliferative state.
  - reference: PMID:42424930
    reference_title: RPP40, a subunit of Ribonuclease P, facilitates hepatocellular carcinoma proliferation by activating the mTOR/MYC signaling.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      RPP40 suppression attenuated cellular migration and proliferation, whereas
      its overexpression enhanced these malignant phenotypes both in vitro and
      in vivo.
    explanation: >-
      This item classifies the cell-culture component of the mixed result. The
      Huh-7 and HepG2 perturbations support an RPP40-dependent malignant
      phenotype in vitro, but did not test pre-tRNA maturation or RNase-P
      specificity.
  - reference: PMID:42424930
    reference_title: RPP40, a subunit of Ribonuclease P, facilitates hepatocellular carcinoma proliferation by activating the mTOR/MYC signaling.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      RPP40 suppression attenuated cellular migration and proliferation, whereas
      its overexpression enhanced these malignant phenotypes both in vitro and
      in vivo.
    explanation: >-
      This separately classifies the subcutaneous mouse-xenograft component of
      the mixed result. It supports an in-vivo model phenotype but neither
      human-tumor causality nor an RNase-P/pre-tRNA mechanism.
  - reference: PMID:42424930
    reference_title: RPP40, a subunit of Ribonuclease P, facilitates hepatocellular carcinoma proliferation by activating the mTOR/MYC signaling.
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      The mTOR/MYC signaling pathway was pinpointed as the key pathway regulated
      by RPP40 in HCC.
    explanation: >-
      The integrated pathway analysis nominates mTOR/MYC downstream of RPP40,
      but the abstract does not establish the intervening RNA-processing branch.
  notes: >-
    This hypothesis is intentionally not wired as a causal pathograph edge.
    Evidence supports the flanking RPP40 and mTOR/MYC observations, not the
    proposed RNase-P/pre-tRNA bridge.
stages:
- name: Localized
  description: >-
    Disease confined to the liver without vascular invasion or extrahepatic
    spread, where resection, transplantation, ablation, or transarterial
    therapy with curative or disease-controlling intent is possible.
- name: Advanced/Metastatic
  description: >-
    Advanced HCC with vascular invasion, portal vein tumor thrombus, or
    extrahepatic spread most often to lung, bone, adrenal gland, or lymph
    node. The metastatic phenotype develops on a background of chronic liver
    disease, viral hepatitis, cirrhosis, and frequent activation of
    Wnt/beta-catenin and angiogenic signaling pathways.
  notes: >-
    Folded in from the former Metastatic_HCC entry (cancer granularity ladder,
    design decisions §3a). Portal vein invasion and extrahepatic spread define
    the transition from locally advanced to metastatic biology;
    alpha-fetoprotein (AFP) is an important biomarker in advanced HCC when
    interpreted alongside imaging and underlying liver function. Clinically
    detected extrahepatic metastasis develops in roughly 13% of treated HCC
    patients by 5 years (PMID:18710423).
  evidence:
  - reference: PMID:18710423
    reference_title: "Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The incidence rate of extrahepatic metastasis, as detected during the lifetime after medical treatment of HCC, was approximately 13% at 5 years.
    explanation: Quantifies progression to the extrahepatic metastatic stage after HCC treatment.
pathophysiology:
- name: Chronic Liver Injury and Cirrhosis
  conforms_to: "tumor_promoting_inflammation#Chronic Inflammatory Stimulus"
  description: >-
    Most HCC arises in the context of chronic liver disease and cirrhosis. Persistent
    hepatocyte death and regeneration in an inflammatory environment promotes accumulation
    of genetic alterations. Cirrhosis itself is a premalignant condition with ongoing
    oxidative stress and genomic instability.
  evidence:
  - reference: PMID:41567639
    reference_title: "Identification of novel germline and somatic mutations associated with hepatocellular carcinoma by next-generation sequencing."
    supports: SUPPORT
    snippet: HCC typically arises in patients with chronic liver disease, including hepatitis, cirrhosis, and non-alcoholic fatty liver diseases.
    explanation: This abstract states that HCC commonly arises in chronic liver disease and cirrhosis, supporting the mechanism described.
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  downstream:
  - target: Telomere Dysfunction and Genomic Instability
    description: Repeated hepatocyte division leads to telomere shortening
  - target: Accumulation of Driver Mutations
    description: Chronic regeneration promotes mutation accumulation
- name: Telomere Dysfunction and Genomic Instability
  conforms_to: "enabling_replicative_immortality#Replicative Senescence and Crisis Barrier"
  description: >-
    Chronic hepatocyte proliferation leads to telomere shortening, causing genomic
    instability.
    TERT promoter mutations, which are the most common HCC mutations, reactivate telomerase
    to enable unlimited replication. This creates a checkpoint bypass allowing survival
    of genetically unstable cells.
  biological_processes:
  - preferred_term: telomere maintenance
    modifier: ABNORMAL
    term:
      id: GO:0000723
      label: telomere maintenance
  downstream:
  - target: WNT/Beta-Catenin Pathway Activation
    description: Genomic instability promotes acquisition of pathway-activating mutations
- name: Accumulation of Driver Mutations
  conforms_to: "genome_instability_mutation#Mutator Phenotype and Chromosomal Instability"
  description: >-
    Multiple driver genes are recurrently mutated in HCC, including TERT promoter
    (60%),
    TP53 (30%), CTNNB1 (30%), AXIN1 (10%), and ARID1A (10%). These mutations affect
    telomere maintenance, cell cycle control, WNT signaling, and chromatin remodeling.
  biological_processes:
  - preferred_term: DNA repair
    modifier: DECREASED
    term:
      id: GO:0006281
      label: DNA repair
  downstream:
  - target: PI3K/AKT/mTOR Pathway Activation
    description: Somatic and expression-level pathway changes select for oncogenic growth signaling.
- name: WNT/Beta-Catenin Pathway Activation
  description: >-
    Activating mutations in CTNNB1 (beta-catenin) or inactivating mutations in AXIN1
    lead to constitutive WNT pathway activation. This drives cell proliferation and
    is
    associated with a distinct molecular subclass of HCC with specific clinical features
    including cholestasis and immune exclusion.
  biological_processes:
  - preferred_term: Wnt signaling pathway
    modifier: INCREASED
    term:
      id: GO:0016055
      label: Wnt signaling pathway
  downstream:
  - target: Enhanced Hepatocyte Proliferation
    description: WNT signaling drives cell proliferation and stemness
  - target: Portal Vein Invasion and Tumor Thrombus
    description: >-
      Wnt/beta-catenin activation promotes hepatocyte migration and survival and
      can contribute to vascular invasion and metastatic progression in a subset
      of HCCs.
- name: PI3K/AKT/mTOR Pathway Activation
  description: >-
    PI3K/AKT/mTOR signaling is a recurrent oncogenic axis in HCC. PI3K/Akt
    activation is reported in 40-60% of HCC tissue, and dysregulated
    pathway-associated genes and upstream receptor inputs increase AKT/TOR
    signaling, supporting hepatocyte survival, anabolic growth, proliferation, and
    immune infiltration patterns relevant to targeted therapy and immunotherapy
    response.
  biological_processes:
  - preferred_term: TOR signaling
    modifier: INCREASED
    term:
      id: GO:0031929
      label: TOR signaling
  - preferred_term: phosphatidylinositol-mediated signaling
    modifier: INCREASED
    term:
      id: GO:0048015
      label: phosphatidylinositol-mediated signaling
  evidence:
  - reference: PMID:29984212
    reference_title: Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The signaling pathways known to be activated in HCC tissue include the Wnt/β-catenin pathway (up to 50% of HCC), the phosphatidylinositol-3-kinase and protein kinase B (PI3K/Akt) pathway (40–60% of HCC), the Myc pathway (30–60%), the Hedgehog pathway (50–60%), and the MET pathway (30–40%).
    explanation: This review summarizes human HCC tissue data and supports recurrent PI3K/Akt activation in a large fraction of HCC.
  - reference: PMID:35592706
    reference_title: "PI3K/AKT/mTOR Pathway-Associated Genes Reveal a Putative Prognostic Signature Correlated with Immune Infiltration in Hepatocellular Carcinoma."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: The dysregulated PI3K/AKT/mTOR pathway acts as the main regulator of tumorigenesis in hepatocellular carcinoma (HCC).
    explanation: >-
      This bioinformatic HCC cohort analysis directly supports PI3K/AKT/mTOR
      dysregulation as an oncogenic signaling axis and links pathway-associated
      gene signatures to immune infiltration.
  downstream:
  - target: Enhanced Hepatocyte Proliferation
    description: PI3K/AKT/mTOR activation promotes tumor-cell growth and survival signaling.
  - target: Immune Evasion and Immunosuppressive Microenvironment
    description: Pathway-associated signatures correlate with immune infiltration and checkpoint expression.
  - target: Aerobic Glycolysis and Metabolic Reprogramming
    description: >-
      Oncogenic PI3K/AKT/mTOR signaling drives the anabolic, glycolytic
      reprogramming modeled by the deregulated-cellular-energetics module.
- name: TP53 Pathway Inactivation
  conforms_to: "evading_growth_suppressors#Tumor Suppressor Inactivation"
  description: >-
    TP53 mutations are common in HCC, particularly in HBV-associated and aflatoxin-associated
    tumors. Loss of p53 function removes a critical checkpoint, allowing survival
    of cells
    with DNA damage and promoting genomic instability.
  biological_processes:
  - preferred_term: apoptotic process
    modifier: DECREASED
    term:
      id: GO:0006915
      label: apoptotic process
- name: Enhanced Hepatocyte Proliferation
  conforms_to: "sustaining_proliferative_signaling#Growth-Factor-Independent Proliferation"
  description: >-
    Combined effects of telomerase reactivation, cell cycle checkpoint loss, and
    mitogenic signaling drive uncontrolled hepatocyte proliferation and tumor growth.
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
- name: Angiogenesis and VEGF Signaling
  conforms_to: "tumor_angiogenesis#Angiogenic Switch and VEGF-Driven Neovascularization"
  description: >-
    HCC is a highly vascular tumor dependent on angiogenesis. VEGF signaling promotes
    new blood vessel formation supplying the tumor. VEGF also has immunosuppressive
    effects, contributing to the immune-excluded microenvironment. This provides the
    rationale for anti-VEGF therapy in combination with immunotherapy.
  evidence:
  - reference: PMID:19637355
    reference_title: "Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature."
    supports: SUPPORT
    snippet: "Hepatocellular carcinoma (HCC) is a highly vascular tumor, and angiogenesis is believed to play a considerable role in its development and progression."
    explanation: "Abstract notes HCC is highly vascular and angiogenesis plays a major role, supporting this mechanism."
  biological_processes:
  - preferred_term: angiogenesis
    modifier: INCREASED
    term:
      id: GO:0001525
      label: angiogenesis
  downstream:
  - target: Immune Evasion and Immunosuppressive Microenvironment
    description: VEGF-mediated immunosuppression contributes to T cell exclusion and checkpoint upregulation
- name: Immune Evasion and Immunosuppressive Microenvironment
  conforms_to: "immune_checkpoint_blockade#Adaptive Immune Resistance"
  description: >-
    HCC develops in a chronically inflamed liver with an inherently
    immunosuppressive microenvironment. Tumor cells upregulate PD-L1,
    VEGF-mediated immunosuppression excludes effector T cells, and
    recruitment of regulatory T cells, myeloid-derived suppressor cells,
    and tumor-associated macrophages creates an immune-tolerant niche.
    The combination of anti-PD-L1 with anti-VEGF addresses both the
    checkpoint-mediated and VEGF-mediated immunosuppression.
  cell_types:
  - preferred_term: CD8-positive, alpha-beta T cell
    term:
      id: CL:0000625
      label: CD8-positive, alpha-beta T cell
  biological_processes:
  - preferred_term: Negative Regulation of T Cell Mediated Immunity
    term:
      id: GO:0002710
      label: negative regulation of T cell mediated immunity
    modifier: INCREASED
  evidence:
  - reference: PMID:32158599
    reference_title: "Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The HCC tumor microenvironment is characterized by a dysfunction of
      the immune system through multiple mechanisms, including accumulation
      of various immunosuppressive factors, recruitment of regulatory T cells
      and myeloid-derived suppressor cells, and induction of T cell exhaustion
      accompanied with the interaction between immune checkpoint ligands and
      receptors.
    explanation: >-
      Review specifically describes HCC's immunosuppressive microenvironment
      including Treg and MDSC recruitment, T cell exhaustion, and checkpoint
      ligand-receptor interactions — directly supporting all claims in this
      node about HCC immune evasion mechanisms.
  - reference: PMID:41794264
    reference_title: "Reshaping the immunosuppressive niche in hepatocellular carcinoma: crosstalk networks, metabolic reprogramming, and therapeutic strategies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The liver tumor microenvironment plays a pivotal role in hepatocellular carcinoma (HCC) progression by fostering immune suppression, which impairs anti-tumor responses and enables tumor growth, invasion, and metastasis.
    explanation: Supports the immunosuppressive microenvironment enabling invasion and metastasis; folded in from the former Metastatic_HCC entry.
- name: Aerobic Glycolysis and Metabolic Reprogramming
  conforms_to: "deregulated_cellular_energetics#Aerobic Glycolysis (Warburg Effect)"
  biological_scale: CELLULAR
  description: >-
    HCC cells reprogram metabolism from oxidative phosphorylation to aerobic glycolysis
    (Warburg effect), enabling rapid ATP regeneration and providing carbon intermediates
    for biosynthesis. This metabolic shift is driven by oncogenic signaling (PI3K/AKT,
    MYC) and supports the high proliferative rate of hepatocellular carcinomas. The
    mechanism linking mitochondrial acetyl-CoA homeostasis to pyruvate transport and
    glycolytic switching remains incompletely characterized.
  biological_processes:
  - preferred_term: Glycolytic Process
    modifier: INCREASED
    term:
      id: GO:0006096
      label: glycolytic process
  evidence:
  - reference: PMID:19460998
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      most cancer cells produce large amounts of lactate regardless of the
      availability of oxygen
    explanation: >-
      Directly states the Warburg phenotype this node models — lactate production
      despite adequate oxygen. This is the same on-claim evidence the module's
      central-effector node carries. Evidence source is OTHER because this is a
      review article.
  - reference: PMID:42520527
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Mechanistically, ACAA2 downregulation reduces mitochondrial acetyl-CoA levels, thereby decreasing mitochondrial pyruvate carrier 1 (MPC1) acetylation and accelerating its proteasomal degradation, which ultimately impairs mitochondrial pyruvate transport to promote glycolysis and cell proliferation.
    explanation: >-
      HCC-specific specialization of the generic module claim: work in HCC-derived
      lines shows loss of mitochondrial pyruvate transport driving the glycolytic
      shift, and links that shift directly to proliferation.
  downstream:
  - target: Enhanced Hepatocyte Proliferation
    description: >-
      The glycolytic shift supplies the ATP and biosynthetic carbon that sustain
      the high proliferative rate; PMID:42520527 reports impaired mitochondrial
      pyruvate transport promoting glycolysis and cell proliferation together.
- name: Portal Vein Invasion and Tumor Thrombus
  conforms_to: "invasion_and_metastasis#Local Invasion and Intravasation"
  description: >-
    Vascular invasion is a defining step in metastatic HCC. Tumor cells leave the
    cancer
    nest, traverse extracellular matrix and vascular barriers, and colonize the portal
    vein,
    creating portal vein tumor thrombus and enabling dissemination.
  evidence:
  - reference: PMID:36318440
    reference_title: "Portal vein tumor thrombosis in hepatocellular carcinoma: molecular mechanism and therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Liver cancer cells potentially experienced multi-steps during PVTT process, including cancer cells leave from cancer nest, migrate in extracellular matrix, invade the vascular barrier, and colonize in the portal vein.
    explanation: This directly supports the sequential invasion biology underlying portal vein tumor thrombus.
  biological_processes:
  - preferred_term: cell migration
    modifier: INCREASED
    term:
      id: GO:0016477
      label: cell migration
  - preferred_term: positive regulation of cell migration
    modifier: INCREASED
    term:
      id: GO:0030335
      label: positive regulation of cell migration
histopathology:
- name: Hepatocellular Carcinoma
  finding_term:
    preferred_term: Hepatocellular Carcinoma
    term:
      id: NCIT:C3099
      label: Hepatocellular Carcinoma
  frequency: VERY_FREQUENT
  description: Hepatocellular carcinoma is the most common primary liver malignancy.
  evidence:
  - reference: PMID:27785449
    reference_title: "Hepatocellular carcinoma: a review."
    supports: SUPPORT
    snippet: "Hepatocellular carcinoma (HCC) is the most common primary liver malignancy"
    explanation: Abstract states that HCC is the most common primary liver malignancy.

phenotypes:
- category: Hepatic
  name: Hepatomegaly
  frequency: FREQUENT
  description: >-
    Liver enlargement from tumor mass. May be palpable as a hard, irregular mass in
    the
    right upper quadrant.
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
- category: Hepatic
  name: Ascites
  frequency: FREQUENT
  description: >-
    Abdominal fluid accumulation from portal hypertension (cirrhosis) and/or tumor-related
    factors. Presence indicates advanced disease and decompensated liver function.
  phenotype_term:
    preferred_term: Ascites
    term:
      id: HP:0001541
      label: Ascites
  evidence:
  - reference: PMID:36396345
    reference_title: "Advanced hepatocellular carcinoma and palliative care: a scoping review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients with advanced hepatocellular carcinoma (HCC) have specific palliative care needs owing to the influence of the disease on abdominal pain, jaundice, bleeding, appetite, ascites, liver function and hepatic encephalopathy.
    explanation: This supports ascites as a key clinical feature of advanced HCC.
- category: Hepatic
  name: Jaundice
  frequency: OCCASIONAL
  description: >-
    Yellowing of skin and sclera from elevated bilirubin. May result from biliary
    obstruction
    by tumor, hepatic failure, or diffuse tumor infiltration.
  phenotype_term:
    preferred_term: Jaundice
    term:
      id: HP:0000952
      label: Jaundice
  evidence:
  - reference: PMID:36396345
    reference_title: "Advanced hepatocellular carcinoma and palliative care: a scoping review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients with advanced hepatocellular carcinoma (HCC) have specific palliative care needs owing to the influence of the disease on abdominal pain, jaundice, bleeding, appetite, ascites, liver function and hepatic encephalopathy.
    explanation: This supports jaundice as a key clinical feature of advanced HCC.
- category: Gastrointestinal
  name: Abdominal Pain
  frequency: FREQUENT
  description: >-
    Right upper quadrant pain or discomfort from liver capsule distension or tumor
    growth.
    Sudden severe pain may indicate tumor rupture.
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
  evidence:
  - reference: PMID:36396345
    reference_title: "Advanced hepatocellular carcinoma and palliative care: a scoping review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients with advanced hepatocellular carcinoma (HCC) have specific palliative care needs owing to the influence of the disease on abdominal pain, jaundice, bleeding, appetite, ascites, liver function and hepatic encephalopathy.
    explanation: This supports abdominal pain as a key clinical feature of advanced HCC.
- category: Constitutional
  name: Weight Loss
  frequency: VERY_FREQUENT
  description: >-
    Unintentional weight loss is common in HCC due to cancer cachexia, reduced oral
    intake,
    and altered metabolism.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
- category: Constitutional
  name: Fatigue
  frequency: VERY_FREQUENT
  description: >-
    Fatigue from liver dysfunction, anemia, and cancer-related factors.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Gastrointestinal
  name: Nausea
  frequency: FREQUENT
  description: >-
    Nausea and anorexia from liver dysfunction and advanced disease.
  phenotype_term:
    preferred_term: Nausea
    term:
      id: HP:0002018
      label: Nausea
biochemical:
- name: Alpha-Fetoprotein (AFP)
  notes: >-
    Serum AFP is elevated in approximately 60% of HCC cases. Levels greater than 400
    ng/mL
    are highly specific for HCC in the setting of cirrhosis. Used for diagnosis (with
    imaging) and monitoring treatment response. AFP-L3 fraction improves specificity.
- name: Liver Function Tests
  notes: >-
    Elevated transaminases, alkaline phosphatase, and bilirubin may occur. Pattern
    depends
    on underlying liver disease and tumor burden. Child-Pugh score assesses hepatic
    reserve
    and guides treatment decisions.
- name: PIVKA-II (DCP)
  notes: >-
    Des-gamma-carboxy prothrombin is an alternative biomarker to AFP. May be elevated
    when AFP is normal. Useful in combination with AFP for surveillance and diagnosis.
diagnosis:
- name: Ultrasound and AFP Surveillance
  description: >-
    High-risk patients, especially those with cirrhosis or chronic HBV, are
    surveilled with repeated liver ultrasonography plus serum alpha-fetoprotein
    to detect HCC at an earlier, potentially curable stage.
  diagnosis_term:
    preferred_term: ultrasonography procedure
    term:
      id: NCIT:C19337
      label: Diagnostic Ultrasound
  markers: Alpha-fetoprotein (AFP)
  results: Detection of a suspicious liver lesion or rising AFP prompts diagnostic cross-sectional imaging.
  evidence:
  - reference: DOI:10.3350/cmh.2024.0824
    reference_title: 'Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Biannual liver ultrasonography and serum α-fetoprotein are the primary surveillance tools for early HCC detection among high-risk patients (e.g., cirrhosis, chronic HBV).
    explanation: This review summarizes current surveillance practice using liver ultrasound plus AFP in high-risk patients.
- name: Multiphasic CT/MRI or Contrast-Enhanced Ultrasound Imaging Diagnosis
  description: >-
    In high-risk patients, HCC can be diagnosed noninvasively using guideline
    imaging algorithms such as LI-RADS/EASL that combine arterial phase
    hyperenhancement, washout, capsule, size, and growth features on
    contrast-enhanced CT, MRI, or ultrasound.
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: NCIT:C124351
      label: Clinical Evaluation
  results: LI-RADS or comparable guideline category consistent with definitive HCC.
  evidence:
  - reference: DOI:10.1007/s00330-024-10606-w
    reference_title: 'ESR Essentials: diagnosis of hepatocellular carcinoma—practice recommendations by ESGAR'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These allow the diagnosis of HCC in high-risk patients in the presence of typical imaging features on contrast-enhanced CT, MRI, or contrast-enhanced ultrasound.
    explanation: ESR/ESGAR practice recommendations summarize the noninvasive imaging context for HCC diagnosis.
  - reference: DOI:10.1007/s00330-024-10606-w
    reference_title: 'ESR Essentials: diagnosis of hepatocellular carcinoma—practice recommendations by ESGAR'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Size, non-rim arterial phase hyperenhancement, non-peripheral washout, enhancing capsule, and growth are major imaging features and they should be combined for the diagnosis of HCC.
    explanation: This supports the specific imaging features used in LI-RADS/EASL-style diagnostic algorithms.
- name: BCLC Staging Assessment
  description: >-
    Barcelona Clinic Liver Cancer staging integrates tumor burden, liver function,
    and performance status to classify HCC stage and guide treatment selection.
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: NCIT:C124351
      label: Clinical Evaluation
  results: BCLC stage assignment used for prognosis and treatment planning.
  evidence:
  - reference: DOI:10.1007/s12029-023-00961-0
    reference_title: 'Clinical Practice Guidelines For the Management of Hepatocellular Carcinoma: A Systematic Review'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Fourteen guidelines (67%) endorsed using the BCLC staging system.
    explanation: This systematic review of guidelines supports BCLC staging as a commonly endorsed HCC staging framework.
genetic:
- name: TERT Promoter
  association: Somatic Activating Mutation
  notes: >-
    TERT promoter mutations (C228T, C250T) are the most common genetic alterations
    in HCC,
    present in approximately 60% of cases. These mutations create binding sites for
    ETS
    transcription factors, reactivating telomerase expression and enabling unlimited
    cell division.
  evidence:
  - reference: PMID:40243493
    reference_title: "Geographic and Viral Etiology Patterns of TERT Promoter and CTNNB1 Exon 3 Mutations in Hepatocellular Carcinoma: A Comprehensive Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Our analysis, encompassing over 4000 HCC cases, revealed that TERTp mutations were present in 49.2% of tumors, with C228T being the predominant variant (93.3% among mutated cases).
    explanation: Supports TERT promoter mutation as the most frequent somatic alteration in HCC.
- name: TP53
  gene_term:
    preferred_term: TP53
    term:
      id: hgnc:11998
      label: TP53
  association: Somatic Loss of Function
  notes: >-
    TP53 mutations occur in approximately 30% of HCC, enriched in HBV-associated and
    aflatoxin-associated tumors. The R249S hotspot mutation is specifically associated
    with aflatoxin B1 exposure.
  evidence:
  - reference: PMID:29391887
    reference_title: "Targeted sequencing of cancer-associated genes in hepatocellular carcinoma using next-generation sequencing."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most common somatic mutations identified were tumor protein 53 (TP53; 35.6%) and β-catenin 1 (CTNNB1; 30.5%), and the most frequent variants of those genes were missense variants.
    explanation: Supports TP53 as a recurrent somatic alteration in HCC.
- name: CTNNB1
  gene_term:
    preferred_term: CTNNB1
    term:
      id: hgnc:2514
      label: CTNNB1
  association: Somatic Activating Mutation
  notes: >-
    CTNNB1 (beta-catenin) mutations occur in approximately 30% of HCC, causing constitutive
    WNT pathway activation. Associated with distinct clinical features including
    cholestasis and immune exclusion, potentially affecting immunotherapy response.
  evidence:
  - reference: PMID:40243493
    reference_title: "Geographic and Viral Etiology Patterns of TERT Promoter and CTNNB1 Exon 3 Mutations in Hepatocellular Carcinoma: A Comprehensive Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: CTNNB1 exon 3 mutations were identified in 23.1% of HCCs, showing a similar association with viral etiology, being more common in HCV-related cases (30.7%) than in HBV-related tumors (12.8%).
    explanation: Supports CTNNB1 as a frequent driver mutation in HCC with etiology-specific patterns.
- name: AXIN1
  gene_term:
    preferred_term: AXIN1
    term:
      id: hgnc:903
      label: AXIN1
  association: Somatic Loss of Function
  notes: >-
    AXIN1 inactivating mutations occur in approximately 10% of HCC, also activating
    WNT signaling. AXIN1 and CTNNB1 mutations are typically mutually exclusive.
- name: ARID1A
  gene_term:
    preferred_term: ARID1A
    term:
      id: hgnc:11110
      label: ARID1A
  association: Somatic Loss of Function
  notes: >-
    ARID1A mutations affect chromatin remodeling and occur in approximately 10% of
    HCC.
    Part of the SWI/SNF complex alterations seen across multiple cancer types.
treatments:
- name: Atezolizumab plus Bevacizumab
  description: >-
    First-line standard of care for unresectable HCC based on IMbrave150 trial. Anti-PD-L1
    (atezolizumab) combined with anti-VEGF (bevacizumab) demonstrated superior overall
    survival compared to sorafenib. Requires adequate liver function (Child-Pugh A)
    and no high-risk varices. Immunotherapy trials in HCC require careful interpretation due to
    delayed treatment effects and potential violations of proportional hazard assumptions,
    which may affect the apparent magnitude of benefit from surrogate endpoints like PFS.
  notes: >-
    HCC trial interpretation requires careful consideration of endpoint selection and
    validity of surrogates. Overall survival remains the most robust endpoint, though
    progression-free survival, time-to-progression, and objective response rate are
    frequently used to accelerate drug development. The validity of surrogate endpoints
    in HCC is debated due to tumor heterogeneity, competing risks related to liver disease
    (e.g., hepatic decompensation, hepatic encephalopathy), and the influence of
    post-progression therapies. Immunotherapy trials like IMbrave150 present additional
    challenges: delayed treatment effects that violate traditional proportional hazards
    assumptions and complex patterns of response not fully captured by conventional
    endpoint definitions. These methodological nuances should be considered when
    interpreting efficacy data and comparing trials with different endpoints and
    follow-up durations.
  evidence:
  - reference: PMID:39687036
    reference_title: "Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib"
    explanation: "IMbrave150 abstract reports improved overall and progression-free survival with atezolizumab plus bevacizumab versus sorafenib."
  - reference: PMID:42184925
    reference_title: "Beyond hazard ratios: interpreting trial endpoints and survival analysis in systemic therapy for hepatocellular carcinoma."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "immunotherapy has introduced challenges to traditional statistical models through delayed treatment effects and violations of the proportional hazard assumption"
    explanation: >-
      This methodology review highlights critical interpretation issues for immunotherapy trials in HCC, including delayed treatment effects and proportional hazards violations that affect OS and PFS endpoint validity in IMbrave150 and similar trials.
  - reference: PMID:38502889
    reference_title: "Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Atezolizumab + bevacizumab (atezo + bev) or durvalumab + tremelimumab (durva + treme) may be offered first-line for patients with advanced HCC, Child-Pugh class A liver disease, and Eastern Cooperative Oncology Group performance status 0-1."
    explanation: The 2024 ASCO guideline recommends atezolizumab plus bevacizumab as a first-line option for advanced HCC with Child-Pugh A liver function.
  - reference: DOI:10.1159/000539897
    reference_title: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in IMbrave150.
    explanation: IMbrave150 supports atezolizumab plus bevacizumab in unresectable HCC, including portal-vein-invasion disease; folded in from the former Metastatic_HCC entry.
  treatment_term:
    preferred_term: immunotherapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
    therapeutic_agent:
    - preferred_term: atezolizumab
      term:
        id: NCIT:C106250
        label: Atezolizumab
    - preferred_term: bevacizumab
      term:
        id: NCIT:C2039
        label: Bevacizumab
  target_mechanisms:
  - target: Immune Evasion and Immunosuppressive Microenvironment
    treatment_effect: INHIBITS
    description: >-
      Atezolizumab (anti-PD-L1) blocks PD-L1-mediated T cell suppression
      while bevacizumab (anti-VEGF) reverses VEGF-mediated immunosuppression,
      together restoring anti-tumor immunity in HCC.
    evidence:
    - reference: PMID:39687036
      reference_title: "Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib"
      explanation: >-
        Superior outcomes with combined anti-PD-L1/anti-VEGF demonstrate that
        targeting both checkpoint-mediated and VEGF-mediated immunosuppression
        is effective in HCC.
  - target: Angiogenesis and VEGF Signaling
    treatment_effect: INHIBITS
    description: >-
      Bevacizumab directly inhibits VEGF-driven angiogenesis that sustains
      HCC tumor growth.
    evidence:
    - reference: PMID:32402160
      reference_title: "Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        atezolizumab combined with bevacizumab resulted in better overall and
        progression-free survival outcomes than sorafenib.
      explanation: >-
        The IMbrave150 trial established the anti-VEGF antibody bevacizumab
        (combined with atezolizumab) as effective first-line therapy, supporting
        its action on the angiogenesis/VEGF-signaling node in HCC.
- name: Durvalumab plus Tremelimumab
  description: >-
    Alternative first-line immunotherapy option. HIMALAYA trial demonstrated durvalumab
    (anti-PD-L1) with single priming dose of tremelimumab (anti-CTLA-4) improves survival
    compared to sorafenib. Option for patients who cannot receive bevacizumab. Like other
    HCC immunotherapy trials, trial interpretation requires careful consideration of delayed treatment
    effects and proportional hazards violations when assessing surrogate endpoints.
  evidence:
  - reference: PMID:38382875
    reference_title: "Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly improved overall survival (OS) versus sorafenib; durvalumab monotherapy was noninferior to sorafenib for OS."
    explanation: >-
      The phase III HIMALAYA trial provides primary efficacy evidence that the STRIDE regimen (durvalumab plus a single priming dose of tremelimumab) significantly improved overall survival versus sorafenib, directly anchoring the efficacy claim in the treatment description.
  - reference: PMID:42184925
    reference_title: "Beyond hazard ratios: interpreting trial endpoints and survival analysis in systemic therapy for hepatocellular carcinoma."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The validity of surrogate endpoints in hepatocellular carcinoma remains debated due to tumor heterogeneity, competing risks related to liver disease, and the influence of post‑progression therapies"
    explanation: >-
      This methodology review clarifies critical context for HIMALAYA trial interpretation: surrogate endpoints (PFS, TTP, ORR) in HCC are complicated by tumor heterogeneity, competing risks from underlying cirrhosis, and post-progression therapy confounding, highlighting why OS improvement is particularly meaningful for durvalumab + tremelimumab.
  treatment_term:
    preferred_term: immunotherapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
    therapeutic_agent:
    - preferred_term: durvalumab
      term:
        id: NCIT:C103194
        label: Durvalumab
    - preferred_term: tremelimumab
      term:
        id: NCIT:C49085
        label: Tremelimumab
  target_mechanisms:
  - target: Immune Evasion and Immunosuppressive Microenvironment
    treatment_effect: INHIBITS
    description: >-
      Durvalumab (anti-PD-L1) blocks adaptive immune resistance while
      tremelimumab (anti-CTLA-4) priming dose expands the T cell repertoire,
      together overcoming the immunosuppressive HCC microenvironment.
    evidence:
    - reference: PMID:38382875
      reference_title: "Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly
        improved overall survival (OS) versus sorafenib; durvalumab monotherapy
        was noninferior to sorafenib for OS.
      explanation: >-
        The phase III HIMALAYA study shows dual anti-CTLA-4/anti-PD-L1 blockade
        (STRIDE) improves survival, supporting its action on the immune-evasion
        and immunosuppressive-microenvironment node in HCC.
- name: Sorafenib
  target_mechanisms:
  - target: Angiogenesis and VEGF Signaling
    treatment_effect: INHIBITS
    description: Sorafenib is a multikinase inhibitor with anti-angiogenic activity (VEGFR/PDGFR/RAF), suppressing the VEGF-driven neovascularization that sustains HCC growth.
  description: >-
    Multi-kinase inhibitor targeting RAF, VEGFR, and PDGFR. Was first systemic therapy
    to improve survival in HCC. Now used in second line or when immunotherapy is
    contraindicated.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: sorafenib
      term:
        id: CHEBI:50924
        label: sorafenib
  evidence:
  - reference: PMID:38502889
    reference_title: "Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Where there are contraindications to these therapies, sorafenib, lenvatinib, or durvalumab may be offered first-line."
    explanation: The 2024 ASCO guideline offers sorafenib (or lenvatinib/durvalumab) first-line when atezolizumab-bevacizumab or durvalumab-tremelimumab are contraindicated.
- name: Lenvatinib
  target_mechanisms:
  - target: Angiogenesis and VEGF Signaling
    treatment_effect: INHIBITS
    description: Lenvatinib is a multikinase inhibitor targeting VEGFR1-3 and FGFR1-4, inhibiting tumor angiogenesis in HCC.
  description: >-
    Multi-kinase inhibitor with activity against VEGFR, FGFR, PDGFR, RET, and KIT.
    Non-inferior to sorafenib in first line. Alternative when immunotherapy not appropriate.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: lenvatinib
      term:
        id: CHEBI:85994
        label: lenvatinib
- name: Surgical Resection
  description: >-
    Potentially curative for early-stage HCC in patients with preserved liver function
    (Child-Pugh A). Limited by underlying cirrhosis in many patients. Requires adequate
    future liver remnant.
  treatment_term:
    preferred_term: hepatic resection
    term:
      id: NCIT:C15249
      label: Hepatectomy
- name: Liver Transplantation
  description: >-
    Potentially curative treatment that addresses both tumor and underlying cirrhosis.
    Milan criteria (single tumor 5 cm or less or up to 3 tumors each 3 cm or less,
    no
    vascular invasion, no metastases) guide patient selection. Limited by organ availability.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: NCIT:C15289
      label: Organ Transplantation
- name: Transarterial Chemoembolization (TACE)
  description: >-
    Locoregional therapy delivering chemotherapy directly to tumor via hepatic artery
    followed by embolization. Standard for intermediate-stage HCC (BCLC-B). Can be
    used
    as bridge to transplant or with systemic therapy.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: NCIT:C15632
      label: Chemotherapy
- name: Radiofrequency/Microwave Ablation
  description: >-
    Thermal ablation for small tumors (typically less than 3 cm). Effective alternative
    to resection for early-stage HCC, particularly in patients with limited liver
    function.
  treatment_term:
    preferred_term: ablation therapy
    term:
      id: NCIT:C20985
      label: Ablation Therapy
disease_term:
  preferred_term: hepatocellular carcinoma
  term:
    id: MONDO:0007256
    label: hepatocellular carcinoma
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0007256
      label: hepatocellular carcinoma
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: MONDO provides an exact disease term for hepatocellular carcinoma.
  icd10cm_mappings:
  - term:
      id: ICD10CM:C22.0
      label: Liver cell carcinoma
    mapping_predicate: skos:exactMatch
    mapping_source: ICD-10-CM
    mapping_justification: ICD-10-CM provides an exact code for liver cell carcinoma / hepatocellular carcinoma.
  ncit_mappings:
  - term:
      id: NCIT:C3099
      label: Hepatocellular Carcinoma
    mapping_predicate: skos:exactMatch
    mapping_source: NCIT
    mapping_justification: NCIT provides an exact neoplasm term for hepatocellular carcinoma.

classifications:
  icdo_morphology:
    classification_value: Carcinoma
  harrisons_chapter:
  - classification_value: ONCOLOGY_HEMATOLOGY
    evidence:
    - reference: DOI:10.1007/s00330-024-10606-w
      reference_title: "ESR Essentials: diagnosis of hepatocellular carcinoma—practice recommendations by ESGAR"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy and a leading cause of cancer related death worldwide."
      explanation: ESR/ESGAR practice recommendations characterise HCC as a primary hepatic malignancy and a leading cancer cause of death, anchoring the Harrison's Oncology and Hematology classification.
  - classification_value: GASTROINTESTINAL
    evidence:
    - reference: DOI:10.1007/s00330-024-10606-w
      reference_title: "ESR Essentials: diagnosis of hepatocellular carcinoma—practice recommendations by ESGAR"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy and a leading cause of cancer related death worldwide."
      explanation: The same review locates HCC in the liver, supporting an additional Harrison's Gastrointestinal classification since hepatic cancers are addressed in the GI Part.
discussions:
- discussion_id: gap_rpp40_trna_processing_mtor_myc_causality
  prompt: >-
    Does RPP40 sustain mTOR/MYC signaling in hepatocellular carcinoma
    specifically through RNase P-mediated 5-prime pre-tRNA maturation, or are
    the reported effects better explained by RNase MRP/pre-rRNA and ribosome
    biogenesis, an RPP40-specific noncanonical activity, or expression
    downstream of proliferative state?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - mechanistic_hypotheses#rpp40_rnase_p_pretrna_mtor_myc_bridge
  - pathophysiology#PI3K/AKT/mTOR Pathway Activation
  - pathophysiology#Enhanced Hepatocyte Proliferation
  rationale: >-
    RNase P and RNase MRP are distinct ribonucleoprotein complexes that share
    RPP40: RNase P removes 5-prime leaders from pre-tRNAs, whereas RNase MRP
    processes pre-rRNA in ribosome biogenesis. PMID:42424930 reports RPP40
    perturbation phenotypes and nominates mTOR/MYC, but it does not measure
    either RNA-processing branch or establish temporal ordering. PMID:40517827
    independently links RPP40 to ribosomal-RNA and ribosomal-gene transcription
    in HCC cells, making an rRNA/ribosome-biogenesis route a concrete competing
    explanation without proving RNase MRP catalytic mediation. Pan-cancer
    profiling further classifies RPP40 as a broadly essential,
    cell-cycle-coupled dependency, raising a generic biosynthetic-demand
    alternative without proving that RPP40 elevation is merely downstream in
    HCC. Independent HCC evidence also places mTORC1 upstream of a
    ribosome-biogenesis effector, so reverse directionality remains plausible.
    The current evidence therefore does not justify a causal
    RPP40-to-mTOR/MYC graph edge.
  proposed_experiments:
  - experiment_id: exp_rpp40_processing_dependence_and_epistasis
    name: >-
      Acute complex-specific RPP40-RNase P/RNase MRP branch test
    description: >-
      First compare acute depletion of shared-subunit RPP40 with an
      RNase-P-specific perturbation and an RNase-MRP-specific perturbation in
      two authenticated HCC-derived lines. Collect targeted RNA-processing,
      signaling, and proliferation measurements before loss of viability. Only
      after this primary branch-selection stage should branch-specific rescue,
      mTOR/MYC epistasis, global omics, or organoid validation be added.
    experiment_type:
      preferred_term: time-resolved complex-specific perturbation study
    model_systems:
    - name: Authenticated HCC-derived cell-line pair
      description: >-
        Use Huh-7 plus an independently authenticated HCC-derived line such as
        Hep3B, with short time courses and matched perturbation efficiency.
    - name: HepG2 seed-study replication model
      description: >-
        Retain HepG2 only as a secondary replication context because it was used
        in the cited study; label it correctly as hepatoblastoma-derived rather
        than as an HCC-derived line.
    perturbations:
    - name: Acute RPP40 depletion
      target: gene#RPP40
      description: >-
        Use inducible degradation or CRISPR interference with multiple reagents
        and sample before secondary cell-cycle arrest or loss of viability.
      gene:
        preferred_term: RPP40
        term:
          id: hgnc:20992
          label: RPP40
    - name: RNase-P-specific perturbation
      target: gene#RPP21
      description: >-
        Acutely deplete RPP21, an RNase-P-specific protein subunit, with an
        orthogonal RPPH1 perturbation reserved for confirmation.
      gene:
        preferred_term: RPP21
        term:
          id: hgnc:21300
          label: RPP21
    - name: RNase-MRP-specific perturbation
      target: gene#C18orf21
      description: >-
        Acutely deplete the RNase-MRP-specific subunit C18orf21 (RMP24), with an
        orthogonal RMRP perturbation reserved for confirmation.
      gene:
        preferred_term: C18orf21
        term:
          id: hgnc:28802
          label: C18orf21
    - name: Combined RNase-P-specific and RNase-MRP-specific perturbation
      target: gene#RPP21
      description: >-
        Acutely co-deplete RPP21 and C18orf21, with simultaneous RPPH1 and RMRP
        perturbation as an orthogonal confirmation, to reproduce the dual
        RNase-P and RNase-MRP loss caused by shared-subunit RPP40 depletion.
        This arm is required before an RPP40-only phenotype is interpreted as
        noncanonical rather than as synergy between the two processing defects.
      genes:
      - preferred_term: RPP21
        term:
          id: hgnc:21300
          label: RPP21
      - preferred_term: C18orf21
        term:
          id: hgnc:28802
          label: C18orf21
    - name: Conditional downstream mTOR/MYC epistasis
      target: pathophysiology#PI3K/AKT/mTOR Pathway Activation
      description: >-
        After a processing branch is selected, test whether independent mTORC1
        or MYC activation rescues the branch-specific signaling and
        proliferation phenotype. This orders downstream signaling but cannot by
        itself identify the upstream RNA-processing branch.
      genes:
      - preferred_term: MTOR
        term:
          id: hgnc:3942
          label: MTOR
      - preferred_term: MYC
        term:
          id: hgnc:7553
          label: MYC
    - name: Reciprocal mTOR/MYC and proliferation-state perturbation
      target: pathophysiology#PI3K/AKT/mTOR Pathway Activation
      description: >-
        After the branch-selection stage, acutely inhibit mTORC1 or MYC and
        independently impose a matched proliferation arrest without depleting
        RPP40. Measure early RPP40 transcript and protein abundance and both
        RNA-processing outputs to test the competing possibility that RPP40
        elevation is downstream of oncogenic signaling or proliferative state.
      genes:
      - preferred_term: MTOR
        term:
          id: hgnc:3942
          label: MTOR
      - preferred_term: MYC
        term:
          id: hgnc:7553
          label: MYC
    readouts:
    - name: RNase P pre-tRNA maturation
      target: biological_process#tRNA processing
      description: >-
        Quantify 5-prime-leader-containing pre-tRNAs and
        precursor-to-mature-tRNA ratios at early time points.
      biological_processes:
      - preferred_term: tRNA processing
        term:
          id: GO:0008033
          label: tRNA processing
      assays:
      - preferred_term: precursor-specific RT-qPCR
      - preferred_term: northern blot
    - name: RNase MRP pre-rRNA and 40S maturation
      target: biological_process#rRNA processing
      description: >-
        Quantify uncleaved ITS1-containing pre-rRNA, mature 18S-rRNA production,
        and the 40S-to-60S ribosomal-subunit ratio at matched early time points.
      biological_processes:
      - preferred_term: rRNA processing
        term:
          id: GO:0006364
          label: rRNA processing
      assays:
      - preferred_term: ITS1-specific RT-qPCR and northern blot
      - preferred_term: sucrose-gradient polysome profiling
    - name: mTOR/MYC temporal response
      target: pathophysiology#PI3K/AKT/mTOR Pathway Activation
      description: >-
        Measure phospho-S6K, phospho-4E-BP1, and MYC protein alongside nascent
        translation before proliferation or viability diverges.
      assays:
      - preferred_term: immunoblot time course
      - preferred_term: nascent-protein-synthesis assay
    - name: Proliferation and viability
      target: pathophysiology#Enhanced Hepatocyte Proliferation
      description: >-
        Measure EdU incorporation, cell-cycle state, and viability so early
        pathway effects can be separated from later generic ribosome-loss
        toxicity.
      assays:
      - preferred_term: EdU incorporation assay
      - preferred_term: live-cell viability assay
    controls:
    - name: Perturbation controls
      description: >-
        Use non-targeting and multiple independent guides, mock-degron controls,
        matched perturbation efficiencies, and prespecified early sampling
        windows.
    - name: Complex-specific activity controls
      description: >-
        Require RPP21 loss to produce its expected pre-tRNA defect and C18orf21
        loss to produce its expected pre-rRNA defect before interpreting a
        negative signaling result.
    - name: Matched dual-complex activity control
      description: >-
        Require the combined RPP21-plus-C18orf21 or RPPH1-plus-RMRP arm to match
        the early pre-tRNA and pre-rRNA defects produced by RPP40 loss before
        using a discordant signaling phenotype to infer an RPP40-specific
        noncanonical activity.
    decision_criterion: >-
      The RNase-P/pre-tRNA bridge is supported only if RPP40 loss and
      RNase-P-specific loss share an early pre-tRNA defect followed by the same
      mTOR/MYC decline, while a validated RNase-MRP-specific perturbation causes
      its expected pre-rRNA defect without that early signaling signature. An
      RNase MRP alternative is favored, and the narrow RNase P hypothesis is
      refuted in that model, if RPP40 and C18orf21/RMRP perturbations instead
      share an ordered pre-rRNA/40S defect and mTOR/MYC decline while RPP21/RPPH1
      loss impairs pre-tRNA maturation without the signaling effect. A
      signaling change unique to RPP40 favors a noncanonical role only if a
      combined RNase-P-specific plus RNase-MRP-specific perturbation matches
      both early processing defects without reproducing that signaling change;
      discordance from either single perturbation alone may instead reflect
      dual-loss synergy. Signaling changes that appear only after generalized
      translation failure, cell-cycle arrest, or loss of viability do not
      establish either branch. Reciprocal mTOR/MYC inhibition and matched
      proliferation arrest support the downstream-state alternative if they
      reduce RPP40 before either processing output changes. Branch-specific
      rescue and bidirectional mTOR/MYC epistasis should be attempted only after
      this primary discriminator is met.
    would_support:
    - mechanistic_hypotheses#rpp40_rnase_p_pretrna_mtor_myc_bridge
    would_refute:
    - mechanistic_hypotheses#rpp40_rnase_p_pretrna_mtor_myc_bridge
    evidence:
    - reference: PMID:41136609
      reference_title: RNase MRP subunit composition and role in 40S ribosome biogenesis.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Notably, RNase P includes a unique subunit, RPP21, whereas no RNase
        MRP-specific proteins have been found in humans, limiting molecular
        analyses of RNase MRP function. Here, we identify the RNase MRP-specific
        proteins, C18orf21 (RMP24) and NEPRO (RMP64).
      explanation: >-
        This human-cell study supplies experimentally defined complex-specific
        perturbation handles for the primary RNase P-versus-RNase MRP
        discriminator; it does not establish an HCC mechanism.
    - reference: PMID:40533478
      reference_title: Reversible proliferative arrest induced by rapid depletion of RNase MRP.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Here we report that rapid depletion of RNase MRP, a deeply conserved
        RNA-based enzyme required for rRNA biosynthesis, induces a long-term yet
        reversible proliferative arrest in human cells. Severely compromised
        biogenesis of rRNAs along with acute transcriptional reprogramming
        precede a gradual decline of the critical cellular functions.
      explanation: >-
        The temporal sequence after rapid RNase MRP depletion supports early
        RNA-processing measurements and cautions against interpreting later
        proliferative arrest as an HCC-specific mTOR/MYC mechanism.
  evidence:
  - reference: PMID:42424930
    reference_title: RPP40, a subunit of Ribonuclease P, facilitates hepatocellular carcinoma proliferation by activating the mTOR/MYC signaling.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      While the ribonucleoprotein complex subunit RPP40 plays a critical role in
      precursor tRNA processing and has demonstrated prognostic value in several
      cancer types, its specific function and underlying mechanisms in HCC
      pathogenesis remain poorly understood.
    explanation: >-
      The seed paper explicitly identifies the unresolved HCC mechanism while
      separating RPP40's known canonical role from the HCC-specific question.
  - reference: PMID:40517827
    reference_title: Ribonuclease P/MRP subunit RPP40 coordinates the transcription of pre-rRNA and ribosomal protein genes to promote Hepatocellular carcinoma malignancy.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Our findings reveal that RPP40 can coordinate the transcription of
      ribosomal RNA and the expression of ribosomal genes, thereby promoting the
      malignancy of HCC.
    explanation: >-
      A separate HCC-cell study provides a concrete rRNA/ribosomal-gene
      alternative to the proposed pre-tRNA bridge, but does not establish RNase
      MRP-mediated pre-rRNA processing or temporal ordering upstream of
      mTOR/MYC.
  - reference: PMID:41933259
    reference_title: Comprehensive profiling of RPP40 across human cancers reveals its essential role and multidimensional clinical correlates.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      RPP40 expression was significantly upregulated in most cancers and their
      subtypes
    explanation: >-
      Pan-cancer patient-tumor expression supports a broadly shared association
      and motivates testing HCC selectivity. It does not establish dependency,
      directionality, or an HCC-specific processing mechanism.
  - reference: PMID:41933259
    reference_title: Comprehensive profiling of RPP40 across human cancers reveals its essential role and multidimensional clinical correlates.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      it was identified as a broadly essential gene for cancer cell survival.
    explanation: >-
      The integrated CRISPR-screen result supports a broad cancer-cell
      dependency rather than HCC selectivity. It does not identify the relevant
      RNase P or RNase MRP branch or show that RPP40 elevation is downstream of
      proliferation.
  - reference: PMID:41933259
    reference_title: Comprehensive profiling of RPP40 across human cancers reveals its essential role and multidimensional clinical correlates.
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      Functionally, RPP40 likely promotes tumor proliferation by activating cell
      cycle pathways, and its expression displays strong cell cycle dependency.
    explanation: >-
      Integrated pathway and cell-cycle analyses support the
      proliferative-state alternative, but the authors' qualified inference
      does not establish causal ordering in HCC.
  - reference: PMID:37247644
    reference_title: Nucleolar HEAT Repeat Containing 1 Up-regulated by the Mechanistic Target of Rapamycin Complex 1 Signaling Promotes Hepatocellular Carcinoma Growth by Dominating Ribosome Biogenesis and Proteome Homeostasis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      HEATR1 expression was regulated by the transcription factor specificity
      protein 1, which can be activated by insulin-like growth factor
      1-mammalian target of rapamycin complex 1 signaling in HCC cells.
    explanation: >-
      This independent HCC-cell result places mTORC1 upstream of a
      ribosome-biogenesis effector and therefore supports the experiment's
      reverse-direction test. It does not test RPP40, RNase P, or RNase MRP.
- discussion_id: gap_acaa2_mpc1_acetylation_pyruvate_transport
  prompt: >-
    Does ACAA2-dependent mitochondrial acetyl-CoA homeostasis regulate metabolic
    switching from oxidative phosphorylation to aerobic glycolysis in HCC specifically
    through MPC1 protein acetylation and proteasomal stability, or do alternative
    mechanisms of acetyl-CoA-dependent regulation (histone acetylation, other protein
    targets, non-acetylation sensing) dominate?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Aerobic Glycolysis and Metabolic Reprogramming
  rationale: >-
    PMID:42520527 demonstrates that ACAA2 downregulation reduces mitochondrial acetyl-CoA,
    leading to MPC1 acetylation loss, MPC1 proteasomal degradation, and impaired pyruvate
    transport with consequent glycolytic shift. However, the paper does not directly
    measure acetyl-CoA-dependent protein acetylation stoichiometry, does not use
    acetylation-site-specific MPC1 mutations to establish acetylation as mechanistically
    sufficient, and does not test proteasomal inhibitors or direct acetyl-CoA supplementation.
    Alternative explanations remain open: direct allosteric effects of acetyl-CoA on MPC1,
    ACAA2-FAO support for histone acetylation and epigenetic reprogramming upstream of
    MPC1, acetylation of autophagy or mitochondrial chaperone machinery affecting MPC1
    indirectly, and competing acetyl-CoA sources (glutaminolysis, pyruvate carboxylase)
    that may bypass this pathway.
  proposed_experiments:
  - experiment_id: exp_acaa2_acetyl_coa_mpc1_acetylation_causality
    name: Acetyl-CoA and MPC1 acetylation-site mechanism
    description: >-
      Test acetylation-site sufficiency by combining acute ACAA2 depletion, direct
      acetyl-CoA pathway manipulation (ACS2 inhibition, pyruvate carboxylase inhibition),
      and MPC1 acetylation-site mutation (K99R or identified sites) in HCC-derived lines
      (Huh-7, Hep3B). Measure MPC1 acetylation stoichiometry via mass-spec or
      acetyl-lysine blots, MPC1 protein stability (pulse-chase or proteasomal inhibition),
      pyruvate oxidation (13C-pyruvate tracing), and glycolytic flux (ATP, ECAR, lactate)
      to validate the proposed chain. Use catalytically defective ACAA2 variants to
      distinguish FAO-dependent acetyl-CoA from other ACAA2 functions.
    experiment_type:
      preferred_term: protein acetylation and metabolic switching mechanism study
    model_systems:
    - name: HCC-derived cell lines with metabolic tracing
      description: >-
        Huh-7 and Hep3B lines with 13C-pyruvate tracing to distinguish pyruvate
        oxidation, glycolytic lactate, alanine synthesis, and anaplerosis under
        perturbation.
  evidence:
  - reference: PMID:42520527
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      While acetyl-CoA acts as a pivotal metabolic molecule involved in protein acetylation, whether ACAA2 regulates metabolic reprogramming through acetyl-CoA-mediated mitochondrial protein acetylation remains unclear.
    explanation: >-
      Authors explicitly identify the unresolved role of acetyl-CoA-mediated protein
      acetylation in ACAA2-dependent metabolic switching, the core of this gap.
  - reference: PMID:42520527
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Mounting evidence indicates that metabolic reprogramming contributes substantially to tumor development by promoting cancer cell proliferation and metastasis. However, the underlying mechanisms remain incompletely understood.
    explanation: >-
      Establishes the broader mechanistic gap in HCC metabolic reprogramming that
      this ACAA2-acetyl-CoA-MPC1-pyruvate axis helps address.
references:
- reference: DOI:10.1007/s00330-024-10606-w
  title: 'ESR Essentials: diagnosis of hepatocellular carcinoma—practice recommendations by ESGAR'
  found_in:
  - Hepatocellular_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy and a leading cause of cancer related death worldwide.
    supporting_text: Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy and a leading cause of cancer related death worldwide.
    evidence:
    - reference: DOI:10.1007/s00330-024-10606-w
      reference_title: 'ESR Essentials: diagnosis of hepatocellular carcinoma—practice recommendations by ESGAR'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy and a leading cause of cancer related death worldwide.
      explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.1007/s12029-023-00961-0
  title: 'Clinical Practice Guidelines For the Management of Hepatocellular Carcinoma: A Systematic Review'
  found_in:
  - Hepatocellular_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, including Australia.
    supporting_text: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, including Australia.
    evidence:
    - reference: DOI:10.1007/s12029-023-00961-0
      reference_title: 'Clinical Practice Guidelines For the Management of Hepatocellular Carcinoma: A Systematic Review'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, including Australia.
      explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.1159/000539371
  title: EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  found_in:
  - Hepatocellular_Carcinoma-deep-research-falcon.md
  findings:
  - statement: EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    supporting_text: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the presence of one or more cardiometabolic risk factor(s) and the absence of harmful alcohol intake.
    evidence:
    - reference: DOI:10.1159/000539371
      reference_title: EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the presence of one or more cardiometabolic risk factor(s) and the absence of harmful alcohol intake.
      explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.1186/s12885-023-11112-w
  title: 'Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis'
  found_in:
  - Hepatocellular_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Atezolizumab plus bevacizumab was approved in 2020 as a first-line treatment for advanced hepatocellular carcinoma (HCC).
    supporting_text: Atezolizumab plus bevacizumab was approved in 2020 as a first-line treatment for advanced hepatocellular carcinoma (HCC).
    evidence:
    - reference: DOI:10.1186/s12885-023-11112-w
      reference_title: 'Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Atezolizumab plus bevacizumab was approved in 2020 as a first-line treatment for advanced hepatocellular carcinoma (HCC).
      explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.1186/s12885-024-12407-2
  title: Genomic profiling informs therapies and prognosis for patients with hepatocellular carcinoma in clinical practice
  found_in:
  - Hepatocellular_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Hepatocellular carcinoma (HCC) genomic research has discovered actionable genetic changes that might guide treatment decisions and clinical trials.
    supporting_text: Hepatocellular carcinoma (HCC) genomic research has discovered actionable genetic changes that might guide treatment decisions and clinical trials.
    evidence:
    - reference: DOI:10.1186/s12885-024-12407-2
      reference_title: Genomic profiling informs therapies and prognosis for patients with hepatocellular carcinoma in clinical practice
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Hepatocellular carcinoma (HCC) genomic research has discovered actionable genetic changes that might guide treatment decisions and clinical trials.
      explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.1186/s12920-024-01965-w
  title: Genomic landscape of hepatocellular carcinoma in Egyptian patients by whole exome sequencing
  found_in:
  - Hepatocellular_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Genomic landscape of hepatocellular carcinoma in Egyptian patients by whole exome sequencing
    supporting_text: Genomic landscape of hepatocellular carcinoma in Egyptian patients by whole exome sequencing
- reference: DOI:10.1186/s12943-024-02062-3
  title: 'Single-cell tumor heterogeneity landscape of hepatocellular carcinoma: unraveling the pro-metastatic subtype and its interaction loop with fibroblasts'
  found_in:
  - Hepatocellular_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Tumor heterogeneity presents a formidable challenge in understanding the mechanisms driving tumor progression and metastasis.
    supporting_text: Tumor heterogeneity presents a formidable challenge in understanding the mechanisms driving tumor progression and metastasis.
    evidence:
    - reference: DOI:10.1186/s12943-024-02062-3
      reference_title: 'Single-cell tumor heterogeneity landscape of hepatocellular carcinoma: unraveling the pro-metastatic subtype and its interaction loop with fibroblasts'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Tumor heterogeneity presents a formidable challenge in understanding the mechanisms driving tumor progression and metastasis.
      explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.1200/jco.23.02745
  title: 'Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update'
  found_in:
  - Hepatocellular_Carcinoma-deep-research-falcon.md
  findings:
  - statement: To update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC).
    supporting_text: To update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC).
    evidence:
    - reference: DOI:10.1200/jco.23.02745
      reference_title: 'Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: To update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC).
      explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.14744/hf.2023.2023.0028
  title: Cross talk between genetics and biochemistry in the pathogenesis of hepatocellular carcinoma
  found_in:
  - Hepatocellular_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Cross talk between genetics and biochemistry in the pathogenesis of hepatocellular carcinoma
    supporting_text: Cross talk between genetics and biochemistry in the pathogenesis of hepatocellular carcinoma
- reference: DOI:10.20517/2394-5079.2024.16
  title: Introduction to 2023 Chinese expert consensus on the whole-course management of hepatocellular carcinoma
  found_in:
  - Hepatocellular_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Introduction to 2023 Chinese expert consensus on the whole-course management of hepatocellular carcinoma
    supporting_text: Introduction to 2023 Chinese expert consensus on the whole-course management of hepatocellular carcinoma
- reference: DOI:10.21037/hbsn-22-469
  title: 'A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights'
  found_in:
  - Hepatocellular_Carcinoma-deep-research-falcon.md
  findings:
  - statement: 'A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights'
    supporting_text: 'A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights'
- reference: DOI:10.2147/jhc.s478604
  title: 'Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study'
  found_in:
  - Hepatocellular_Carcinoma-deep-research-falcon.md
  findings:
  - statement: 'Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study'
    supporting_text: 'Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study'
- reference: DOI:10.3350/cmh.2024.0824
  title: 'Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment'
  found_in:
  - Hepatocellular_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Hepatocellular carcinoma (HCC) is a major global burden, ranking as the third leading cause of cancer-related mortality.
    supporting_text: Hepatocellular carcinoma (HCC) is a major global burden, ranking as the third leading cause of cancer-related mortality.
    evidence:
    - reference: DOI:10.3350/cmh.2024.0824
      reference_title: 'Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Hepatocellular carcinoma (HCC) is a major global burden, ranking as the third leading cause of cancer-related mortality.
      explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.3389/fphar.2024.1416295
  title: Novel genetic alterations in liver cancer distinguish distinct clinical outcomes and combination immunotherapy responses
  found_in:
  - Hepatocellular_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Genomic profiling has revolutionized therapeutic interventions and the clinical management of liver cancer.
    supporting_text: Genomic profiling has revolutionized therapeutic interventions and the clinical management of liver cancer.
    evidence:
    - reference: DOI:10.3389/fphar.2024.1416295
      reference_title: Novel genetic alterations in liver cancer distinguish distinct clinical outcomes and combination immunotherapy responses
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Genomic profiling has revolutionized therapeutic interventions and the clinical management of liver cancer.
      explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.3390/biom14060656
  title: Molecular Mechanisms in Tumorigenesis of Hepatocellular Carcinoma and in Target Treatments—An Overview
  found_in:
  - Hepatocellular_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Hepatocellular carcinoma is the most common primary malignancy of the liver, with hepatocellular differentiation.
    supporting_text: Hepatocellular carcinoma is the most common primary malignancy of the liver, with hepatocellular differentiation.
    evidence:
    - reference: DOI:10.3390/biom14060656
      reference_title: Molecular Mechanisms in Tumorigenesis of Hepatocellular Carcinoma and in Target Treatments—An Overview
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Hepatocellular carcinoma is the most common primary malignancy of the liver, with hepatocellular differentiation.
      explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.3390/biomedicines12071624
  title: 'Preclinical Models of Hepatocellular Carcinoma: Current Utility, Limitations, and Challenges'
  found_in:
  - Hepatocellular_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Hepatocellular carcinoma (HCC), the predominant primary liver tumor, remains one of the most lethal cancers worldwide, despite the advances in therapy in recent years.
    supporting_text: Hepatocellular carcinoma (HCC), the predominant primary liver tumor, remains one of the most lethal cancers worldwide, despite the advances in therapy in recent years.
    evidence:
    - reference: DOI:10.3390/biomedicines12071624
      reference_title: 'Preclinical Models of Hepatocellular Carcinoma: Current Utility, Limitations, and Challenges'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Hepatocellular carcinoma (HCC), the predominant primary liver tumor, remains one of the most lethal cancers worldwide, despite the advances in therapy in recent years.
      explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.3390/cancers16030666
  title: 'Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape'
  found_in:
  - Hepatocellular_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Liver cancer is the third most common cause of cancer-related deaths worldwide, and hepatocellular carcinoma (HCC) makes up the majority of liver cancer cases.
    supporting_text: Liver cancer is the third most common cause of cancer-related deaths worldwide, and hepatocellular carcinoma (HCC) makes up the majority of liver cancer cases.
    evidence:
    - reference: DOI:10.3390/cancers16030666
      reference_title: 'Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Liver cancer is the third most common cause of cancer-related deaths worldwide, and hepatocellular carcinoma (HCC) makes up the majority of liver cancer cases.
      explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.3390/cancers16050901
  title: 'Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets'
  found_in:
  - Hepatocellular_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Liver cancer, predominantly hepatocellular carcinoma (HCC), globally ranks sixth in incidence and third in cancer-related deaths.
    supporting_text: Liver cancer, predominantly hepatocellular carcinoma (HCC), globally ranks sixth in incidence and third in cancer-related deaths.
    evidence:
    - reference: DOI:10.3390/cancers16050901
      reference_title: 'Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Liver cancer, predominantly hepatocellular carcinoma (HCC), globally ranks sixth in incidence and third in cancer-related deaths.
      explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.3390/cancers16233933
  title: 'Hepatocellular Carcinoma Surveillance Strategies: Major Guidelines and Screening Advances'
  found_in:
  - Hepatocellular_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, with prognosis and treatment outcomes that are significantly influenced by the stage at diagnosis.
    supporting_text: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, with prognosis and treatment outcomes that are significantly influenced by the stage at diagnosis.
    evidence:
    - reference: DOI:10.3390/cancers16233933
      reference_title: 'Hepatocellular Carcinoma Surveillance Strategies: Major Guidelines and Screening Advances'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, with prognosis and treatment outcomes that are significantly influenced by the stage at diagnosis.
      explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.3748/wjg.v30.i19.2488
  title: Hepatocellular carcinoma-the role of the underlying liver disease in clinical practice
  found_in:
  - Hepatocellular_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality.
    supporting_text: Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality.
    evidence:
    - reference: DOI:10.3748/wjg.v30.i19.2488
      reference_title: Hepatocellular carcinoma-the role of the underlying liver disease in clinical practice
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality.
      explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.4254/wjh.v16.i5.716
  title: 'Genetic screening of liver cancer: State of the art'
  found_in:
  - Hepatocellular_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Liver cancer, primarily hepatocellular carcinoma, remains a global health challenge with rising incidence and limited therapeutic options.
    supporting_text: Liver cancer, primarily hepatocellular carcinoma, remains a global health challenge with rising incidence and limited therapeutic options.
    evidence:
    - reference: DOI:10.4254/wjh.v16.i5.716
      reference_title: 'Genetic screening of liver cancer: State of the art'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Liver cancer, primarily hepatocellular carcinoma, remains a global health challenge with rising incidence and limited therapeutic options.
      explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.7150/thno.95971
  title: Single cell analyses reveal the PD-1 blockade response-related immune features in hepatocellular carcinoma
  found_in:
  - Hepatocellular_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Single cell analyses reveal the PD-1 blockade response-related immune features in hepatocellular carcinoma
    supporting_text: Single cell analyses reveal the PD-1 blockade response-related immune features in hepatocellular carcinoma
- reference: DOI:10.1159/000539897
  title: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150
  found_in:
  - Hepatocellular_Carcinoma-deep-research-falcon.md
  findings: []
- reference: DOI:10.1001/jamanetworkopen.2024.45525
  title: Trends in Hepatocellular Carcinoma Mortality Rates in the US and Projections Through 2040
  found_in:
  - Metastatic_HCC-deep-research-falcon.md
  findings:
  - statement: ImportanceThe burden of liver cancer varies worldwide.
    supporting_text: ImportanceThe burden of liver cancer varies worldwide.
    evidence:
    - reference: DOI:10.1001/jamanetworkopen.2024.45525
      reference_title: Trends in Hepatocellular Carcinoma Mortality Rates in the US and Projections Through 2040
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: ImportanceThe burden of liver cancer varies worldwide.
      explanation: Deep research cited this publication as relevant literature for Metastatic HCC.
- reference: DOI:10.1001/jamaoncol.2023.2677
  title: Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma
  found_in:
  - Metastatic_HCC-deep-research-falcon.md
  findings:
  - statement: ImportanceThe combination of immune checkpoint inhibitors with antiangiogenic agents has revolutionized the treatment landscape of advanced hepatocellular carcinoma (HCC).
    supporting_text: ImportanceThe combination of immune checkpoint inhibitors with antiangiogenic agents has revolutionized the treatment landscape of advanced hepatocellular carcinoma (HCC).
    evidence:
    - reference: DOI:10.1001/jamaoncol.2023.2677
      reference_title: Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma
      supports: SUPPORT
      evidence_source: OTHER
      snippet: ImportanceThe combination of immune checkpoint inhibitors with antiangiogenic agents has revolutionized the treatment landscape of advanced hepatocellular carcinoma (HCC).
      explanation: Deep research cited this publication as relevant literature for Metastatic HCC.
- reference: DOI:10.1055/s-0044-1779713
  title: 'Hepatocellular Carcinoma: Advances in Systemic Therapy'
  found_in:
  - Metastatic_HCC-deep-research-falcon.md
  findings:
  - statement: Hepatocellular carcinoma (HCC) is a prevalent primary liver cancer, representing over 90% of cases globally and ranking as the third leading cause of cancer-related death.
    supporting_text: Hepatocellular carcinoma (HCC) is a prevalent primary liver cancer, representing over 90% of cases globally and ranking as the third leading cause of cancer-related death.
    evidence:
    - reference: DOI:10.1055/s-0044-1779713
      reference_title: 'Hepatocellular Carcinoma: Advances in Systemic Therapy'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Hepatocellular carcinoma (HCC) is a prevalent primary liver cancer, representing over 90% of cases globally and ranking as the third leading cause of cancer-related death.
      explanation: Deep research cited this publication as relevant literature for Metastatic HCC.
- reference: DOI:10.1097/cm9.0000000000003264
  title: 'Global epidemiology of liver cancer 2022: An emphasis on geographic disparities'
  found_in:
  - Metastatic_HCC-deep-research-falcon.md
  findings:
  - statement: Liver cancer remains the sixth most commonly diagnosed cancer and the third leading cause of cancer-related deaths worldwide, causing a heavy burden globally.
    supporting_text: Liver cancer remains the sixth most commonly diagnosed cancer and the third leading cause of cancer-related deaths worldwide, causing a heavy burden globally.
    evidence:
    - reference: DOI:10.1097/cm9.0000000000003264
      reference_title: 'Global epidemiology of liver cancer 2022: An emphasis on geographic disparities'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Liver cancer remains the sixth most commonly diagnosed cancer and the third leading cause of cancer-related deaths worldwide, causing a heavy burden globally.
      explanation: Deep research cited this publication as relevant literature for Metastatic HCC.
- reference: DOI:10.1111/apt.17506
  title: 'Review article: Available modalities for screening and imaging diagnosis of hepatocellular carcinoma—Current gaps and challenges'
  found_in:
  - Metastatic_HCC-deep-research-falcon.md
  findings:
  - statement: Hepatocellular carcinoma (HCC) incidence and mortality continue to rise worldwide.
    supporting_text: Hepatocellular carcinoma (HCC) incidence and mortality continue to rise worldwide.
    evidence:
    - reference: DOI:10.1111/apt.17506
      reference_title: 'Review article: Available modalities for screening and imaging diagnosis of hepatocellular carcinoma—Current gaps and challenges'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Hepatocellular carcinoma (HCC) incidence and mortality continue to rise worldwide.
      explanation: Deep research cited this publication as relevant literature for Metastatic HCC.
- reference: DOI:10.1177/10732748241310573
  title: 'Burden of Hepatocellular Carcinoma and Its Underlying Etiologies in China, 1990-2021: Findings From the Global Burden of Disease Study 2021'
  found_in:
  - Metastatic_HCC-deep-research-falcon.md
  findings:
  - statement: The incidence and mortality of hepatocellular carcinoma (HCC) and its underlying etiologies in China are still unclear.
    supporting_text: The incidence and mortality of hepatocellular carcinoma (HCC) and its underlying etiologies in China are still unclear.
    evidence:
    - reference: DOI:10.1177/10732748241310573
      reference_title: 'Burden of Hepatocellular Carcinoma and Its Underlying Etiologies in China, 1990-2021: Findings From the Global Burden of Disease Study 2021'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The incidence and mortality of hepatocellular carcinoma (HCC) and its underlying etiologies in China are still unclear.
      explanation: Deep research cited this publication as relevant literature for Metastatic HCC.
- reference: DOI:10.12771/emj.2024.e53
  title: 'Current perspectives on the pharmacological treatment of advanced hepatocellular carcinoma: a narrative review'
  found_in:
  - Metastatic_HCC-deep-research-falcon.md
  findings:
  - statement: Hepatocellular carcinoma (HCC) remains a critical health concern in Korea, ranking as the second leading cause of cancer mortality and imposing substantial economic burdens, particularly among the working-age population.
    supporting_text: Hepatocellular carcinoma (HCC) remains a critical health concern in Korea, ranking as the second leading cause of cancer mortality and imposing substantial economic burdens, particularly among the working-age population.
    evidence:
    - reference: DOI:10.12771/emj.2024.e53
      reference_title: 'Current perspectives on the pharmacological treatment of advanced hepatocellular carcinoma: a narrative review'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Hepatocellular carcinoma (HCC) remains a critical health concern in Korea, ranking as the second leading cause of cancer mortality and imposing substantial economic burdens, particularly among the working-age population.
      explanation: Deep research cited this publication as relevant literature for Metastatic HCC.
- reference: DOI:10.2147/jhc.s480958
  title: 'Efficacy and Safety of Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Inhibitors for Hepatocellular Carcinoma Patients with Extrahepatic Metastases: A Multicenter Retrospective Study'
  found_in:
  - Metastatic_HCC-deep-research-falcon.md
  findings:
  - statement: 'Efficacy and Safety of Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Inhibitors for Hepatocellular Carcinoma Patients with Extrahepatic Metastases: A Multicenter Retrospective Study'
    supporting_text: 'Efficacy and Safety of Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Inhibitors for Hepatocellular Carcinoma Patients with Extrahepatic Metastases: A Multicenter Retrospective Study'
- reference: DOI:10.3389/fimmu.2024.1480520
  title: The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients
  found_in:
  - Metastatic_HCC-deep-research-falcon.md
  findings:
  - statement: The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients
    supporting_text: Chronic viral infection may lead to an immunosuppressive microenvironment, whereas the association between virus-related indicators and treatment response in hepatocellular carcinoma(HCC) patients undergoing immune checkpoint inhibitors(ICIs) therapy remains a topic of debate.
    evidence:
    - reference: DOI:10.3389/fimmu.2024.1480520
      reference_title: The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Chronic viral infection may lead to an immunosuppressive microenvironment, whereas the association between virus-related indicators and treatment response in hepatocellular carcinoma(HCC) patients undergoing immune checkpoint inhibitors(ICIs) therapy remains a topic of debate.
      explanation: Deep research cited this publication as relevant literature for Metastatic HCC.
- reference: DOI:10.3390/cancers15030817
  title: 'Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA'
  found_in:
  - Metastatic_HCC-deep-research-falcon.md
  findings:
  - statement: Hepatocellular carcinoma (HCC) accounts for 90% of primary hepatic malignancies and is one of the major causes of cancer-related death.
    supporting_text: Hepatocellular carcinoma (HCC) accounts for 90% of primary hepatic malignancies and is one of the major causes of cancer-related death.
    evidence:
    - reference: DOI:10.3390/cancers15030817
      reference_title: 'Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Hepatocellular carcinoma (HCC) accounts for 90% of primary hepatic malignancies and is one of the major causes of cancer-related death.
      explanation: Deep research cited this publication as relevant literature for Metastatic HCC.
- reference: DOI:10.3390/cancers15153880
  title: Advances in the Early Detection of Hepatobiliary Cancers
  found_in:
  - Metastatic_HCC-deep-research-falcon.md
  findings:
  - statement: Hepatocellular cancer (HCC) and biliary tract cancers (BTCs) have poor survival rates and a low likelihood of a cure, especially in advanced-stage disease.
    supporting_text: Hepatocellular cancer (HCC) and biliary tract cancers (BTCs) have poor survival rates and a low likelihood of a cure, especially in advanced-stage disease.
    evidence:
    - reference: DOI:10.3390/cancers15153880
      reference_title: Advances in the Early Detection of Hepatobiliary Cancers
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Hepatocellular cancer (HCC) and biliary tract cancers (BTCs) have poor survival rates and a low likelihood of a cure, especially in advanced-stage disease.
      explanation: Deep research cited this publication as relevant literature for Metastatic HCC.
- reference: DOI:10.3390/cancers16132387
  title: 'Evolution of Systemic Treatment for Hepatocellular Carcinoma: Changing Treatment Strategies and Concepts'
  found_in:
  - Metastatic_HCC-deep-research-falcon.md
  findings:
  - statement: Systemic therapy for hepatocellular carcinoma (HCC) has undergone substantial advancements.
    supporting_text: Systemic therapy for hepatocellular carcinoma (HCC) has undergone substantial advancements.
    evidence:
    - reference: DOI:10.3390/cancers16132387
      reference_title: 'Evolution of Systemic Treatment for Hepatocellular Carcinoma: Changing Treatment Strategies and Concepts'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Systemic therapy for hepatocellular carcinoma (HCC) has undergone substantial advancements.
      explanation: Deep research cited this publication as relevant literature for Metastatic HCC.
- reference: DOI:10.3390/cancers16193400
  title: Role of Imaging in Screening for Hepatocellular Carcinoma
  found_in:
  - Metastatic_HCC-deep-research-falcon.md
  findings:
  - statement: Primary liver cancer is among the most common cancers globally.
    supporting_text: Primary liver cancer is among the most common cancers globally.
    evidence:
    - reference: DOI:10.3390/cancers16193400
      reference_title: Role of Imaging in Screening for Hepatocellular Carcinoma
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Primary liver cancer is among the most common cancers globally.
      explanation: Deep research cited this publication as relevant literature for Metastatic HCC.
- reference: DOI:10.3390/jcm13226770
  title: 'Beyond the Liver: A Comprehensive Review of Strategies to Prevent Hepatocellular Carcinoma'
  found_in:
  - Metastatic_HCC-deep-research-falcon.md
  findings:
  - statement: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, primarily developing in the context of chronic liver disease.
    supporting_text: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, primarily developing in the context of chronic liver disease.
    evidence:
    - reference: DOI:10.3390/jcm13226770
      reference_title: 'Beyond the Liver: A Comprehensive Review of Strategies to Prevent Hepatocellular Carcinoma'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, primarily developing in the context of chronic liver disease.
      explanation: Deep research cited this publication as relevant literature for Metastatic HCC.
- reference: DOI:10.3390/vaccines12111254
  title: 'Hepatitis B Virus-Related Cirrhosis and Hepatocellular Carcinoma Hospital Discharge Rates from 2005 to 2021 in Spain: Impact of Universal Vaccination'
  found_in:
  - Metastatic_HCC-deep-research-falcon.md
  findings:
  - statement: The main consequences of chronic hepatitis B virus (HBV) infections are cirrhosis and hepatocellular carcinoma (HCC), both associated with frequent hospitalization.
    supporting_text: The main consequences of chronic hepatitis B virus (HBV) infections are cirrhosis and hepatocellular carcinoma (HCC), both associated with frequent hospitalization.
    evidence:
    - reference: DOI:10.3390/vaccines12111254
      reference_title: 'Hepatitis B Virus-Related Cirrhosis and Hepatocellular Carcinoma Hospital Discharge Rates from 2005 to 2021 in Spain: Impact of Universal Vaccination'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The main consequences of chronic hepatitis B virus (HBV) infections are cirrhosis and hepatocellular carcinoma (HCC), both associated with frequent hospitalization.
      explanation: Deep research cited this publication as relevant literature for Metastatic HCC.
- reference: DOI:10.5114/ceji.2024.142418
  title: Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors
  found_in:
  - Metastatic_HCC-deep-research-falcon.md
  findings:
  - statement: To explore the progression patterns of advanced hepatocellular carcinoma (HCC) in patients treated with a combination of local therapies, targeted drugs, and PD-1/PD-L1 inhibitors.
    supporting_text: To explore the progression patterns of advanced hepatocellular carcinoma (HCC) in patients treated with a combination of local therapies, targeted drugs, and PD-1/PD-L1 inhibitors.
    evidence:
    - reference: DOI:10.5114/ceji.2024.142418
      reference_title: Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: To explore the progression patterns of advanced hepatocellular carcinoma (HCC) in patients treated with a combination of local therapies, targeted drugs, and PD-1/PD-L1 inhibitors.
      explanation: Deep research cited this publication as relevant literature for Metastatic HCC.
datasets:
- accession: ega:EGAS00001000217
  title: Exome-sequencing identifies new oncogenes and tumor suppressor genes recurrently altered in hepatocellular carcinoma
  description: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. High-resolution copy number analysis of 125 tumors of which 24 were subjected to whole-exome sequencing identified 135 homozygous deletions and 994 somatic gene mutations with predicted functional consequences. We identified new recurrent alterations in 4 genes (ARID1A, RPS6KA3, NFE2L2 and IRF2) not previously described in HCC. Functional analyses demonstrated tumor suppressor properties for IRF2 whose inactivation, exclusively found in hepatitis B virus related tumors, leads to impaired TP53 function.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: WES
  publication: PMID:22561517
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Hepatocellular Carcinoma"); description-level mentions were not accepted. EGA study_type: Exome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001000325
  title: Whole genome sequencing of hepatocellular carcinoma tumors and their matched noncancerous liver tissues and the background germline
  description: We performed whole-genome sequencing on multifocal hepatocellular carcinoma tumors and their matched noncancerous liver tissues and the background germline. We found that the noncancerous liver tissues presented varying degrees of genomic alterations that were associated with the background liver diseases. Most of the genomic alterations in the metastatic tumors were inherited from the primary tumor and a small number developed de novo. Few genomic alterations were shared between the multicentric tumors with the exception of the alterations that also existed in the noncancerous liver tissue.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: WGS
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Hepatocellular Carcinoma"); description-level mentions were not accepted. EGA study_type: Whole Genome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001000372
  title: Poly(A) RNA sequencing of hepatocellular carcinoma tumors and their matched noncancerous liver tissues
  description: We performed poly(A) RNA sequencing on multiple hepatocellular carcinoma tumors and their matched noncancerous liver tissues.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Hepatocellular Carcinoma"); description-level mentions were not accepted. EGA study_type: Transcriptome Analysis. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: metabolomics_workbench:ST000230
  title: Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Hepatocellular Carcinoma"). Retrieved 2026-08-02.
- accession: metabolomics_workbench:ST000865
  title: Identification of Race-Associated Metabolite Biomarkers for Hepatocellular Carcinoma
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Hepatocellular Carcinoma"). Retrieved 2026-08-02.
- accession: metabolomics_workbench:ST001152
  title: Metabolomic Analysis of Liver Tissues for Characterization of Hepatocellular Carcinoma
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Hepatocellular Carcinoma"). Retrieved 2026-08-02.
- accession: ega:EGAS00001004468
  title: A Single-Cell Atlas of the Multicellular Ecosystem of Primary and Metastatic Hepatocellular Carcinoma
  description: Hepatocellular carcinoma (HCC) represents a paradigm of the relation between tumor microenvironment (TME) and tumor development. Here, we generated a single-cell atlas of the multicellular ecosystem of HCCs from four relevant sites. Antitumor central memory T (TCM) cells were found in tertiary lymphoid structures (TLSs). Chronic HBV/HCV infection increases infiltration of CD8+ T cells in tumors but aggravates T cell exhaustion. We identified CD11b+ macrophages to be terminally differentiated tumor-associated macrophages (TAMs) and two distinct differentiation trajectories contribute to their accumulation.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Metastatic Hepatocellular Carcinoma"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
environmental:
- name: Chronic hepatitis B or C infection
  influences_mechanisms:
  - target: Chronic Liver Injury and Cirrhosis
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Persistent viral hepatitis is one of the chronic liver injury states
      this node is made of, supplying the regenerative pressure and
      inflammation on which the tumour arises. The exposure constitutes the
      node rather than acting on it from outside.
    evidence:
    - reference: PMID:41567639
      reference_title: "Identification of novel germline and somatic mutations associated with hepatocellular carcinoma by next-generation sequencing."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "HCC typically arises in patients with chronic liver disease, including hepatitis, cirrhosis, and non-alcoholic fatty liver diseases."
      explanation: >-
        States that hepatocellular carcinoma typically arises in patients with
        chronic liver disease including hepatitis, naming both the exposure
        and this node's substrate.
  notes: Viral hepatitis is a major substrate for hepatocarcinogenesis and later metastasis.
  evidence:
  - reference: PMID:41567639
    reference_title: Identification of novel germline and somatic mutations associated with hepatocellular carcinoma by next-generation sequencing.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: HCC typically arises in patients with chronic liver disease, including hepatitis, cirrhosis, and non-alcoholic fatty liver diseases.
    explanation: This supports chronic hepatitis as a foundational risk factor for HCC.
- name: Alcohol and aflatoxin exposure
  influences_mechanisms:
  - target: Chronic Liver Injury and Cirrhosis
    environmental_effect: PREDISPOSES
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Graded below the hepatitis and cirrhosis links into this same node for
      two reasons that are worth stating rather than leaving to inference: the
      cited sentence covers only the aflatoxin half of this bundled exposure
      and says nothing about alcohol, and it is hedged as a belief about
      prevalence rather than a measured interaction.
    evidence:
    - reference: PMID:29984212
      reference_title: "Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The interaction of aflatoxin B1 (a contaminant found in food) with HBV infection is believed to increase the prevalence of HCC."
      explanation: >-
        Reports that aflatoxin B1 interacting with hepatitis B infection is
        believed to raise hepatocellular carcinoma prevalence. It supports the
        aflatoxin component only, and at the level of population prevalence
        rather than liver substrate.
  notes: Alcohol and aflatoxin can cooperate with viral and cirrhotic injury to drive aggressive HCC.
  evidence:
  - reference: PMID:29984212
    reference_title: "Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The interaction of aflatoxin B1 (a contaminant found in food) with HBV infection is believed to increase the prevalence of HCC.
    explanation: This supports aflatoxin exposure as a contributor to HCC risk, particularly in the context of HBV co-infection.

📚

References & Deep Research

References

DOI:10.1007/s00330-024-10606-w

ESR Essentials: diagnosis of hepatocellular carcinoma—practice recommendations by ESGAR

1 finding

Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy and a leading cause of cancer related death worldwide.

"Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy and a leading cause of cancer related death worldwide."

Show evidence (1 reference)

DOI:10.1007/s00330-024-10606-w SUPPORT Human Clinical

"Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy and a leading cause of cancer related death worldwide."

Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.

DOI:10.1007/s12029-023-00961-0

Clinical Practice Guidelines For the Management of Hepatocellular Carcinoma: A Systematic Review

1 finding

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, including Australia.

"Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, including Australia."

Show evidence (1 reference)

DOI:10.1007/s12029-023-00961-0 SUPPORT Other

"Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, including Australia."

Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.

DOI:10.1159/000539371

EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

1 finding

EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

"Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the presence of one or more cardiometabolic risk factor(s) and the absence of harmful alcohol intake."

Show evidence (1 reference)

DOI:10.1159/000539371 SUPPORT Other

Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.

DOI:10.1186/s12885-023-11112-w

Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis

1 finding

Atezolizumab plus bevacizumab was approved in 2020 as a first-line treatment for advanced hepatocellular carcinoma (HCC).

"Atezolizumab plus bevacizumab was approved in 2020 as a first-line treatment for advanced hepatocellular carcinoma (HCC)."

Show evidence (1 reference)

DOI:10.1186/s12885-023-11112-w SUPPORT Other

"Atezolizumab plus bevacizumab was approved in 2020 as a first-line treatment for advanced hepatocellular carcinoma (HCC)."

Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.

DOI:10.1186/s12885-024-12407-2

Genomic profiling informs therapies and prognosis for patients with hepatocellular carcinoma in clinical practice

1 finding

Hepatocellular carcinoma (HCC) genomic research has discovered actionable genetic changes that might guide treatment decisions and clinical trials.

"Hepatocellular carcinoma (HCC) genomic research has discovered actionable genetic changes that might guide treatment decisions and clinical trials."

Show evidence (1 reference)

DOI:10.1186/s12885-024-12407-2 SUPPORT Human Clinical

"Hepatocellular carcinoma (HCC) genomic research has discovered actionable genetic changes that might guide treatment decisions and clinical trials."

Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.

DOI:10.1186/s12920-024-01965-w

Genomic landscape of hepatocellular carcinoma in Egyptian patients by whole exome sequencing

1 finding

Genomic landscape of hepatocellular carcinoma in Egyptian patients by whole exome sequencing

"Genomic landscape of hepatocellular carcinoma in Egyptian patients by whole exome sequencing"

DOI:10.1186/s12943-024-02062-3

Single-cell tumor heterogeneity landscape of hepatocellular carcinoma: unraveling the pro-metastatic subtype and its interaction loop with fibroblasts

1 finding

Tumor heterogeneity presents a formidable challenge in understanding the mechanisms driving tumor progression and metastasis.

"Tumor heterogeneity presents a formidable challenge in understanding the mechanisms driving tumor progression and metastasis."

Show evidence (1 reference)

DOI:10.1186/s12943-024-02062-3 SUPPORT Other

"Tumor heterogeneity presents a formidable challenge in understanding the mechanisms driving tumor progression and metastasis."

Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.

DOI:10.1200/jco.23.02745

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update

1 finding

To update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC).

"To update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC)."

Show evidence (1 reference)

DOI:10.1200/jco.23.02745 SUPPORT Other

"To update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC)."

Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.

DOI:10.14744/hf.2023.2023.0028

Cross talk between genetics and biochemistry in the pathogenesis of hepatocellular carcinoma

1 finding

Cross talk between genetics and biochemistry in the pathogenesis of hepatocellular carcinoma

"Cross talk between genetics and biochemistry in the pathogenesis of hepatocellular carcinoma"

DOI:10.20517/2394-5079.2024.16

Introduction to 2023 Chinese expert consensus on the whole-course management of hepatocellular carcinoma

1 finding

Introduction to 2023 Chinese expert consensus on the whole-course management of hepatocellular carcinoma

"Introduction to 2023 Chinese expert consensus on the whole-course management of hepatocellular carcinoma"

DOI:10.21037/hbsn-22-469

A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights

1 finding

A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights

"A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights"

DOI:10.2147/jhc.s478604

Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study

1 finding

Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study

"Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study"

DOI:10.3350/cmh.2024.0824

Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

1 finding

Hepatocellular carcinoma (HCC) is a major global burden, ranking as the third leading cause of cancer-related mortality.

"Hepatocellular carcinoma (HCC) is a major global burden, ranking as the third leading cause of cancer-related mortality."

Show evidence (1 reference)

DOI:10.3350/cmh.2024.0824 SUPPORT Human Clinical

"Hepatocellular carcinoma (HCC) is a major global burden, ranking as the third leading cause of cancer-related mortality."

Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.

DOI:10.3389/fphar.2024.1416295

Novel genetic alterations in liver cancer distinguish distinct clinical outcomes and combination immunotherapy responses

1 finding

Genomic profiling has revolutionized therapeutic interventions and the clinical management of liver cancer.

"Genomic profiling has revolutionized therapeutic interventions and the clinical management of liver cancer."

Show evidence (1 reference)

DOI:10.3389/fphar.2024.1416295 SUPPORT Human Clinical

"Genomic profiling has revolutionized therapeutic interventions and the clinical management of liver cancer."

Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.

DOI:10.3390/biom14060656

Molecular Mechanisms in Tumorigenesis of Hepatocellular Carcinoma and in Target Treatments—An Overview

1 finding

Hepatocellular carcinoma is the most common primary malignancy of the liver, with hepatocellular differentiation.

"Hepatocellular carcinoma is the most common primary malignancy of the liver, with hepatocellular differentiation."

Show evidence (1 reference)

DOI:10.3390/biom14060656 SUPPORT Human Clinical

"Hepatocellular carcinoma is the most common primary malignancy of the liver, with hepatocellular differentiation."

Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.

DOI:10.3390/biomedicines12071624

Preclinical Models of Hepatocellular Carcinoma: Current Utility, Limitations, and Challenges

1 finding

Hepatocellular carcinoma (HCC), the predominant primary liver tumor, remains one of the most lethal cancers worldwide, despite the advances in therapy in recent years.

"Hepatocellular carcinoma (HCC), the predominant primary liver tumor, remains one of the most lethal cancers worldwide, despite the advances in therapy in recent years."

Show evidence (1 reference)

DOI:10.3390/biomedicines12071624 SUPPORT Model Organism

"Hepatocellular carcinoma (HCC), the predominant primary liver tumor, remains one of the most lethal cancers worldwide, despite the advances in therapy in recent years."

Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.

DOI:10.3390/cancers16030666

Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape

1 finding

Liver cancer is the third most common cause of cancer-related deaths worldwide, and hepatocellular carcinoma (HCC) makes up the majority of liver cancer cases.

"Liver cancer is the third most common cause of cancer-related deaths worldwide, and hepatocellular carcinoma (HCC) makes up the majority of liver cancer cases."

Show evidence (1 reference)

DOI:10.3390/cancers16030666 SUPPORT Human Clinical

"Liver cancer is the third most common cause of cancer-related deaths worldwide, and hepatocellular carcinoma (HCC) makes up the majority of liver cancer cases."

Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.

DOI:10.3390/cancers16050901

Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets

1 finding

Liver cancer, predominantly hepatocellular carcinoma (HCC), globally ranks sixth in incidence and third in cancer-related deaths.

"Liver cancer, predominantly hepatocellular carcinoma (HCC), globally ranks sixth in incidence and third in cancer-related deaths."

Show evidence (1 reference)

DOI:10.3390/cancers16050901 SUPPORT Human Clinical

"Liver cancer, predominantly hepatocellular carcinoma (HCC), globally ranks sixth in incidence and third in cancer-related deaths."

Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.

DOI:10.3390/cancers16233933

Hepatocellular Carcinoma Surveillance Strategies: Major Guidelines and Screening Advances

1 finding

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, with prognosis and treatment outcomes that are significantly influenced by the stage at diagnosis.

"Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, with prognosis and treatment outcomes that are significantly influenced by the stage at diagnosis."

Show evidence (1 reference)

DOI:10.3390/cancers16233933 SUPPORT Human Clinical

"Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, with prognosis and treatment outcomes that are significantly influenced by the stage at diagnosis."

Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.

DOI:10.3748/wjg.v30.i19.2488

Hepatocellular carcinoma-the role of the underlying liver disease in clinical practice

1 finding

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality.

"Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality."

Show evidence (1 reference)

DOI:10.3748/wjg.v30.i19.2488 SUPPORT Human Clinical

"Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality."

Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.

DOI:10.4254/wjh.v16.i5.716

Genetic screening of liver cancer: State of the art

1 finding

Liver cancer, primarily hepatocellular carcinoma, remains a global health challenge with rising incidence and limited therapeutic options.

"Liver cancer, primarily hepatocellular carcinoma, remains a global health challenge with rising incidence and limited therapeutic options."

Show evidence (1 reference)

DOI:10.4254/wjh.v16.i5.716 SUPPORT Other

"Liver cancer, primarily hepatocellular carcinoma, remains a global health challenge with rising incidence and limited therapeutic options."

Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.

DOI:10.7150/thno.95971

Single cell analyses reveal the PD-1 blockade response-related immune features in hepatocellular carcinoma

1 finding

Single cell analyses reveal the PD-1 blockade response-related immune features in hepatocellular carcinoma

"Single cell analyses reveal the PD-1 blockade response-related immune features in hepatocellular carcinoma"

DOI:10.1159/000539897

Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150

No top-level findings curated for this source.

DOI:10.1001/jamanetworkopen.2024.45525

Trends in Hepatocellular Carcinoma Mortality Rates in the US and Projections Through 2040

1 finding

ImportanceThe burden of liver cancer varies worldwide.

"ImportanceThe burden of liver cancer varies worldwide."

Show evidence (1 reference)

DOI:10.1001/jamanetworkopen.2024.45525 SUPPORT Human Clinical

"ImportanceThe burden of liver cancer varies worldwide."

Deep research cited this publication as relevant literature for Metastatic HCC.

DOI:10.1001/jamaoncol.2023.2677

Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma

1 finding

ImportanceThe combination of immune checkpoint inhibitors with antiangiogenic agents has revolutionized the treatment landscape of advanced hepatocellular carcinoma (HCC).

"ImportanceThe combination of immune checkpoint inhibitors with antiangiogenic agents has revolutionized the treatment landscape of advanced hepatocellular carcinoma (HCC)."

Show evidence (1 reference)

DOI:10.1001/jamaoncol.2023.2677 SUPPORT Other

"ImportanceThe combination of immune checkpoint inhibitors with antiangiogenic agents has revolutionized the treatment landscape of advanced hepatocellular carcinoma (HCC)."

Deep research cited this publication as relevant literature for Metastatic HCC.

DOI:10.1055/s-0044-1779713

Hepatocellular Carcinoma: Advances in Systemic Therapy

1 finding

Hepatocellular carcinoma (HCC) is a prevalent primary liver cancer, representing over 90% of cases globally and ranking as the third leading cause of cancer-related death.

"Hepatocellular carcinoma (HCC) is a prevalent primary liver cancer, representing over 90% of cases globally and ranking as the third leading cause of cancer-related death."

Show evidence (1 reference)

DOI:10.1055/s-0044-1779713 SUPPORT Human Clinical

"Hepatocellular carcinoma (HCC) is a prevalent primary liver cancer, representing over 90% of cases globally and ranking as the third leading cause of cancer-related death."

Deep research cited this publication as relevant literature for Metastatic HCC.

DOI:10.1097/cm9.0000000000003264

Global epidemiology of liver cancer 2022: An emphasis on geographic disparities

1 finding

Liver cancer remains the sixth most commonly diagnosed cancer and the third leading cause of cancer-related deaths worldwide, causing a heavy burden globally.

"Liver cancer remains the sixth most commonly diagnosed cancer and the third leading cause of cancer-related deaths worldwide, causing a heavy burden globally."

Show evidence (1 reference)

DOI:10.1097/cm9.0000000000003264 SUPPORT Human Clinical

"Liver cancer remains the sixth most commonly diagnosed cancer and the third leading cause of cancer-related deaths worldwide, causing a heavy burden globally."

Deep research cited this publication as relevant literature for Metastatic HCC.

DOI:10.1111/apt.17506

Review article: Available modalities for screening and imaging diagnosis of hepatocellular carcinoma—Current gaps and challenges

1 finding

Hepatocellular carcinoma (HCC) incidence and mortality continue to rise worldwide.

"Hepatocellular carcinoma (HCC) incidence and mortality continue to rise worldwide."

Show evidence (1 reference)

DOI:10.1111/apt.17506 SUPPORT Human Clinical

"Hepatocellular carcinoma (HCC) incidence and mortality continue to rise worldwide."

Deep research cited this publication as relevant literature for Metastatic HCC.

DOI:10.1177/10732748241310573

Burden of Hepatocellular Carcinoma and Its Underlying Etiologies in China, 1990-2021: Findings From the Global Burden of Disease Study 2021

1 finding

The incidence and mortality of hepatocellular carcinoma (HCC) and its underlying etiologies in China are still unclear.

"The incidence and mortality of hepatocellular carcinoma (HCC) and its underlying etiologies in China are still unclear."

Show evidence (1 reference)

DOI:10.1177/10732748241310573 SUPPORT Human Clinical

"The incidence and mortality of hepatocellular carcinoma (HCC) and its underlying etiologies in China are still unclear."

Deep research cited this publication as relevant literature for Metastatic HCC.

DOI:10.12771/emj.2024.e53

Current perspectives on the pharmacological treatment of advanced hepatocellular carcinoma: a narrative review

1 finding

Hepatocellular carcinoma (HCC) remains a critical health concern in Korea, ranking as the second leading cause of cancer mortality and imposing substantial economic burdens, particularly among the working-age population.

"Hepatocellular carcinoma (HCC) remains a critical health concern in Korea, ranking as the second leading cause of cancer mortality and imposing substantial economic burdens, particularly among the working-age population."

Show evidence (1 reference)

DOI:10.12771/emj.2024.e53 SUPPORT Human Clinical

Deep research cited this publication as relevant literature for Metastatic HCC.

DOI:10.2147/jhc.s480958

Efficacy and Safety of Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Inhibitors for Hepatocellular Carcinoma Patients with Extrahepatic Metastases: A Multicenter Retrospective Study

1 finding

"Efficacy and Safety of Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Inhibitors for Hepatocellular Carcinoma Patients with Extrahepatic Metastases: A Multicenter Retrospective Study"

DOI:10.3389/fimmu.2024.1480520

The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients

1 finding

The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients

"Chronic viral infection may lead to an immunosuppressive microenvironment, whereas the association between virus-related indicators and treatment response in hepatocellular carcinoma(HCC) patients undergoing immune checkpoint inhibitors(ICIs) therapy remains a topic of debate."

Show evidence (1 reference)

DOI:10.3389/fimmu.2024.1480520 SUPPORT Other

Deep research cited this publication as relevant literature for Metastatic HCC.

DOI:10.3390/cancers15030817

Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA

1 finding

Hepatocellular carcinoma (HCC) accounts for 90% of primary hepatic malignancies and is one of the major causes of cancer-related death.

"Hepatocellular carcinoma (HCC) accounts for 90% of primary hepatic malignancies and is one of the major causes of cancer-related death."

Show evidence (1 reference)

DOI:10.3390/cancers15030817 SUPPORT Human Clinical

"Hepatocellular carcinoma (HCC) accounts for 90% of primary hepatic malignancies and is one of the major causes of cancer-related death."

Deep research cited this publication as relevant literature for Metastatic HCC.

DOI:10.3390/cancers15153880

Advances in the Early Detection of Hepatobiliary Cancers

1 finding

Hepatocellular cancer (HCC) and biliary tract cancers (BTCs) have poor survival rates and a low likelihood of a cure, especially in advanced-stage disease.

"Hepatocellular cancer (HCC) and biliary tract cancers (BTCs) have poor survival rates and a low likelihood of a cure, especially in advanced-stage disease."

Show evidence (1 reference)

DOI:10.3390/cancers15153880 SUPPORT Human Clinical

"Hepatocellular cancer (HCC) and biliary tract cancers (BTCs) have poor survival rates and a low likelihood of a cure, especially in advanced-stage disease."

Deep research cited this publication as relevant literature for Metastatic HCC.

DOI:10.3390/cancers16132387

Evolution of Systemic Treatment for Hepatocellular Carcinoma: Changing Treatment Strategies and Concepts

1 finding

Systemic therapy for hepatocellular carcinoma (HCC) has undergone substantial advancements.

"Systemic therapy for hepatocellular carcinoma (HCC) has undergone substantial advancements."

Show evidence (1 reference)

DOI:10.3390/cancers16132387 SUPPORT Human Clinical

"Systemic therapy for hepatocellular carcinoma (HCC) has undergone substantial advancements."

Deep research cited this publication as relevant literature for Metastatic HCC.

DOI:10.3390/cancers16193400

Role of Imaging in Screening for Hepatocellular Carcinoma

1 finding

Primary liver cancer is among the most common cancers globally.

"Primary liver cancer is among the most common cancers globally."

Show evidence (1 reference)

DOI:10.3390/cancers16193400 SUPPORT Human Clinical

"Primary liver cancer is among the most common cancers globally."

Deep research cited this publication as relevant literature for Metastatic HCC.

DOI:10.3390/jcm13226770

Beyond the Liver: A Comprehensive Review of Strategies to Prevent Hepatocellular Carcinoma

1 finding

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, primarily developing in the context of chronic liver disease.

"Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, primarily developing in the context of chronic liver disease."

Show evidence (1 reference)

DOI:10.3390/jcm13226770 SUPPORT Human Clinical

"Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, primarily developing in the context of chronic liver disease."

Deep research cited this publication as relevant literature for Metastatic HCC.

DOI:10.3390/vaccines12111254

Hepatitis B Virus-Related Cirrhosis and Hepatocellular Carcinoma Hospital Discharge Rates from 2005 to 2021 in Spain: Impact of Universal Vaccination

1 finding

The main consequences of chronic hepatitis B virus (HBV) infections are cirrhosis and hepatocellular carcinoma (HCC), both associated with frequent hospitalization.

"The main consequences of chronic hepatitis B virus (HBV) infections are cirrhosis and hepatocellular carcinoma (HCC), both associated with frequent hospitalization."

Show evidence (1 reference)

DOI:10.3390/vaccines12111254 SUPPORT Human Clinical

"The main consequences of chronic hepatitis B virus (HBV) infections are cirrhosis and hepatocellular carcinoma (HCC), both associated with frequent hospitalization."

Deep research cited this publication as relevant literature for Metastatic HCC.

DOI:10.5114/ceji.2024.142418

Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors

1 finding

To explore the progression patterns of advanced hepatocellular carcinoma (HCC) in patients treated with a combination of local therapies, targeted drugs, and PD-1/PD-L1 inhibitors.

"To explore the progression patterns of advanced hepatocellular carcinoma (HCC) in patients treated with a combination of local therapies, targeted drugs, and PD-1/PD-L1 inhibitors."

Show evidence (1 reference)

DOI:10.5114/ceji.2024.142418 SUPPORT Human Clinical

"To explore the progression patterns of advanced hepatocellular carcinoma (HCC) in patients treated with a combination of local therapies, targeted drugs, and PD-1/PD-L1 inhibitors."

Deep research cited this publication as relevant literature for Metastatic HCC.

Deep Research

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 71 citations 2026-05-08T19:35:16.062652

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Hepatocellular Carcinoma
MONDO ID: (if available)
Category:

Research Objectives

Please provide a comprehensive research report on Hepatocellular Carcinoma covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Hepatocellular Carcinoma (HCC) — Disease Characteristics Research Report (2023–2024 prioritized)

Target disease

Disease name: Hepatocellular carcinoma (HCC)
MONDO ID: Not recovered from the available evidence in this run (see Identifiers table) (OpenTargets Search: hepatocellular carcinoma)
Category: Malignant neoplasm; primary liver cancer (HCC comprises ~75–90% of primary liver cancers depending on source) (hwang2024hepatocellularcarcinomaupdates pages 1-3, kinsey2024managementofhepatocellular pages 1-2)

1. Disease information

1.1 Definition / overview (current understanding)

Hepatocellular carcinoma is the most common primary hepatic malignancy and a leading cause of cancer mortality worldwide (cannella2024esressentialsdiagnosis pages 1-3, hwang2024hepatocellularcarcinomaupdates pages 1-3). HCC typically arises in the setting of chronic liver disease/cirrhosis; cirrhosis confers markedly elevated risk compared with non-cirrhotic liver, and clinical management must simultaneously address the tumor and the underlying liver dysfunction (hwang2024hepatocellularcarcinomaupdates pages 1-3, mattos2024hepatocellularcarcinomatherole pages 1-2).

1.2 Key identifiers and synonyms

A compact normalization table is provided below.

Disease name	Common synonyms / alternative names	Identifier system	Code / ID	Status / note	Source	URL / DOI
Hepatocellular carcinoma	HCC; hepatoma	Open Targets / EFO	EFO_0000182	Retrieved in current evidence as the disease entity used for target associations	Open Targets disease-target association (OpenTargets Search: hepatocellular carcinoma)	https://platform.opentargets.org/disease/EFO_0000182
Hepatocellular carcinoma	HCC; hepatoma	ICD-10	C22.0	Malignant neoplasm of liver and intrahepatic bile ducts, liver cell carcinoma	AASLD/CMH surveillance and diagnosis reviews referencing current HCC guideline nomenclature and disease classification context (hwang2024hepatocellularcarcinomaupdates pages 6-7, hwang2024hepatocellularcarcinomaupdates pages 1-3)	https://icd.who.int/browse10/2019/en#/C22.0
Hepatocellular carcinoma	HCC; hepatoma	MONDO	Not available	MONDO identifier was not retrieved in the current evidence set and should be treated as unavailable here	No MONDO ID recovered in gathered evidence; Open Targets search returned EFO disease mapping instead (OpenTargets Search: hepatocellular carcinoma)	Not available
Hepatocellular carcinoma	HCC; hepatoma	MeSH	Not retrieved in current evidence	MeSH identifier not directly retrieved in the available evidence, though HCC is consistently defined as the major primary liver cancer	Recent HCC reviews/guidelines use the disease term consistently but do not provide a MeSH code in the retrieved excerpts (hwang2024hepatocellularcarcinomaupdates pages 1-3, cannella2024esressentialsdiagnosis pages 1-3)	https://www.ncbi.nlm.nih.gov/mesh/
Hepatocellular carcinoma	HCC; hepatoma; liver cell carcinoma	Guideline/common usage	Not a formal code	Common naming supported by recent guideline and review literature; HCC is described as the predominant primary liver cancer	Hwang et al. 2024; ESR/ESGAR 2024; ASCO 2024 (hwang2024hepatocellularcarcinomaupdates pages 1-3, cannella2024esressentialsdiagnosis pages 1-3, gordan2024systemictherapyfor pages 1-2)	https://doi.org/10.3350/cmh.2024.0824 ; https://doi.org/10.1007/s00330-024-10606-w ; https://doi.org/10.1200/JCO.23.02745

Table: This table compiles the key identifiers and common names for hepatocellular carcinoma that were recoverable from the gathered evidence. It is useful as a compact normalization reference for knowledge-base curation, while clearly marking identifiers that were not retrieved in the current evidence set.

Synonyms / alternative names: “HCC”, “hepatoma”, “liver cell carcinoma” (common clinical usage in contemporary guidelines/reviews) (kinsey2024managementofhepatocellular pages 1-2, hwang2024hepatocellularcarcinomaupdates pages 1-3).

1.3 Evidence source type

The information synthesized here is largely aggregated disease-level evidence from international guidelines/reviews and meta-analyses (e.g., ASCO 2024 systemic therapy guideline update; ESR/ESGAR 2024 imaging recommendations; EASL-EASD-EASO 2024 MASLD guideline; CMH 2024 epidemiology review) plus selected primary/real-world clinical studies and genomic cohort studies (gordan2024systemictherapyfor pages 1-2, cannella2024esressentialsdiagnosis pages 1-3, (easo)2024easleasdeasoclinicalpractice pages 46-48, hwang2024hepatocellularcarcinomaupdates pages 1-3, shen2024efficacyofatezolizumab pages 1-2, song2024genomicprofilinginforms pages 1-2).

2. Etiology

2.1 Primary causal factors

HCC arises through the interaction of chronic liver injury/inflammation/fibrosis with acquired (somatic) genetic and epigenetic alterations in hepatocytes, commonly driven by: chronic viral hepatitis (HBV/HCV), alcohol-associated liver disease (ALD), and metabolic dysfunction–associated steatotic liver disease (MASLD) / metabolic dysfunction–associated steatohepatitis (MASH) (hwang2024hepatocellularcarcinomaupdates pages 1-3, kinsey2024managementofhepatocellular pages 1-2).

2.2 Risk factors (genetic + environmental)

Major clinical risk factors consistently highlighted across guidelines include cirrhosis, chronic HBV infection, chronic HCV infection, alcohol use/ALD, obesity, type 2 diabetes, and MASLD/MASH; aflatoxin exposure remains important in some regions (kinsey2024managementofhepatocellular pages 1-2, hwang2024hepatocellularcarcinomaupdates pages 4-6).

Regional/global etiology proportions (GBD 2021, liver cancer overall): HBV ~39% of cases (37% of deaths), HCV ~29% (30% deaths), ALD ~19% (19% deaths) (hwang2024hepatocellularcarcinomaupdates pages 4-6).

Genetic susceptibility / modifiers (selected examples): A 2024 “state of the art” genetic screening review notes that germline polymorphisms in lipid metabolism genes (e.g., PNPLA3, TM6SF2, HSD17B13) modulate NASH/alcohol-related disease severity and influence HCC risk, and that variants in WNT genes or TERT can modulate HCC risk (peruhova2024geneticscreeningof pages 2-4).

2.3 Protective factors

At the population level, the declining fraction of HBV- and HCV-related HCC is attributed to HBV vaccination and effective antiviral therapy reducing chronic viral hepatitis burden (hwang2024hepatocellularcarcinomaupdates pages 1-3, hwang2024hepatocellularcarcinomaupdates pages 4-6). In MASLD, reduction/regression of fibrosis is linked with reduced liver-related risk, supporting fibrosis reduction as a protective strategy against downstream outcomes including HCC ((easo)2024easleasdeasoclinicalpractice pages 46-48).

2.4 Gene–environment interactions

The etiology-specific differences in key somatic events (e.g., TERT promoter mutation rates differing by HBV/HCV/nonviral) highlight gene–environment interplay (virus-driven vs metabolic drivers with different mutational selection pressures) (ucdal2024crosstalkbetween pages 1-2).

3. Phenotypes

3.1 Core clinical phenotypes

HCC is frequently asymptomatic until advanced stages; consequently, surveillance aims to detect tumors at a curable stage (wu2024hepatocellularcarcinomasurveillance pages 1-2). Underlying cirrhosis drives common co-phenotypes/complications that influence treatment eligibility (portal hypertension/varices, synthetic dysfunction, etc.), motivating staging systems that integrate liver function and performance status (seth2024clinicalpracticeguidelines pages 2-3, gordan2024systemictherapyfor pages 1-2).

3.2 Ontology suggestions (HPO; non-exhaustive)

Because detailed symptom-frequency tables were not available in the retrieved evidence excerpts, below are suggested HPO terms for common HCC/cirrhosis-associated clinical features seen in practice (term suggestions only; frequencies not extracted here): - HP:0001402 Hepatomegaly - HP:0001394 Jaundice - HP:0001548 Ascites - HP:0002615 Esophageal varices - HP:0003073 Elevated serum alpha-fetoprotein - HP:0002240 Abdominal pain

3.3 Quality of life impact

A multidisciplinary, patient-centered model and early palliative-care integration are increasingly emphasized in 2024-era HCC management reviews because liver dysfunction plus cancer symptoms/toxicities can substantially impair daily functioning (kinsey2024managementofhepatocellular pages 1-2).

4. Genetic / molecular information

4.1 Somatic driver landscape (key concepts)

HCC is dominated by somatic alterations rather than single-gene Mendelian causation. Commonly altered genes repeatedly highlighted include TERT promoter, TP53, and Wnt/β-catenin pathway genes (e.g., CTNNB1, AXIN1) along with chromatin regulators (ARID1A/ARID2), and signaling pathway members spanning PI3K/AKT/mTOR, RAS/MAPK, Hippo, Notch, etc. (ucdal2024crosstalkbetween pages 1-2, szilveszter2024molecularmechanismsin pages 2-4, peruhova2024geneticscreeningof pages 2-4).

Quantitative frequency ranges (from a 2024 clinical-genomics cohort summary): TERT promoter ~60%; TP53 ~12–48%; CTNNB1 ~11–37% (song2024genomicprofilinginforms pages 1-2). Another 2024 mechanistic review describes TERT promoter as “the single most common HCC mutation (up to 60%)” and provides etiology-stratified frequencies: HCV ~44%, non-viral ~38%, HBV ~23% (ucdal2024crosstalkbetween pages 1-2).

4.2 Pathways and mechanistic chain (example)

A common causal chain described in contemporary reviews is: 1) chronic injury (HBV/HCV, alcohol, MASLD/MASH) → 2) inflammation/fibrosis/cirrhosis microenvironment → 3) selection for telomerase activation (TERT promoter) and oncogenic signaling alterations (Wnt/β-catenin, PI3K/AKT/mTOR, RAS/MAPK, Hippo, Notch) → 4) tumor initiation/progression with immunosuppressive tumor microenvironment and angiogenesis → 5) clinical HCC with recurrence/metastasis risk (hwang2024hepatocellularcarcinomaupdates pages 1-3, szilveszter2024molecularmechanismsin pages 2-4, pessino2024hepatocellularcarcinomaold pages 15-17).

4.3 Clinically relevant associations and biomarkers

Immune microenvironment associations with genotype: TP53 mutations have been associated with increased immune infiltration, while CTNNB1 and KMT2D mutations correlate with decreased immune infiltration (implicating Wnt-driven “immune-cold” phenotypes relevant to immunotherapy) (song2024genomicprofilinginforms pages 1-2).
Prognostic genomic alterations (example cohort): LATS1 alterations associated with markedly shorter recurrence-free survival (RFS 5.57 vs 22.47 months) in a 2024 targeted-sequencing cohort (wang2024novelgeneticalterations pages 1-2).

4.4 Epigenetics

While detailed locus-level methylation/histone data were not extracted from a single primary epigenome paper in this run, 2024 reviews emphasize that harmful epigenetic modifications (DNA methylation/chromatin changes) interact with driver mutations and contribute to intratumoral heterogeneity and progression; these are also being explored therapeutically in combination regimens (szilveszter2024molecularmechanismsin pages 2-4).

4.5 Ontology suggestions

GO biological process (examples): Wnt signaling (GO:0016055), angiogenesis (GO:0001525), epithelial–mesenchymal transition (GO:0001837), inflammatory response (GO:0006954), T cell activation (GO:0042110).

5. Environmental information

5.1 Environmental and lifestyle contributors

Alcohol: ALD is a major and rising contributor to HCC incidence (hwang2024hepatocellularcarcinomaupdates pages 1-3, hwang2024hepatocellularcarcinomaupdates pages 4-6). The MASLD guideline discourages alcohol consumption in all individuals with steatotic liver disease, noting that alcohol worsens liver outcomes and increases HCC risk versus abstinence ((easo)2024easleasdeasoclinicalpractice pages 10-11).
Diet/obesity/physical activity: MASLD guideline highlights associations between unhealthy dietary patterns (e.g., sugar-sweetened beverages, red/processed meat) and higher risk of MASLD and liver cancer, while healthy lifestyle and physical activity reduce risk of MASLD, HCC, and liver-related mortality ((easo)2024easleasdeasoclinicalpractice pages 10-11).
Aflatoxin: geographic concentrations include Sub-Saharan Africa, Southeast Asia, and China (hwang2024hepatocellularcarcinomaupdates pages 4-6).

5.2 Infectious agents

HBV and HCV are key infectious causes (hwang2024hepatocellularcarcinomaupdates pages 4-6). Chronic HBV/HCV contributions to liver cancer incidence and death are quantified above (hwang2024hepatocellularcarcinomaupdates pages 4-6).

6. Mechanism / pathophysiology

6.1 Molecular pathways (selected high-confidence)

Pathways repeatedly emphasized in 2024-era mechanistic and clinical-genomics literature include: - Wnt/β-catenin (CTNNB1, AXIN1) (ucdal2024crosstalkbetween pages 1-2, szilveszter2024molecularmechanismsin pages 2-4) - PI3K/AKT/mTOR (common pathway alteration; mutational contributors include PTEN, PIK3CA, MTOR, AKT2) (pessino2024hepatocellularcarcinomaold pages 15-17) - RAS/RAF/MAPK (frequently altered signaling; also prominent in DEN mouse model mutational spectrum) (szilveszter2024molecularmechanismsin pages 2-4, cigliano2024preclinicalmodelsof pages 9-10) - Hippo, Notch, Hedgehog (enriched in WES pathway analyses and reviews) (kassem2024genomiclandscapeof pages 1-2, szilveszter2024molecularmechanismsin pages 2-4)

6.2 Immune system involvement (2024 single-cell/spatial advances)

Single-cell and spatial transcriptomics studies in 2024 provide mechanistic insight into why only a subset of patients respond to PD-1/PD-L1 blockade: - An “immune barrier” composed of macrophages and cancer-associated fibroblasts (CAFs) can physically/chemically impede CD8+ T-cell infiltration; non-responders show increased immunosuppressive macrophage states (e.g., TREM2+ macrophages, SPP1+ macrophages) and CAF markers (e.g., POSTN) (li2024singlecellanalyses pages 1-2, li2024singlecellanalyses pages 6-8). - A large integrated single-cell+spatial analysis mapped malignant-cell heterogeneity and identified a pro-metastatic EMT-like tumor-cell subtype with TGF-β/SMAD3 activation, associated with worse prognosis and an immune-poor (“deserted”) microenvironment; a tumor–fibroblast feedback loop (SPP1–CD44 and CCN2/TGF-β–TGFBR1) was proposed as actionable (guo2024singlecelltumorheterogeneity pages 1-2).

6.3 Cell types (CL suggestions)

CL:0000182 hepatocyte
CL:0000235 macrophage (tumor-associated macrophages)
CL:0000066 fibroblast (including CAFs)
CL:0000624 CD8-positive, alpha-beta T cell
CL:0000115 endothelial cell

7. Anatomical structures affected

7.1 Organ/tissue level (UBERON suggestions)

Primary organ: liver (UBERON:0002107)
Commonly co-affected tissue state: cirrhotic liver parenchyma / fibrotic liver (context of chronic liver disease) (mattos2024hepatocellularcarcinomatherole pages 1-2, hwang2024hepatocellularcarcinomaupdates pages 1-3)

7.2 Subcellular/cellular components (GO cellular component suggestions)

Given the strong emphasis on transcriptional reprogramming, signaling, and metabolism in HCC, commonly implicated compartments include nucleus (GO:0005634), mitochondrion (GO:0005739), and plasma membrane (GO:0005886) (pathway-level support in 2024 mechanistic reviews) (szilveszter2024molecularmechanismsin pages 2-4).

8. Temporal development

8.1 Onset and progression

HCC usually develops over years in the context of chronic liver disease with progressive fibrosis/cirrhosis. Contemporary reviews emphasize that shifting etiologies (MASLD/ALD) may worsen ultrasound performance and complicate surveillance because MASLD-associated HCC can occur without cirrhosis (25–30% of MASLD-HCC cases without cirrhosis) (hwang2024hepatocellularcarcinomaupdates pages 6-7).

8.2 Staging systems (current practice)

Major guidelines commonly endorse Barcelona Clinic Liver Cancer (BCLC) staging to integrate tumor burden, liver function, and performance status, guiding therapy selection (seth2024clinicalpracticeguidelines pages 2-3, seth2024clinicalpracticeguidelines pages 10-11).

9. Inheritance and population

9.1 Epidemiology (recent statistics)

Global burden (GBD 2021): ~529,000 new liver cancer cases and ~483,800 deaths in 2021; >70% of cases occur in Asia (hwang2024hepatocellularcarcinomaupdates pages 1-3).
A 2024 surveillance review reports HCC as >800,000 new cases/year and 5-year overall survival ~18% (global summary) (wu2024hepatocellularcarcinomasurveillance pages 1-2).

9.2 Demographics

Sex disparity (higher incidence and mortality in men) and marked geographic variation by etiology (HBV-dominant regions in Asia/Africa; HCV prominent in specific countries; rising MASLD/ALD in Western settings) are emphasized in 2024 reviews (kinsey2024managementofhepatocellular pages 1-2, hwang2024hepatocellularcarcinomaupdates pages 1-3).

10. Diagnostics

10.1 Surveillance (real-world implementation)

AASLD-aligned surveillance: semi-annual (every 6 months) abdominal ultrasound plus AFP for at-risk populations (e.g., Child-Pugh A/B cirrhosis any etiology; Child-Pugh C if transplant candidate; selected non-cirrhotic HBV by risk stratification) (wu2024hepatocellularcarcinomasurveillance pages 4-5, hwang2024hepatocellularcarcinomaupdates pages 6-7). A contemporary review underscores that even ultrasound+AFP still misses over one-third of early-stage HCC (hwang2024hepatocellularcarcinomaupdates pages 6-7).

MASLD-specific considerations (EASL-EASD-EASO 2024): surveillance is strongly recommended for MASLD-related cirrhosis; not recommended for non-cirrhotic MASLD/MASH without severe fibrosis (<F3), while F3 may be considered case-by-case; MRI can be used when ultrasound visualization is poor ((easo)2024easleasdeasoclinicalpractice pages 46-48, (easo)2024easleasdeasoclinicalpractice pages 20-21).

10.2 Diagnostic imaging criteria (noninvasive diagnosis)

International imaging guidelines converge that noninvasive HCC diagnosis applies only to high-risk patients, and relies on multiphasic contrast-enhanced CT or MRI as first-line diagnostic exams (cannella2024esressentialsdiagnosis pages 1-3, cannella2024esressentialsdiagnosis pages 3-5). Major imaging features include: - Non-rim arterial phase hyperenhancement (APHE) - Non-peripheral washout - Enhancing capsule - Threshold growth (e.g., LI-RADS ≥50% increase in <6 months) (cannella2024esressentialsdiagnosis pages 5-7, cannella2024esressentialsdiagnosis pages 7-10)

A guideline-comparison table (cropped) is available here and summarizes the major features and size thresholds across EASL/AASLD(LI-RADS)/APASL/KLCA-NCC frameworks (cannella2024esressentialsdiagnosis media b948aa3a).

Performance characteristics cited in ESR/ESGAR 2024: a cited meta-analysis reports similar specificity for CT and MRI (>90%) but higher sensitivity for MRI (61–82% vs 48–66%), supporting MRI preference for small lesions when feasible (cannella2024esressentialsdiagnosis pages 3-5).

10.3 Biopsy

Biopsy is generally reserved for inconclusive imaging or non-cirrhotic contexts; it carries risks (bleeding, seeding) and non-trivial false-negative rate (~33% reported in a guideline review) (seth2024clinicalpracticeguidelines pages 2-3).

11. Outcome / prognosis

11.1 Survival statistics

Global surveillance review summary: 5-year overall survival around ~18% (wu2024hepatocellularcarcinomasurveillance pages 1-2).
When detected at early stage and treated curatively, 5-year survival can exceed 60% after resection or transplant in selected patients (wu2024hepatocellularcarcinomasurveillance pages 1-2).

11.2 Prognostic factors (examples)

Liver function and tumor burden drive outcomes and treatment selection, motivating integrated staging frameworks (BCLC) and liver-function measures (e.g., ALBI) (xie2023areviewof pages 1-2, gordan2024systemictherapyfor pages 1-2).
Molecular features can stratify recurrence and survival in genomic cohorts (e.g., LATS1 recurrence association; immune infiltration differences by TP53 vs CTNNB1) (wang2024novelgeneticalterations pages 1-2, song2024genomicprofilinginforms pages 1-2).

12. Treatment

12.1 Curative-intent local therapies (real-world implementations)

Contemporary guideline syntheses describe the standard curative-intent options for early-stage disease: surgical resection, percutaneous ablation (e.g., RFA), and liver transplantation, with transplant selection often using Milan criteria (single ≤5 cm or ≤3 lesions each ≤3 cm, no macrovascular invasion or extrahepatic spread) (wu2024hepatocellularcarcinomasurveillance pages 1-2, seth2024clinicalpracticeguidelines pages 10-11).

12.2 Locoregional therapies

Intermediate-stage disease often uses transarterial therapies (TACE) and other locoregional approaches; recent paradigms include combining locoregional with systemic therapy and conversion/downstaging approaches to enable later resection/transplant (li2024introductionto2023 pages 7-7, kinsey2024managementofhepatocellular pages 1-2).

Example real-world combination implementation (2024): TACE combined with atezolizumab+bevacizumab in an unresectable HCC multicenter cohort (n=92) had ORR 54.3% (mRECIST) / 41.3% (RECIST 1.1), median OS 15.9 months, median PFS 9.1 months, and grade 3/4 treatment-related AEs 16.3% (shen2024efficacyofatezolizumab pages 1-2).

12.3 Systemic therapy (authoritative 2024 guideline recommendations)

ASCO Guideline Update (May 2024): - Preferred first-line (Child-Pugh A; ECOG PS 0–1): atezolizumab + bevacizumab or durvalumab + tremelimumab (gordan2024systemictherapyfor pages 1-2, gordan2024systemictherapyfor pages 2-4). - If contraindications to those combinations: sorafenib, lenvatinib, or durvalumab may be offered first-line (gordan2024systemictherapyfor pages 2-4). - Subsequent-line therapy depends on prior regimen; after atezo+bev, options include TKIs and ramucirumab for AFP ≥400 ng/mL; after durva+treme, a TKI is recommended; after sorafenib/lenvatinib, options include cabozantinib/regorafenib/ramucirumab (AFP ≥400) and immune checkpoint combinations (nivo+ipi) in selected patients (gordan2024systemictherapyfor pages 2-4, gordan2024systemictherapyfor pages 13-14). - Panel emphasizes variceal screening/management prior to atezo+bev because bevacizumab increases bleeding risk, and recommends caution for Child-Pugh B patients (gordan2024systemictherapyfor pages 4-5, gordan2024systemictherapyfor pages 14-14).

Pivotal efficacy benchmarks for atezolizumab+bevacizumab (IMbrave150): Updated median OS 19.2 vs 13.4 months compared with sorafenib (HR 0.66, 95% CI 0.52–0.85) (finn2024efficacyandsafety pages 2-4). A 2024 IMbrave150 subgroup analysis for Vp4 portal vein tumor thrombosis reported median OS 7.6 vs 5.5 months and median PFS 5.4 vs 2.8 months for atezo+bev vs sorafenib, with grade ≥3 treatment-related AEs 43% vs 48% (finn2024efficacyandsafety pages 1-2).

Real-world effectiveness (meta-analytic): A 2023 single-arm meta-analysis of atezo+bev (23 studies; 3168 patients) reported pooled median OS 14.7 months, median PFS 6.66 months, ORR 26% (RECIST, long-term), and grade ≥3 AEs 30% (gao2023efficacyandsafety pages 1-2).

12.4 MAXO term suggestions (non-exhaustive)

Liver transplantation; surgical resection; radiofrequency ablation; transarterial chemoembolization; immune checkpoint inhibitor therapy; anti-VEGF therapy; tyrosine kinase inhibitor therapy.

13. Prevention

13.1 Primary prevention

HBV vaccination and antiviral therapy are credited with reducing HBV-related HCC burden over time (hwang2024hepatocellularcarcinomaupdates pages 1-3, hwang2024hepatocellularcarcinomaupdates pages 4-6).
Lifestyle/metabolic risk reduction (MASLD guideline, 2024): weight loss targets for overweight MASLD: ≥5% reduces liver fat; 7–10% improves inflammation; ≥10% improves fibrosis; physical activity targets >150 min/week moderate or 75 min/week vigorous; discouraging alcohol and avoiding ultra-processed foods/sugar-sweetened beverages are recommended ((easo)2024easleasdeasoclinicalpractice pages 46-48, (easo)2024easleasdeasoclinicalpractice pages 10-11).

13.2 Secondary prevention (screening/surveillance)

Semi-annual ultrasound ± AFP surveillance in high-risk groups is the central population-level approach (wu2024hepatocellularcarcinomasurveillance pages 4-5, hwang2024hepatocellularcarcinomaupdates pages 6-7). For MASLD, surveillance is recommended for cirrhosis and individualized for F3 fibrosis ((easo)2024easleasdeasoclinicalpractice pages 46-48, (easo)2024easleasdeasoclinicalpractice pages 20-21).

14. Other species / natural disease

No veterinary or wildlife comparative HCC evidence was retrieved in the current evidence set. (No claim can be supported here without additional targeted retrieval.)

15. Model organisms and experimental models

15.1 Model system landscape (2024 synthesis)

A 2024 review summarizes HCC models spanning chemically/dietary induced models (e.g., DEN; CCl4; NASH diets), genetic/oncogene-driven models (including hydrodynamic tail vein injection and transposon systems), transplantation models (xenografts/PDX; heterotopic and orthotopic), and advanced ex vivo/in vitro platforms (precision-cut tissue slices, organoids, organ-on-chip) (cigliano2024preclinicalmodelsof pages 1-2, cigliano2024preclinicalmodelsof pages 17-18).

15.2 Key examples and limitations

DEN chemical model: typically yields HCC by ~40 weeks, male predominant; commonly produces Ras/MAPK-leaning mutation spectra (activating Hras/Braf/Egfr), which can differ from human CTNNB1 mutation patterns (cigliano2024preclinicalmodelsof pages 7-9, cigliano2024preclinicalmodelsof pages 9-10).
CCl4 and NASH/fibrosis models: used to induce liver injury/fibrosis and model NASH→HCC contexts; outcomes are strain- and protocol-dependent (cigliano2024preclinicalmodelsof pages 17-18, cigliano2024preclinicalmodelsof pages 9-10).
Hydrodynamic tail vein injection (HTVI): enables rapid, pathway-specific tumor modeling (e.g., AKT/Ras; c-Met/sgPten; AKT/β-catenin), supporting targeted drug testing and mechanistic studies of initiation (cigliano2024preclinicalmodelsof pages 15-17, cigliano2024preclinicalmodelsof pages 20-21).
Organoids: can retain genomic features/heterogeneity and support screening, but often lack immune/vascular components and can be technically challenging with limited establishment success (e.g., ~30% patient-derived tumoroids reported) (cigliano2024preclinicalmodelsof pages 6-7, cigliano2024preclinicalmodelsof pages 1-2).

Expert opinions / analysis (authoritative sources, 2024)

1) Systemic therapy sequencing remains complex: ASCO (2024) emphasizes shared decision-making (toxicity, cost, bleeding risk, autoimmune risk) and cautions extrapolation beyond trial populations (mostly Child-Pugh A), reflecting real-world complexity in patients with cirrhosis (gordan2024systemictherapyfor pages 2-4, gordan2024systemictherapyfor pages 14-14).

2) Noninvasive imaging diagnosis requires context: ESR/ESGAR (2024) stresses that noninvasive diagnosis is restricted to high-risk patients and requires combining major imaging features, not relying on a single sign; guideline differences around hepatobiliary phase features can alter sensitivity/specificity (cannella2024esressentialsdiagnosis pages 1-3, cannella2024esressentialsdiagnosis pages 7-10).

3) Etiology shift is altering detection and outcomes: The CMH 2024 epidemiology update argues ultrasound surveillance may perform worse as MASLD/ALD increase, and MASLD-associated HCC can arise without cirrhosis—challenging traditional “cirrhosis-only” surveillance paradigms (hwang2024hepatocellularcarcinomaupdates pages 6-7, hwang2024hepatocellularcarcinomaupdates pages 1-3).

Notes on evidence gaps in this run

MONDO and MeSH IDs were not successfully retrieved in the available evidence excerpts; additional ontology-specific retrieval would be required for a fully populated identifier panel.
PMID-level citations were not consistently available from the retrieved excerpts; therefore this report cites DOI/URLs and the provided evidence context IDs.

Key URLs (selected)

ASCO 2024 guideline update (published May 2024): https://doi.org/10.1200/JCO.23.02745 (gordan2024systemictherapyfor pages 1-2)
ESR/ESGAR imaging recommendations (published Feb 2024): https://doi.org/10.1007/s00330-024-10606-w (cannella2024esressentialsdiagnosis pages 1-3)
EASL-EASD-EASO MASLD guideline (published Jun 2024): https://doi.org/10.1159/000539371 ((easo)2024easleasdeasoclinicalpractice pages 46-48)
CMH epidemiology/surveillance update (published Dec 2024 online): https://doi.org/10.3350/cmh.2024.0824 (hwang2024hepatocellularcarcinomaupdates pages 1-3)
IMbrave150 Vp4 PVTT subgroup analysis (published Jun 2024): https://doi.org/10.1159/000539897 (finn2024efficacyandsafety pages 1-2)

References

(OpenTargets Search: hepatocellular carcinoma): Open Targets Query (hepatocellular carcinoma, 13 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(hwang2024hepatocellularcarcinomaupdates pages 1-3): Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, and Ju Dong Yang. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clinical and Molecular Hepatology, Dec 2024. URL: https://doi.org/10.3350/cmh.2024.0824, doi:10.3350/cmh.2024.0824. This article has 238 citations.
(kinsey2024managementofhepatocellular pages 1-2): Emily Kinsey and Hannah M. Lee. Management of hepatocellular carcinoma in 2024: the multidisciplinary paradigm in an evolving treatment landscape. Cancers, 16:666, Feb 2024. URL: https://doi.org/10.3390/cancers16030666, doi:10.3390/cancers16030666. This article has 136 citations.
(cannella2024esressentialsdiagnosis pages 1-3): Roberto Cannella, Marc Zins, and Giuseppe Brancatelli. Esr essentials: diagnosis of hepatocellular carcinoma—practice recommendations by esgar. European Radiology, 34:2127-2139, Feb 2024. URL: https://doi.org/10.1007/s00330-024-10606-w, doi:10.1007/s00330-024-10606-w. This article has 32 citations and is from a domain leading peer-reviewed journal.
(mattos2024hepatocellularcarcinomatherole pages 1-2): Angelo Zambam de Mattos, Isadora Zanotelli Bombassaro, Arndt Vogel, and Jose D Debes. Hepatocellular carcinoma-the role of the underlying liver disease in clinical practice. World Journal of Gastroenterology, 30:2488-2495, May 2024. URL: https://doi.org/10.3748/wjg.v30.i19.2488, doi:10.3748/wjg.v30.i19.2488. This article has 13 citations.
(hwang2024hepatocellularcarcinomaupdates pages 6-7): Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, and Ju Dong Yang. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clinical and Molecular Hepatology, Dec 2024. URL: https://doi.org/10.3350/cmh.2024.0824, doi:10.3350/cmh.2024.0824. This article has 238 citations.
(gordan2024systemictherapyfor pages 1-2): John D. Gordan, Erin B. Kennedy, Ghassan K. Abou-Alfa, Eliza Beal, Richard S. Finn, Terence P. Gade, Laura Goff, Shilpi Gupta, Jennifer Guy, Hang T. Hoang, Renuka Iyer, Ishmael Jaiyesimi, Minaxi Jhawer, Asha Karippot, Ahmed O. Kaseb, R. Kate Kelley, Jeremy Kortmansky, Andrea Leaf, William M. Remak, Davendra P.S. Sohal, Tamar H. Taddei, Andrea Wilson Woods, Mark Yarchoan, and Michal G. Rose. Systemic therapy for advanced hepatocellular carcinoma: asco guideline update. Journal of Clinical Oncology, 42:1830-1850, May 2024. URL: https://doi.org/10.1200/jco.23.02745, doi:10.1200/jco.23.02745. This article has 285 citations and is from a highest quality peer-reviewed journal.
((easo)2024easleasdeasoclinicalpractice pages 46-48): European Association for the Study of the Liver (EASL). Easl-easd-easo clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (masld). Obesity Facts, 17:374-444, Jun 2024. URL: https://doi.org/10.1159/000539371, doi:10.1159/000539371. This article has 316 citations and is from a peer-reviewed journal.
(shen2024efficacyofatezolizumab pages 1-2): Xiao Shen, Jin-Xing Zhang, Jin Liu, Sheng Liu, Hai-Bin Shi, Yuan Cheng, Qing-Qiao Zhang, Guo-Wen Yin, and Qing-Quan Zu. Efficacy of atezolizumab plus bevacizumab combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study. Journal of Hepatocellular Carcinoma, 11:1993-2003, Oct 2024. URL: https://doi.org/10.2147/jhc.s478604, doi:10.2147/jhc.s478604. This article has 4 citations and is from a peer-reviewed journal.
(song2024genomicprofilinginforms pages 1-2): Mengqi Song, Haoyue Cheng, Hao Zou, Kai Ma, Lianfang Lu, Qian Wei, Zejiang Xu, Zirui Tang, Yuanzheng Zhang, Yinan Wang, and Chuandong Sun. Genomic profiling informs therapies and prognosis for patients with hepatocellular carcinoma in clinical practice. BMC Cancer, Jun 2024. URL: https://doi.org/10.1186/s12885-024-12407-2, doi:10.1186/s12885-024-12407-2. This article has 8 citations and is from a peer-reviewed journal.
(hwang2024hepatocellularcarcinomaupdates pages 4-6): Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, and Ju Dong Yang. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clinical and Molecular Hepatology, Dec 2024. URL: https://doi.org/10.3350/cmh.2024.0824, doi:10.3350/cmh.2024.0824. This article has 238 citations.
(peruhova2024geneticscreeningof pages 2-4): Milena Peruhova, Sonya Banova-Chakarova, Dimitrina Georgieva Miteva, and Tsvetelina Velikova. Genetic screening of liver cancer: state of the art. World Journal of Hepatology, 16:716-730, May 2024. URL: https://doi.org/10.4254/wjh.v16.i5.716, doi:10.4254/wjh.v16.i5.716. This article has 7 citations.
(ucdal2024crosstalkbetween pages 1-2): Mete Ucdal, Ayşe Buruş, and B. Çeltikçi. Cross talk between genetics and biochemistry in the pathogenesis of hepatocellular carcinoma. Hepatology Forum, 5:150-160, Jul 2024. URL: https://doi.org/10.14744/hf.2023.2023.0028, doi:10.14744/hf.2023.2023.0028. This article has 2 citations.
(wu2024hepatocellularcarcinomasurveillance pages 1-2): Gavin Wu, Nojan Bajestani, Nooruddin Pracha, Cindy Chen, and Mina S. Makary. Hepatocellular carcinoma surveillance strategies: major guidelines and screening advances. Cancers, 16:3933, Nov 2024. URL: https://doi.org/10.3390/cancers16233933, doi:10.3390/cancers16233933. This article has 24 citations.
(seth2024clinicalpracticeguidelines pages 2-3): Ishith Seth, Adrian Siu, Lyndel Hewitt, Ulvi Budak, Beshoy Farah, and Mouhannad Jaber. Clinical practice guidelines for the management of hepatocellular carcinoma: a systematic review. Journal of Gastrointestinal Cancer, 55:318-331, Jul 2024. URL: https://doi.org/10.1007/s12029-023-00961-0, doi:10.1007/s12029-023-00961-0. This article has 4 citations.
(szilveszter2024molecularmechanismsin pages 2-4): Raluca-Margit Szilveszter, M. Muntean, and Adrian-Florin Florea. Molecular mechanisms in tumorigenesis of hepatocellular carcinoma and in target treatments—an overview. Biomolecules, 14:656, Jun 2024. URL: https://doi.org/10.3390/biom14060656, doi:10.3390/biom14060656. This article has 18 citations.
(pessino2024hepatocellularcarcinomaold pages 15-17): Greta Pessino, Claudia Scotti, and Maristella Maggi. Hepatocellular carcinoma: old and emerging therapeutic targets. Cancers, 16:901, Feb 2024. URL: https://doi.org/10.3390/cancers16050901, doi:10.3390/cancers16050901. This article has 42 citations.
(wang2024novelgeneticalterations pages 1-2): Yizhou Wang, Pei-pei Shang, Chang Xu, Wei Dong, Xiaofeng Zhang, Yong Xia, Chengjun Sui, and Cheng Yang. Novel genetic alterations in liver cancer distinguish distinct clinical outcomes and combination immunotherapy responses. Frontiers in Pharmacology, Jun 2024. URL: https://doi.org/10.3389/fphar.2024.1416295, doi:10.3389/fphar.2024.1416295. This article has 3 citations.
((easo)2024easleasdeasoclinicalpractice pages 10-11): European Association for the Study of the Liver (EASL). Easl-easd-easo clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (masld). Obesity Facts, 17:374-444, Jun 2024. URL: https://doi.org/10.1159/000539371, doi:10.1159/000539371. This article has 316 citations and is from a peer-reviewed journal.
(cigliano2024preclinicalmodelsof pages 9-10): Antonio Cigliano, Weiting Liao, Giovanni A. Deiana, Davide Rizzo, Xin Chen, and Diego F. Calvisi. Preclinical models of hepatocellular carcinoma: current utility, limitations, and challenges. Biomedicines, 12:1624, Jul 2024. URL: https://doi.org/10.3390/biomedicines12071624, doi:10.3390/biomedicines12071624. This article has 26 citations.
(kassem2024genomiclandscapeof pages 1-2): Perihan Hamdy Kassem, Iman Fawzy Montasser, Ramy Mohamed Mahmoud, Rasha Ahmed Ghorab, Dina A. AbdelHakam, Marium EL Sayed Ahmad Fathi, Marwa A. Abdel Wahed, Khaled Mohey, Mariam Ibrahim, Mohamed El Hadidi, Yasmine M. Masssoud, Manar Salah, Arwa Abugable, Mohamad Bahaa, Sherif El Khamisy, and Mahmoud El Meteini. Genomic landscape of hepatocellular carcinoma in egyptian patients by whole exome sequencing. BMC Medical Genomics, Aug 2024. URL: https://doi.org/10.1186/s12920-024-01965-w, doi:10.1186/s12920-024-01965-w. This article has 5 citations and is from a peer-reviewed journal.
(li2024singlecellanalyses pages 1-2): Yao Li, Fengwei Li, Lei Xu, Xiaodong Shi, Hui Xue, Jianwei Liu, Shilei Bai, Yeye Wu, Zhao Yang, Feng Xue, Yong Xia, Hui Dong, Feng Shen, and Kui Wang. Single cell analyses reveal the pd-1 blockade response-related immune features in hepatocellular carcinoma. Theranostics, 14:3526-3547, Jun 2024. URL: https://doi.org/10.7150/thno.95971, doi:10.7150/thno.95971. This article has 22 citations and is from a domain leading peer-reviewed journal.
(li2024singlecellanalyses pages 6-8): Yao Li, Fengwei Li, Lei Xu, Xiaodong Shi, Hui Xue, Jianwei Liu, Shilei Bai, Yeye Wu, Zhao Yang, Feng Xue, Yong Xia, Hui Dong, Feng Shen, and Kui Wang. Single cell analyses reveal the pd-1 blockade response-related immune features in hepatocellular carcinoma. Theranostics, 14:3526-3547, Jun 2024. URL: https://doi.org/10.7150/thno.95971, doi:10.7150/thno.95971. This article has 22 citations and is from a domain leading peer-reviewed journal.
(guo2024singlecelltumorheterogeneity pages 1-2): De-Zhen Guo, Xin Zhang, Sen-Quan Zhang, Shi-Yu Zhang, Xiang-Yu Zhang, Jia-Yan Yan, San-Yuan Dong, Kai Zhu, Xin-Rong Yang, Jia Fan, Jian Zhou, and Ao Huang. Single-cell tumor heterogeneity landscape of hepatocellular carcinoma: unraveling the pro-metastatic subtype and its interaction loop with fibroblasts. Molecular Cancer, Aug 2024. URL: https://doi.org/10.1186/s12943-024-02062-3, doi:10.1186/s12943-024-02062-3. This article has 69 citations and is from a highest quality peer-reviewed journal.
(seth2024clinicalpracticeguidelines pages 10-11): Ishith Seth, Adrian Siu, Lyndel Hewitt, Ulvi Budak, Beshoy Farah, and Mouhannad Jaber. Clinical practice guidelines for the management of hepatocellular carcinoma: a systematic review. Journal of Gastrointestinal Cancer, 55:318-331, Jul 2024. URL: https://doi.org/10.1007/s12029-023-00961-0, doi:10.1007/s12029-023-00961-0. This article has 4 citations.
(wu2024hepatocellularcarcinomasurveillance pages 4-5): Gavin Wu, Nojan Bajestani, Nooruddin Pracha, Cindy Chen, and Mina S. Makary. Hepatocellular carcinoma surveillance strategies: major guidelines and screening advances. Cancers, 16:3933, Nov 2024. URL: https://doi.org/10.3390/cancers16233933, doi:10.3390/cancers16233933. This article has 24 citations.
((easo)2024easleasdeasoclinicalpractice pages 20-21): European Association for the Study of the Liver (EASL). Easl-easd-easo clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (masld). Obesity Facts, 17:374-444, Jun 2024. URL: https://doi.org/10.1159/000539371, doi:10.1159/000539371. This article has 316 citations and is from a peer-reviewed journal.
(cannella2024esressentialsdiagnosis pages 3-5): Roberto Cannella, Marc Zins, and Giuseppe Brancatelli. Esr essentials: diagnosis of hepatocellular carcinoma—practice recommendations by esgar. European Radiology, 34:2127-2139, Feb 2024. URL: https://doi.org/10.1007/s00330-024-10606-w, doi:10.1007/s00330-024-10606-w. This article has 32 citations and is from a domain leading peer-reviewed journal.
(cannella2024esressentialsdiagnosis pages 5-7): Roberto Cannella, Marc Zins, and Giuseppe Brancatelli. Esr essentials: diagnosis of hepatocellular carcinoma—practice recommendations by esgar. European Radiology, 34:2127-2139, Feb 2024. URL: https://doi.org/10.1007/s00330-024-10606-w, doi:10.1007/s00330-024-10606-w. This article has 32 citations and is from a domain leading peer-reviewed journal.
(cannella2024esressentialsdiagnosis pages 7-10): Roberto Cannella, Marc Zins, and Giuseppe Brancatelli. Esr essentials: diagnosis of hepatocellular carcinoma—practice recommendations by esgar. European Radiology, 34:2127-2139, Feb 2024. URL: https://doi.org/10.1007/s00330-024-10606-w, doi:10.1007/s00330-024-10606-w. This article has 32 citations and is from a domain leading peer-reviewed journal.
(cannella2024esressentialsdiagnosis media b948aa3a): Roberto Cannella, Marc Zins, and Giuseppe Brancatelli. Esr essentials: diagnosis of hepatocellular carcinoma—practice recommendations by esgar. European Radiology, 34:2127-2139, Feb 2024. URL: https://doi.org/10.1007/s00330-024-10606-w, doi:10.1007/s00330-024-10606-w. This article has 32 citations and is from a domain leading peer-reviewed journal.
(xie2023areviewof pages 1-2): Di-Yang Xie, Kai Zhu, Zheng-Gang Ren, Jian Zhou, Jia Fan, and Qiang Gao. A review of 2022 chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surgery and Nutrition, 12:216-228, Apr 2023. URL: https://doi.org/10.21037/hbsn-22-469, doi:10.21037/hbsn-22-469. This article has 157 citations and is from a peer-reviewed journal.
(li2024introductionto2023 pages 7-7): Jiexun Li, Zhuoran Qi, Jian Zhang, Sinuo Chen, and Jinglin Xia. Introduction to 2023 chinese expert consensus on the whole-course management of hepatocellular carcinoma. Hepatoma Research, Mar 2024. URL: https://doi.org/10.20517/2394-5079.2024.16, doi:10.20517/2394-5079.2024.16. This article has 0 citations.
(gordan2024systemictherapyfor pages 2-4): John D. Gordan, Erin B. Kennedy, Ghassan K. Abou-Alfa, Eliza Beal, Richard S. Finn, Terence P. Gade, Laura Goff, Shilpi Gupta, Jennifer Guy, Hang T. Hoang, Renuka Iyer, Ishmael Jaiyesimi, Minaxi Jhawer, Asha Karippot, Ahmed O. Kaseb, R. Kate Kelley, Jeremy Kortmansky, Andrea Leaf, William M. Remak, Davendra P.S. Sohal, Tamar H. Taddei, Andrea Wilson Woods, Mark Yarchoan, and Michal G. Rose. Systemic therapy for advanced hepatocellular carcinoma: asco guideline update. Journal of Clinical Oncology, 42:1830-1850, May 2024. URL: https://doi.org/10.1200/jco.23.02745, doi:10.1200/jco.23.02745. This article has 285 citations and is from a highest quality peer-reviewed journal.
(gordan2024systemictherapyfor pages 13-14): John D. Gordan, Erin B. Kennedy, Ghassan K. Abou-Alfa, Eliza Beal, Richard S. Finn, Terence P. Gade, Laura Goff, Shilpi Gupta, Jennifer Guy, Hang T. Hoang, Renuka Iyer, Ishmael Jaiyesimi, Minaxi Jhawer, Asha Karippot, Ahmed O. Kaseb, R. Kate Kelley, Jeremy Kortmansky, Andrea Leaf, William M. Remak, Davendra P.S. Sohal, Tamar H. Taddei, Andrea Wilson Woods, Mark Yarchoan, and Michal G. Rose. Systemic therapy for advanced hepatocellular carcinoma: asco guideline update. Journal of Clinical Oncology, 42:1830-1850, May 2024. URL: https://doi.org/10.1200/jco.23.02745, doi:10.1200/jco.23.02745. This article has 285 citations and is from a highest quality peer-reviewed journal.
(gordan2024systemictherapyfor pages 4-5): John D. Gordan, Erin B. Kennedy, Ghassan K. Abou-Alfa, Eliza Beal, Richard S. Finn, Terence P. Gade, Laura Goff, Shilpi Gupta, Jennifer Guy, Hang T. Hoang, Renuka Iyer, Ishmael Jaiyesimi, Minaxi Jhawer, Asha Karippot, Ahmed O. Kaseb, R. Kate Kelley, Jeremy Kortmansky, Andrea Leaf, William M. Remak, Davendra P.S. Sohal, Tamar H. Taddei, Andrea Wilson Woods, Mark Yarchoan, and Michal G. Rose. Systemic therapy for advanced hepatocellular carcinoma: asco guideline update. Journal of Clinical Oncology, 42:1830-1850, May 2024. URL: https://doi.org/10.1200/jco.23.02745, doi:10.1200/jco.23.02745. This article has 285 citations and is from a highest quality peer-reviewed journal.
(gordan2024systemictherapyfor pages 14-14): John D. Gordan, Erin B. Kennedy, Ghassan K. Abou-Alfa, Eliza Beal, Richard S. Finn, Terence P. Gade, Laura Goff, Shilpi Gupta, Jennifer Guy, Hang T. Hoang, Renuka Iyer, Ishmael Jaiyesimi, Minaxi Jhawer, Asha Karippot, Ahmed O. Kaseb, R. Kate Kelley, Jeremy Kortmansky, Andrea Leaf, William M. Remak, Davendra P.S. Sohal, Tamar H. Taddei, Andrea Wilson Woods, Mark Yarchoan, and Michal G. Rose. Systemic therapy for advanced hepatocellular carcinoma: asco guideline update. Journal of Clinical Oncology, 42:1830-1850, May 2024. URL: https://doi.org/10.1200/jco.23.02745, doi:10.1200/jco.23.02745. This article has 285 citations and is from a highest quality peer-reviewed journal.
(finn2024efficacyandsafety pages 2-4): Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Norelle Reilly, Alan Nicholas, Sairy Hernandez, Ning Ma, Philippe Merle, Riad Salem, Daneng Li, and Valeriy Breder. Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma with main trunk and/or contralateral portal vein invasion in imbrave150. Liver Cancer, 13:1-14, Jun 2024. URL: https://doi.org/10.1159/000539897, doi:10.1159/000539897. This article has 50 citations and is from a peer-reviewed journal.
(finn2024efficacyandsafety pages 1-2): Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Norelle Reilly, Alan Nicholas, Sairy Hernandez, Ning Ma, Philippe Merle, Riad Salem, Daneng Li, and Valeriy Breder. Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma with main trunk and/or contralateral portal vein invasion in imbrave150. Liver Cancer, 13:1-14, Jun 2024. URL: https://doi.org/10.1159/000539897, doi:10.1159/000539897. This article has 50 citations and is from a peer-reviewed journal.
(gao2023efficacyandsafety pages 1-2): Xiaoqiang Gao, Rui Zhao, Huaxing Ma, and Shi Zuo. Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis. BMC Cancer, Jul 2023. URL: https://doi.org/10.1186/s12885-023-11112-w, doi:10.1186/s12885-023-11112-w. This article has 28 citations and is from a peer-reviewed journal.
(cigliano2024preclinicalmodelsof pages 1-2): Antonio Cigliano, Weiting Liao, Giovanni A. Deiana, Davide Rizzo, Xin Chen, and Diego F. Calvisi. Preclinical models of hepatocellular carcinoma: current utility, limitations, and challenges. Biomedicines, 12:1624, Jul 2024. URL: https://doi.org/10.3390/biomedicines12071624, doi:10.3390/biomedicines12071624. This article has 26 citations.
(cigliano2024preclinicalmodelsof pages 17-18): Antonio Cigliano, Weiting Liao, Giovanni A. Deiana, Davide Rizzo, Xin Chen, and Diego F. Calvisi. Preclinical models of hepatocellular carcinoma: current utility, limitations, and challenges. Biomedicines, 12:1624, Jul 2024. URL: https://doi.org/10.3390/biomedicines12071624, doi:10.3390/biomedicines12071624. This article has 26 citations.
(cigliano2024preclinicalmodelsof pages 7-9): Antonio Cigliano, Weiting Liao, Giovanni A. Deiana, Davide Rizzo, Xin Chen, and Diego F. Calvisi. Preclinical models of hepatocellular carcinoma: current utility, limitations, and challenges. Biomedicines, 12:1624, Jul 2024. URL: https://doi.org/10.3390/biomedicines12071624, doi:10.3390/biomedicines12071624. This article has 26 citations.
(cigliano2024preclinicalmodelsof pages 15-17): Antonio Cigliano, Weiting Liao, Giovanni A. Deiana, Davide Rizzo, Xin Chen, and Diego F. Calvisi. Preclinical models of hepatocellular carcinoma: current utility, limitations, and challenges. Biomedicines, 12:1624, Jul 2024. URL: https://doi.org/10.3390/biomedicines12071624, doi:10.3390/biomedicines12071624. This article has 26 citations.
(cigliano2024preclinicalmodelsof pages 20-21): Antonio Cigliano, Weiting Liao, Giovanni A. Deiana, Davide Rizzo, Xin Chen, and Diego F. Calvisi. Preclinical models of hepatocellular carcinoma: current utility, limitations, and challenges. Biomedicines, 12:1624, Jul 2024. URL: https://doi.org/10.3390/biomedicines12071624, doi:10.3390/biomedicines12071624. This article has 26 citations.
(cigliano2024preclinicalmodelsof pages 6-7): Antonio Cigliano, Weiting Liao, Giovanni A. Deiana, Davide Rizzo, Xin Chen, and Diego F. Calvisi. Preclinical models of hepatocellular carcinoma: current utility, limitations, and challenges. Biomedicines, 12:1624, Jul 2024. URL: https://doi.org/10.3390/biomedicines12071624, doi:10.3390/biomedicines12071624. This article has 26 citations.

OpenScientist ▸

Hepatocellular Carcinoma: A Comprehensive Disease Characteristics Report

openscientist-autonomous 84 citations 2026-07-26T04:11:50.102934

Hepatocellular Carcinoma: A Comprehensive Disease Characteristics Report

Disease: Hepatocellular Carcinoma (HCC) Suggested MONDO ID: MONDO:0007256 (hepatocellular carcinoma) Category: Malignant epithelial neoplasm of the liver (primary liver cancer) Report scope: 15-section disease knowledge-base template Evidence base: 15 confirmed findings; 92 papers reviewed

Summary

Hepatocellular carcinoma (HCC) is the dominant form of primary liver cancer, accounting for approximately 80% of primary liver tumors, and ranks as the third leading cause of cancer-related mortality worldwide (PMID: 35782375). It arises overwhelmingly (~80–90% of cases) on a background of chronic liver disease and cirrhosis, driven by a well-defined set of etiologies: chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, alcohol-associated liver disease, non-alcoholic fatty liver disease/steatohepatitis (NAFLD/NASH, now often termed MASLD/MASH), and dietary aflatoxin B1 exposure (PMID: 31347138). Globally the etiologic landscape is shifting: viral HCC is declining because of HBV vaccination and effective antivirals, while metabolic (NASH/obesity/diabetes-related) HCC is rising and may become the dominant cause (PMID: 32319693).

At the molecular level, HCC is characterized by a small set of recurrent somatic driver events — TERT promoter, TP53, and CTNNB1 (Wnt/β-catenin) mutations serve as the core initiating drivers, with AXIN1 and other alterations converging on a defined group of oncogenic pathways (Wnt/β-catenin, PI3K/AKT/mTOR, RAS/MAPK/ERK, HGF/c-MET, Hippo-YAP/TAZ, TGF-β) (PMID: 33958712; PMID: 41476776). Epigenetic dysregulation (DNA methylation imbalance, histone modification, chromatin reorganization, non-coding RNAs) and metabolic reprogramming (a Warburg-like aerobic glycolysis and altered lipid metabolism) are additional hallmarks, and the tumor develops within an immunosuppressive microenvironment enriched for regulatory T cells and M0/M2 macrophages that both drives aggressive recurrence and provides the rationale for anti-VEGF plus checkpoint-inhibitor therapy.

Clinically, HCC is remarkable among solid tumors in that it can be diagnosed noninvasively in at-risk cirrhotic patients using dynamic contrast imaging (LI-RADS: arterial-phase hyperenhancement + washout ± capsule) supported by serum AFP and PIVKA-II. It shows a strong male predominance (~2–4:1) with a sex-hormone mechanistic basis. Management is stage-based following the BCLC framework — curative resection/ablation/transplantation for early disease, TACE/radioembolization for intermediate disease, and now immunotherapy-based systemic combinations (atezolizumab+bevacizumab or durvalumab+tremelimumab) for advanced disease. Prevention is anchored by HBV vaccination (proven primary prevention) and semiannual ultrasound ± AFP surveillance, with coffee consumption a robust dose-dependent protective factor. This report details all of these dimensions across the 15-section template.

Section 1: Disease Information

Overview. Hepatocellular carcinoma is a malignant epithelial tumor arising from hepatocytes. It is the dominant primary liver cancer and represents a major global oncologic burden. "Hepatocellular carcinoma (HCC) accounts for some 80% of primary liver tumors... HCC is the sixth most common type of cancer and the third leading cause of cancer-related mortality worldwide" (PMID: 35782375).

Key identifiers (suggested):

Resource	Identifier
MONDO	MONDO:0007256
MeSH	D006528 (Carcinoma, Hepatocellular)
ICD-10	C22.0
ICD-11	2C12.0
DOID	DOID:684
NCI Thesaurus	C3099

Synonyms / alternative names: hepatocellular carcinoma; HCC; hepatoma; malignant hepatoma; primary liver cell carcinoma; liver cell carcinoma; hepatocarcinoma. (Note: HCC is distinct from intrahepatic cholangiocarcinoma and from combined hepatocellular-cholangiocarcinoma [cHCC-CCA], a rare 2–5% mixed entity — PMID: 42272781.)

Information source type: The content in this report is derived predominantly from aggregated disease-level resources (systematic reviews, meta-analyses, cohort studies, genomic consortia such as TCGA/ICGC, GWAS meta-analyses), rather than from individual EHR patient records. Some cited studies use EHR/registry data (e.g., TriNetX cohorts).

Section 2: Etiology

Primary causal factors. HCC is a multifactorial disease caused by chronic hepatocellular injury from infectious, toxic, and metabolic insults, on which somatic genetic/epigenetic drivers accumulate. The principal causes: "the major risk factors for HCC development are chronic liver disease and cirrhosis due to hepatitis B virus (HBV) and/or hepatitis C virus (HCV), alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), steatohepatitis, intake of aflatoxin-contaminated food, diabetes, and obesity" (PMID: 31347138). Approximately 80–90% of HCC arises on established cirrhosis.

Environmental / lifestyle risk factors: chronic viral hepatitis (HBV, HCV), heavy alcohol use, aflatoxin B1 dietary exposure, tobacco smoking, obesity, type 2 diabetes, metabolic syndrome, older age, and male sex. Metabolic risk factors are increasing: "the prevalence of metabolic risk factors for HCC, including metabolic syndrome, obesity, type II diabetes and non-alcoholic fatty liver disease (NAFLD) are increasing and may jointly become the major cause of HCC globally" (PMID: 32319693).

Genetic risk factors (germline susceptibility). A multi-ancestry GWAS meta-analysis of 17,697 cases identified 15 genome-wide significant risk loci, including MAP3K9, DHRS1, MTTP, and 8q24.21 (PMID: 42357869). Established susceptibility genes influencing lipid/metabolic handling include PNPLA3, TM6SF2, MBOAT7, and TERT (PMID: 41699549). The PNPLA3 I148M (rs738409) variant is a particularly important, fibrosis-independent risk allele (see Section 4/10).

Protective factors. Environmental: coffee consumption is a robust, dose-dependent protective factor (~35% risk reduction per 2 extra cups/day; see Finding F011). HBV vaccination and antiviral therapy prevent virally driven HCC. Pharmacologic: metformin use in diabetics may lower risk — cumulative metformin exposure after HCV cure was associated with lower HCC risk (HR 0.46 per year; 95% CI 0.27–0.77) (PMID: 42499017). Genetic protective: rare loss-of-function/protective alleles at metabolic loci are under investigation but not firmly established.

Gene–environment interactions. The clearest example is PNPLA3 I148M acting on a background of fatty liver disease to raise HCC risk independent of fibrosis (PMID: 25278690). Diabetes/hyperinsulinemia interacts with hepatic oncogenic signaling (insulin/IGF-1 → PI3K/AKT/mTOR and RAS/MAPK), amplifying the Warburg effect and chronic inflammation (PMID: 42364319). CHB–MAFLD comorbidity has dual, dose-dependent effects on hepatocarcinogenesis (PMID: 42367770).

Section 3: Phenotypes

HCC is frequently asymptomatic in early stages (detected on surveillance imaging) and produces nonspecific symptoms as it advances. Clinical presentation "extends from right upper abdominal quadrant pain and weight loss to obstructive jaundice and lethargy" (PMID: 28839428).

Phenotype	Type	HPO suggestion	Notes / frequency
Right upper quadrant / abdominal pain	Symptom	HP:0002027 (abdominal pain)	Common in symptomatic disease
Weight loss / cachexia	Constitutional	HP:0001824	Advanced disease
Fatigue / lethargy	Symptom	HP:0012378	Common
Hepatomegaly / abdominal mass	Clinical sign	HP:0002240	Palpable in large tumors
Jaundice	Sign	HP:0000952	Obstructive/advanced
Ascites	Sign	HP:0001541	Cirrhosis/portal hypertension
Elevated alpha-fetoprotein	Lab abnormality	HP:0006254 (abnormal AFP)	Diagnostic/prognostic biomarker
Portal vein thrombosis	Complication	HP:0030242	Marker of macrovascular invasion

Paraneoplastic phenotypes. Paraneoplastic syndromes (PNS) occur in 20–40% of HCC patients and portend poor prognosis (Finding F014): "a significant proportion (20-40%) of patients with HCC develop paraneoplastic syndromes" (PMID: 35649187). In a 534-patient cohort, 22.3% were PNS-positive, with hypercalcemia (~6.3%), hypoglycemia (~5.8%), erythrocytosis (~3.9%), thrombocytosis (~3.9%), and hypercholesterolemia (~2.4%) (PMID: 34974464). PNS-positivity is an independent prognostic factor (PMID: 24480222).

Age of onset / severity / progression: adult- to late-onset (typically >50 years); severity variable but often severe given the cirrhotic background; progression typically progressive without treatment. Quality of life is affected by the underlying cirrhosis (ascites, fatigue, portal hypertensive symptoms — including lower urinary tract symptoms, PMID: 24798455) as well as tumor burden.

Section 4: Genetic / Molecular Information

Core somatic drivers (Finding F002). Large-scale genome sequencing has defined a compact set of initiating drivers: "Large-scale HCC genome sequencing analyses have identified core drivers (TERT, TP53, and CTNNB1/AXIN1) as initial molecular events" (PMID: 33958712). Nearly half of HCC patients carry oncogenic driver mutations such as TP53, CTNNB1, or TERT (PMID: 41699549).

Gene (HGNC)	Alteration	Pathway / consequence	Origin
TERT	Promoter mutation (earliest/most frequent)	Telomerase reactivation, cellular immortalization	Somatic
TP53	Missense/nonsense/deletion	Loss of tumor-suppressor / p53 pathway	Somatic (aflatoxin → R249S hotspot)
CTNNB1	Activating missense	Wnt/β-catenin hyperactivation	Somatic
AXIN1	Loss of function	Wnt/β-catenin (negative regulator loss)	Somatic
ARID1A	Loss of function	Chromatin remodeling	Somatic
PNPLA3 (I148M)	Germline risk variant	Hepatic lipid metabolism	Germline
TERT, TM6SF2, MBOAT7	Germline susceptibility loci	Senescence / lipid metabolism	Germline

Variant types/classes: missense, nonsense, frameshift, splice-site, and structural/chromosomal alterations; the TERT lesion is a non-coding promoter point mutation. Somatic drivers are documented in COSMIC/TCGA/ICGC; germline risk variants in GWAS Catalog/gnomAD. In liquid biopsy, CTNNB1 and ARID1A were the most frequently mutated genes in baseline ctDNA (25%), followed by SF3B1 (20%) and TERT (18%) (PMID: 40596669). Concomitant TERT+TP53+CTNNB1 co-mutation within a single clone can occur (PMID: 37968991); single-gene mutations serve as diagnostic/prognostic/predictive biomarkers (PMID: 40765562).

Functional consequences: TERT = gain of telomerase function; CTNNB1 = gain-of-function/constitutive Wnt signaling; TP53/AXIN1/ARID1A = loss of function.

Epigenetic information (Finding F015). Four interconnected epigenetic layers operate in HCC: (1) "global DNA hypomethylation of oncogenes and hypermethylation of tumor suppressors" (PMID: 40057667); (2) aberrant histone modifications; (3) genome-wide chromatin loop rearrangement; (4) non-coding RNA regulation. Specific examples: SFRP5 promoter hypermethylation silences a Wnt antagonist and constitutively activates Wnt/β-catenin (reversible by the demethylating agent 5-Aza) (PMID: 40814770); PAX6 promoter hypermethylation promotes growth/metastasis via CDH1/THBS1 (PMID: 39614377); methylation-silencing of the C14MC (miR-379/miR-656) cluster removes tumor-suppressor miRNAs (PMID: 42286554).

Chromosomal abnormalities: recurrent copy-number alterations and chromosomal instability accompany the point-mutation drivers; 8q24.21 (near MYC) is a germline risk locus (PMID: 42357869).

Section 5: Environmental Information

Environmental factors / toxins: Aflatoxin B1 (a mycotoxin contaminating stored grains/nuts, CHEBI:2504) is a classic hepatocarcinogen causing the TP53 R249S signature. Tobacco smoke is an established risk factor (PMID: 28839428).

Lifestyle factors: heavy alcohol (ethanol, CHEBI:16236) consumption (alcoholic liver disease → cirrhosis → HCC); diet/obesity driving NAFLD/NASH; physical inactivity and diabetes. Coffee is protective (Section 2, F011).

Infectious agents: the two dominant infectious causes are hepatitis B virus (HBV; NCBI:txid10407) and hepatitis C virus (HCV; NCBI:txid11103). Chronic HBV/HCV cause a majority of HCC globally through chronic inflammation, fibrosis, and (for HBV) direct integration/HBx oncogenic effects. Perinatal HBV transmission causes >85% chronic carriage if untreated (PMID: 28870397); transfusion-associated HCV remains a concern in vulnerable groups (PMID: 42488322).

Section 6: Mechanism / Pathophysiology

Molecular pathways (Finding F002). HCC converges on a defined set of oncogenic signaling cascades: "the Wnt/β-catenin, TGF-β, PI3K/AKT/mTOR, MAPK/ERK, HGF/c-MET, Notch and Hippo-YAP/TAZ pathways are known to contribute to promoting aggressive HCC behaviour" (PMID: 41476776). c-MYC is a central oncogenic transcription factor integrating these pathways and metabolic reprogramming (PMID: 40473083); miRNAs shape these same pathways (PMID: 40943288). Suggested GO terms: GO:0016055 (Wnt signaling pathway), GO:0038083 (PI3K signaling), GO:0007179 (TGF-β receptor signaling).

Cellular processes: dysregulated proliferation, evasion of apoptosis, replicative immortality (TERT), chronic inflammation, and impaired autophagy/senescence. GO suggestions: GO:0008283 (cell population proliferation), GO:0006915 (apoptotic process), GO:0006954 (inflammatory response).

Metabolic reprogramming (Finding F012). A Warburg-like aerobic glycolysis and altered lipid metabolism are hallmarks. The fatty-acid receptor CD36 is overexpressed in HCC and drives growth via "mTOR-mediated oncogenic glycolysis via activation of Src/PI3K/AKT signaling axis" (PMID: 33771982). HBV infection dysregulates aerobic glycolysis/lipid metabolism (Glut1 upregulation, glucose influx, lactate secretion — "a classic metabolic signature also observed in cancer cells") (PMID: 28768434).

Immune involvement (Finding F008). HCC harbors an immunosuppressive tumor microenvironment (TME) enriched for regulatory T cells and M0/M2 macrophages with upregulated checkpoints (PD-1, CTLA-4, PD-L1) (PMID: 42470438). Early/polyclonal intrahepatic recurrence is "associated with early recurrence, high phenotypic plasticity and a regulatory T cell enriched immunosuppressive microenvironment" (PMID: 42481381). AID–OSMR–STAT3 signaling remodels the immune microenvironment (PMID: 42462445). CL suggestions: CL:0000815 (regulatory T cell), CL:0000235 (macrophage), CL:0000182 (hepatocyte).

Tissue damage mechanisms: chronic inflammation → oxidative stress → fibrosis/cirrhosis → dysplasia → carcinoma. HBx transgenic models show carcinogenesis "accompanied by the activation of β-catenin and Jun N-terminal kinase (JNK) signaling pathways as well as the production of reactive oxygen species" (PMID: 28874700). NF-κB signaling links hepatitis to HCC (PMID: 30723284).

Sex dimorphism (Finding F013). HCC is strongly male-predominant. Mechanistically, "the androgen/androgen receptor (AR) accelerate cell proliferation and virus infection, especially during the initial stage of HCC, while estrogen/estrogen receptor (ER) function in an opposite way to induce cell apoptosis and immune responses" (PMID: 36563929). Murine models link male predisposition to cytokine-mediated "liver-gender disruption" (PMID: 18089782).

Causal chain (upstream → downstream)

Chronic insult (HBV/HCV/alcohol/NASH/aflatoxin)
│
▼
Chronic inflammation + oxidative stress
│
▼
Fibrosis ──► Cirrhosis (present in 80–90%)
│
▼
Somatic drivers accumulate: TERT (immortalization)
   + TP53 (loss of checkpoint) + CTNNB1/AXIN1 (Wnt ON)
│
▼
Pathway hyperactivation: Wnt/β-catenin, PI3K/AKT/mTOR,
   MAPK/ERK, c-MET, Hippo-YAP; metabolic reprogramming (CD36→glycolysis)
│
▼
Immunosuppressive TME (Tregs, M2 macrophages, PD-L1)
│
▼
Dysplastic nodule ──► Hepatocellular carcinoma ──► vascular invasion / metastasis

Section 7: Anatomical Structures Affected

Organ level: Primary organ = liver (UBERON:0002107); tumor arises from hepatocytes. Secondary involvement: portal vein (macrovascular invasion, UBERON:0002017), regional lymph nodes, lungs (most common extrahepatic metastatic site), bone, and adrenal glands. Body system: digestive/hepatobiliary system (UBERON:0002423, hepatobiliary system).

Tissue / cell level: malignant transformation of hepatocytes (CL:0000182) — parenchymal epithelial cells of the liver. The cholangiocyte-phenotype (CK19+) subtype carries poorer prognosis (PMID: 42400611). Non-parenchymal cells (Kupffer cells/macrophages, hepatic stellate cells driving fibrosis, endothelial cells) participate in the TME.

Subcellular level: nucleus (TERT/TP53/CTNNB1 nuclear signaling; GO:0005634), mitochondria (metabolic reprogramming; GO:0005739), and plasma membrane receptors (CD36, c-MET; GO:0005886).

Localization / lateralization: HCC occurs within the liver parenchyma (often the larger right lobe); may be unifocal, multifocal, or infiltrative. Multifocality can reflect intrahepatic metastasis or multicentric occurrence.

Section 8: Temporal Development

Onset: Typically adult-to-geriatric onset (usually >50 years), developing insidiously over years-to-decades of chronic liver disease. Onset is chronic/insidious; the tumor is often clinically silent until advanced. Early-onset HCC (<50 y) is part of the broader rise in early-onset GI cancers (PMID: 42295754).

Progression / staging (Finding F009). Staged by the Barcelona Clinic Liver Cancer (BCLC) system integrating tumor burden, liver function, and performance status (PMID: 28839428): very early/early (0/A), intermediate (B), advanced (C, with macrovascular invasion/extrahepatic spread), and terminal (D). Progression rate is variable; disease course is progressive without treatment. After curative treatment, recurrence is common and follows distinct clonal modes (early polyclonal vs late) (PMID: 42481381).

Patterns: Remission is treatment-induced (curative resection/ablation/transplant, or sustained response to systemic therapy — durable complete responses are now reported with SIRT + targeted + immunotherapy, PMID: 42022453). Critical intervention window: detecting HCC at early BCLC 0/A stage enables curative therapy — the rationale for surveillance.

Section 9: Inheritance and Population

Epidemiology. HCC is the sixth most common cancer and third leading cause of cancer mortality worldwide (PMID: 35782375). Incidence is highest in East Asia and sub-Saharan Africa (HBV- and aflatoxin-endemic regions); in Western countries NASH-related HCC is rising while viral HCC declines (PMID: 31347138; PMID: 36139633).

Inheritance. HCC is not a Mendelian disease; it is a somatically driven cancer with polygenic/multifactorial germline susceptibility. GWAS identified 15 risk loci (PMID: 42357869); PNPLA3/TM6SF2/MBOAT7/TERT contribute inherited risk (PMID: 41699549). Classical Mendelian concepts (penetrance, anticipation, carrier frequency) do not directly apply.

Demographics. Strong male predominance (~2–4:1) with a sex-hormone mechanistic basis (Section 6, F013). Ethnicity affects prevalence and outcomes: non-Caucasian patients often have poorer survival (PMID: 37344125). Age distribution skews to older adults, with a rising early-onset segment.

Section 10: Diagnostics

Noninvasive imaging diagnosis (Finding F007). Uniquely among solid tumors, HCC can be diagnosed without biopsy in at-risk cirrhotic patients using LI-RADS criteria on multiphase CT or gadoxetic-acid MRI: arterial-phase hyperenhancement, non-peripheral "washout," and enhancing capsule. "For LR-5 in identifying HCC, sensitivity was 79-83%, specificity was 91-97%, and accuracy was 89-92%" (PMID: 38951191). MRI outperforms CT in sensitivity (89.3% vs 78.9% for APASL criteria) (PMID: 40487794). Contrast-enhanced ultrasound (CEUS) adds high specificity (100%) for inconclusive small nodules (PMID: 40055232).

Serum biomarkers. Alpha-fetoprotein (AFP) and PIVKA-II (DCP) aid diagnosis and risk stratification (PMID: 40293522). LOINC: AFP 1834-1. Emerging biomarkers: methylated SEPT9 outperformed AFP (AUROC 0.79 vs 0.71; P=0.002) and, combined with AFP, recovered 78% of AFP-missed cases (PMID: 42390849); the GAAD algorithm (gender/age/AFP/PIVKA-II) and liquid-biopsy ctDNA/cfDNA fragmentomics are advancing (PMID: 42312979; PMID: 42353299).

Pathology / IHC. When biopsy is needed, diagnosis integrates morphology with immunohistochemistry (glypican-3, HSP70, glutamine synthetase; β-catenin/GS for Wnt-activated tumors) and can be supported by driver-mutation detection (TERT/CTNNB1/TP53) (PMID: 40276913). Differential diagnosis: dysplastic nodule, hepatocellular adenoma, intrahepatic cholangiocarcinoma, cHCC-CCA (PMID: 42272781), histiocytic sarcoma (PMID: 42405293), and benign inflammatory mimics (e.g., xanthogranulomatous inflammation) (PMID: 41909198).

Diagnostic pitfalls: LR-M lesions require biopsy (only ~46% are HCC) (PMID: 40293522); benign mimics can simulate LR-5 kinetics in fibrotic livers (PMID: 41909198).

Section 11: Outcome / Prognosis

Survival. Prognosis is stage- and liver-function-dependent (Finding F005). Advanced disease with best current systemic therapy achieves median OS approaching ~19–24 months (IMbrave150 5-year OS 19%) (PMID: 42022453). Early-stage disease treated curatively achieves substantially better long-term survival, though recurrence is frequent.

Prognostic factors (Finding F005). AFP is an independent prognostic factor after hepatectomy — DFS HR 1.391 (95% CI 1.193–1.623) and OS HR 1.267 (95% CI 1.080–1.486); the combined AFP–FIB-4 score improves prediction (DFS HR 1.404; OS HR 1.378) (PMID: 42323530). Microvascular invasion (MVI) is "a critical prognostic risk factor" (PMID: 42480815). BCLC stage and ALBI grade (liver function) are key (PMID: 42449617). Molecular/liquid-biopsy prognostics: ctDNA CTNNB1/TP53/ARID1A/KEAP1 mutations predict poor OS pre-TACE (PMID: 40596669); 5mC gene signatures (PMID: 42304060); radiomics/machine-learning models (PMID: 42413246; PMID: 42344442).

Complications: hepatic decompensation, portal vein thrombosis, variceal bleeding, and paraneoplastic syndromes (20–40%, poor prognosis; F014) (PMID: 35649187). Within PNS, erythrocytosis and thrombocytosis were independent predictors of better prognosis while hypoglycemia/hypercalcemia predicted worse outcome (PMID: 34974464).

Section 12: Treatment

Stage-based (BCLC) framework (Finding F009).

BCLC stage	Standard treatment	MAXO suggestion
Very early / early (0/A)	Resection, local ablation (RFA/MWA/PEI/cryo), liver transplantation (Milan criteria)	MAXO:0001175 (surgical procedure), MAXO:0000004 (radiofrequency ablation)
Intermediate (B)	TACE, radioembolization (TARE/SIRT)	MAXO:0000527 (chemoembolization)
Advanced (C)	Systemic immunotherapy-based combinations	MAXO:0000765 (immunotherapy)
Terminal (D)	Best supportive care	MAXO:0000922 (palliative care)

Curative options. Liver resection, ablation, and transplantation; transplant is restricted to Milan criteria ("one tumor ≤ 5 cm, or up to three tumors no larger than 3 cm, along with the absence of gross vascular invasion or extrahepatic spread") (PMID: 34696292). Downstaging into Milan criteria enables acceptable post-transplant outcomes (PMID: 36813012). For recurrence within Milan criteria after resection, RR/RFA and TACE achieve comparable outcomes except for late recurrence, where RR/RFA is preferred (PMID: 25933127; PMID: 32355732).

First-line systemic therapy is now immunotherapy-based (Finding F003). "Current international guidelines recommend atezolizumab plus bevacizumab (A+T) or durvalumab plus tremelimumab (Dur/Tre) as first-line regimens for unresectable HCC. In the 5-year update of IMbrave150, A+T achieved an objective response rate (ORR) of 30% and a 5-year overall survival (OS) rate of 19%" (PMID: 42022453). This superseded single-agent TKIs (sorafenib/lenvatinib, median OS ~10–14 months) (PMID: 36497349). Network meta-analyses support atezolizumab+bevacizumab superiority over lenvatinib (HR 0.59) (PMID: 34239810; PMID: 33638735).

Mechanistic rationale for anti-VEGF + ICI (Finding F008): "anti-VEGF therapy induces vascular normalization, enhances immune cell infiltration, and reduces immunosuppression within the TME, thereby converting immunologically 'cold' tumors into 'hot' tumors that are more responsive to checkpoint blockade" (PMID: 42467392).

Second-line / other options: regorafenib, cabozantinib, ramucirumab, nivolumab+ipilimumab, pembrolizumab (PMID: 40704000; PMID: 34953051). Emerging/experimental: c-MYC-targeted approaches (PMID: 40473083); RNA therapeutics such as MTL-CEBPA saRNA (PMID: 29511346); miRNA-based strategies (PMID: 40943288); demethylating agents (5-Aza) targeting epigenetic silencing (PMID: 40814770); plant-derived/curcumin adjuncts under preclinical study (PMID: 41044771; PMID: 41751435).

Section 13: Prevention

Primary prevention (Finding F004). HBV vaccination is proven primary prevention: "hepatitis B vaccination can protect them from HCC, as has been demonstrated in Taiwan and other countries" (PMID: 26651252). Perinatal prevention: "This risk is reduced by 90% with HBV vaccine given along with hepatitis B immune globulin (HBIG) starting at birth" (PMID: 28870397). (Note: age-period-cohort analyses caution that secular time-trends also contributed to observed pediatric HCC declines in Taiwan — PMID: 25660961.) Antiviral therapy (nucleos(t)ide analogues for HBV; direct-acting antivirals achieving SVR for HCV) reduces HCC incidence (PMID: 25241970). Other primary prevention: aflatoxin reduction, alcohol moderation, metabolic risk-factor control; coffee consumption and (in diabetics) metformin are protective.

Secondary prevention / surveillance (Finding F004). "Current guidelines recommend semiannual surveillance with ultrasound and α-fetoprotein, but this strategy has suboptimal sensitivity" (PMID: 42017860); fewer than 1 in 4 cirrhotic patients receive adequate surveillance. Risk-stratified surveillance and emerging biomarkers (methylated SEPT9, GAAD, liver stiffness) aim to improve early detection (PMID: 41921193; PMID: 42390849; PMID: 42394831).

Tertiary prevention: management of cirrhosis complications and post-treatment recurrence surveillance. Genetic counseling is limited given the polygenic nature but PNPLA3 genotyping may inform metabolic-HCC risk stratification.

Section 14: Other Species / Natural Disease

Taxonomy: HCC occurs naturally across mammals. Homo sapiens (NCBI:txid9606); animal models include Mus musculus (NCBI:txid10090), Rattus norvegicus (NCBI:txid10116), and the woodchuck Marmota monax.
Natural disease model: The woodchuck hepatitis virus (WHV) produces an HBV-like chronic hepatitis and near-universal HCC, serving as a key natural model of virally driven hepatocarcinogenesis.
Orthologous genes: Tp53, Ctnnb1, Tert are conserved across mouse/rat/human, enabling cross-species mechanistic study.
Comparative biology: HCC develops in companion animals (dogs) and other species; core inflammation → fibrosis → carcinoma mechanisms and oncogenic pathway conservation permit translational study (Alliance of Genome Resources for orthology). Not zoonotic — HCC itself is non-transmissible, though its causal viruses have species-specific counterparts.

Section 15: Model Organisms

Model systems (Finding F006). Rodent models dominate HCC research:

Model	Type	Mechanism / use
DEN (diethylnitrosamine)-treated mice/rats	Chemical carcinogenesis	Genotoxic HCC induction; C57BL/6 background
c-Myc transgenic	Oncogene-driven	Proliferation-driven tumorigenesis
HBx transgenic (e.g., C1485T)	Viral oncogene	β-catenin/JNK/ROS-driven; enhanced DEN susceptibility (PMID: 28874700)
HCV-transgenic + PML deficiency	Viral + tumor-suppressor loss	Spontaneous liver tumors (PMID: 31144474)
TAK1 knockout; Vps33b conditional KO	Tumor-suppressor loss	Inflammation-driven HCC (PMID: 29729199)
NASH/diet-induced models	Metabolic etiology	Recapitulate MASLD-HCC
Woodchuck (WHV)	Natural viral model	HBV-like chronic infection → HCC

Genetic model types: knockout, conditional, transgenic, and humanized models. Etiology-oriented subtyping compares murine tumors to TCGA etiologic subsets (PMID: 30967480).

Limitations: "Murine liver tumors often fail to recapitulate the complexity of human hepatocellular carcinoma (HCC), which might explain the difficulty to translate preclinical mouse studies into clinical science" (PMID: 30967480). Human cell lines (HepG2, Huh7, Hep3B), patient-derived organoids, and iPSC systems complement in vivo models. Resources: MGI, RGD, Cellosaurus.

Mechanistic Model / Interpretation

HCC is best understood as the endpoint of a chronic-injury → inflammation → fibrosis/cirrhosis → dysplasia → carcinoma sequence, on which a compact set of somatic drivers act. The upstream trigger is etiology-specific (HBV, HCV, alcohol, NASH, aflatoxin) but converges on a shared downstream program: sustained hepatocyte injury and regeneration create a mutagenic, inflammatory, and immunosuppressive niche in which TERT-promoter mutation (immortalization), TP53 loss (checkpoint failure), and CTNNB1/AXIN1 alterations (Wnt/β-catenin activation) initiate malignancy. These drivers hyperactivate a defined pathway network (Wnt, PI3K/AKT/mTOR, MAPK/ERK, c-MET, Hippo-YAP), which — reinforced by epigenetic dysregulation and metabolic reprogramming (CD36→Warburg glycolysis) — produces a proliferative, invasive tumor embedded in a Treg/M2-macrophage-rich, checkpoint-high microenvironment.

This model explains the therapeutic landscape: because the tumor is immunosuppressed and highly vascular, anti-VEGF vascular normalization + checkpoint blockade is synergistic and now first-line; because early tumors are curable, surveillance + noninvasive imaging diagnosis is the central strategy; and because HBV is a dominant upstream cause, vaccination is the most effective primary prevention. Sex-hormone signaling (AR pro-tumor, ER protective) accounts for the male predominance, and germline modifiers (PNPLA3, and 15 GWAS loci) tune individual risk on the environmental background.

Evidence Base

Finding	Key PMIDs	Evidence type	Support
F001 Burden & etiology	35782375, 31347138, 32319693	Human review/epi	Strong
F002 Core drivers & pathways	33958712, 41699549, 42357869, 41476776	Genomics/GWAS	Strong
F003 Immunotherapy first-line	42022453, 40704000, 34239810, 33638735	RCT/meta-analysis	Strong
F004 HBV vaccine & surveillance	26651252, 42017860, 28870397	Human/guidelines	Strong
F005 Prognostic factors	42323530, 42480815, 42449617	Cohort	Strong
F006 Animal models	30967480, 28874700, 31144474	Model organism	Moderate
F007 Noninvasive imaging dx	38951191, 40487794, 40055232	Diagnostic accuracy	Strong
F008 Immunosuppressive TME	42467392, 42481381, 42470438	Human/multi-omics	Strong
F009 Stage-based treatment	34696292, 36813012, 33780876	Guidelines	Strong
F010 PNPLA3 / non-cirrhotic NAFLD-HCC	25278690	Human review	Moderate
F011 Coffee protective	28490552, 28846640, 32830818	Dose-response meta-analysis	Strong
F012 Metabolic reprogramming	33771982, 28768434	In vitro/mechanistic	Moderate
F013 Sex dimorphism	36563929, 18089782	Human/mouse	Moderate
F014 Paraneoplastic syndromes	35649187, 24480222, 34974464	Cohort/review	Moderate
F015 Epigenetic dysregulation	40057667, 40814770, 42286554, 39614377	Mechanistic	Strong

Selected landmark evidence. The genomic landscape defining TERT/TP53/CTNNB1 as initiating events (PMID: 33958712) and the multi-ancestry GWAS of 15 risk loci (PMID: 42357869) anchor the genetics sections. The IMbrave150-based practice change (PMID: 42022453) and the TME/anti-VEGF+ICI mechanism (PMID: 42467392) together explain modern treatment. Coffee dose-response meta-analyses (PMID: 28490552; PMID: 28846640) provide the strongest protective-factor evidence.

Limitations and Knowledge Gaps

Etiologic drift not fully quantified. The transition from viral to metabolic (MASLD/MASH) HCC is documented directionally but exact future incidence projections remain uncertain (PMID: 32319693).
Non-cirrhotic HCC. NAFLD-HCC arising in non-cirrhotic livers challenges surveillance strategies keyed to cirrhosis (PMID: 25278690); no validated surveillance protocol exists for this population.
Surveillance sensitivity. Ultrasound ± AFP has suboptimal sensitivity and poor real-world uptake; emerging biomarkers (SEPT9, GAAD, ctDNA) need prospective validation and survival-benefit confirmation (PMID: 42017860; PMID: 42390849).
Model fidelity. Murine models incompletely recapitulate human tumor complexity, limiting translation (PMID: 30967480).
Predictive biomarkers for immunotherapy. No robust biomarker reliably predicts response to atezolizumab+bevacizumab / durvalumab+tremelimumab; ~70% do not achieve objective response.
No dedicated experimental data. This report is a literature synthesis; no primary dataset was analyzed. Findings F001–F015 rest on published human, model-organism, and in vitro evidence, and some ontology IDs (MONDO/HPO/GO/CL/UBERON/CHEBI/MAXO) are suggested and should be verified against current ontology releases.

Proposed Follow-up Experiments / Actions

Validate multi-analyte early-detection panels (methylated SEPT9 + AFP + PIVKA-II/GAAD + cfDNA fragmentomics) prospectively for survival benefit, especially in non-cirrhotic MASLD-HCC.
Develop and validate risk-stratified surveillance models incorporating PNPLA3 genotype, FIB-4/liver stiffness, and etiology to tailor surveillance intensity (PMID: 41921193).
Immunotherapy response biomarkers: correlate TME composition (Treg/M2 density, PD-L1, Wnt/β-catenin activation status) with response to anti-VEGF+ICI to enable patient selection.
Test epigenetic combination therapy: demethylating agents (5-Aza) restoring SFRP5/C14MC + checkpoint blockade in preclinical models.
Chemoprevention trials: prospective evaluation of metformin (in diabetics) and coffee/caffeine as adjunct prevention in high-risk cirrhosis.
Sex-hormone axis intervention: explore AR-targeting strategies given the androgen-driven early carcinogenesis mechanism.
Improve models: develop humanized/organoid systems that better capture the immunosuppressive TME for translational immunotherapy testing.

Report compiled from 15 confirmed findings and 92 reviewed papers. Evidence types span human clinical/epidemiological, model-organism, in vitro, and computational sources as annotated. Ontology suggestions (MONDO, HPO, GO, CL, UBERON, CHEBI, MAXO) are provided for knowledge-base curation and should be verified against current ontology releases.

Ask OpenScientist

OpenScientist Report

Classifications

Mappings

Subtypes

Comorbidities

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Biochemical Markers

Diagnosis

Stages

Related Datasets

Source YAML

References & Deep Research

References

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Hepatocellular Carcinoma (HCC) — Disease Characteristics Research Report (2023–2024 prioritized)

Target disease

1. Disease information

1.1 Definition / overview (current understanding)

1.2 Key identifiers and synonyms

1.3 Evidence source type

2. Etiology

2.1 Primary causal factors

2.2 Risk factors (genetic + environmental)

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes

3.1 Core clinical phenotypes

3.2 Ontology suggestions (HPO; non-exhaustive)

3.3 Quality of life impact

4. Genetic / molecular information

4.1 Somatic driver landscape (key concepts)

4.2 Pathways and mechanistic chain (example)

4.3 Clinically relevant associations and biomarkers

4.4 Epigenetics

4.5 Ontology suggestions

5. Environmental information

5.1 Environmental and lifestyle contributors

5.2 Infectious agents

6. Mechanism / pathophysiology

6.1 Molecular pathways (selected high-confidence)

6.2 Immune system involvement (2024 single-cell/spatial advances)

6.3 Cell types (CL suggestions)

7. Anatomical structures affected

7.1 Organ/tissue level (UBERON suggestions)

7.2 Subcellular/cellular components (GO cellular component suggestions)

8. Temporal development

8.1 Onset and progression

8.2 Staging systems (current practice)

9. Inheritance and population

9.1 Epidemiology (recent statistics)

9.2 Demographics